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Farnesoid X receptor (FXR, NR1H4) is a ligand activated transcription factor 
belonging to the nuclear receptor (NR) superfamily, and is highly expressed in the liver, 
intestine, and kidney, in both humans and rodents. Bile acids (BAs) are the endogenous 
ligands of FXR. FXR mainly functions as the BA sensor by regulating genes that are 
critically involved in BA homeostasis. FXR has also been shown to play important roles 
in lipid, cholesterol and glucose metabolism, as well as inflammation, tumorigenesis, 
and liver regeneration. FXR deficiency is implicated in numerous liver diseases and 
mice with modulation of FXR have been used as animal models to study liver 
physiology and pathology. Genome-wide studies in mouse livers and intestines suggest 
FXR’s diverse and broadly tissue specific functions. In the first aim, we studied the 
genome-wide FXR binding and transcriptome profiles upon FXR activation in primary 
human hepatocytes (PHHs) and HepG2 cells. Chromatin immunoprecipitation followed 
by massive parallel sequencing (ChIP-seq) was performed in PHHs and HepG2 cells, 
treated with a synthetic FXR agonist, GW4064 or DMSO control. In parallel, RNA deep 
sequencing (RNA-seq) and RNA microarray were performed for GW4064 or control 
treated PHHs and wild type (WT) mouse livers, respectively. ChIP-seq showed similar 
profiles of genome-wide FXR binding in humans and mice in terms of motif analysis and 
pathway prediction. However, RNA-seq and microarray showed more different 
transcriptome profiles between PHHs and mouse livers upon GW4064 treatment. In 
summary, we have established genome-wide human FXR binding and transcriptome 
profiles. These results will aid in determining the human FXR functions, as well as 
IV 
 
judging to what level the mouse models could be used to study human FXR functions in 
future studies. 
Recent studies in the field of parenteral nutrition (PN) suggest that down-
regulation of FXR signaling is critically involved in the pathogenesis of PN associated 
liver diseases (PNALD), especially PN associated cholestasis (PNAC) in preterm infants. 
PN is a life-saving therapy for patients who cannot tolerate enteral food intake. However, 
long-term PN can lead to a spectrum of liver diseases, summarized as PNALD. PNAC 
is predominately found in preterm infants and neonates, and has high rate of 
progression into liver failure. Options for clinical management of PNALD are still limited. 
While it is suggested that multiple risk factors are contributing to the development of 
PNALD, the pathogenesis of PNALD remains poorly understood. Animal studies 
obtained from preterm piglets and several mouse models have shed light on the 
mechanisms underlined. To date, whether FXR and BAs are involved in the 
development and progression of PNALD is not well studied. In the second aim, we 
established a valid mouse PN model in our laboratory. Using RNA microarray profiling 
and serum BA profiling, we identified novel signatures involved in BA homeostasis in 
adult PN mice. We detected significantly increased gene expression of cytochrome 
P450, family 7, subfamily a, polypeptide 1 (Cyp7a1) and decreased gene expression of 
cytochrome P450, family 8, subfamily b, polypeptide 1 (Cyp8b1) in the livers of PN mice. 
Several FXR and liver X receptor alpha (LXRα) target genes involved in BA 
homeostasis were also altered in the livers of PN mice. Consistent with the gene 
expression alterations, both the levels and the percentages of tauro β-muricholic acid 
(T-β-MCA) as well as total non-12α-OH BAs in the serum of PN mice increased 
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significantly compared to saline controls. These results suggest that BA homeostasis 
could be disrupted in PN patients as well and the deregulation of BA synthesis and 
metabolism could contribute to the development and progression of PNALD when 
additional risk factors are present. Additional altered genes and pathways were also 
detected from the microarray analysis for the PN mice. These results will aid us in future 
studies of the contributions of FXR and BA signaling, as well as other potential factors 
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Chapter 1: Introduction and Background 
1.1 FXR and BA Homeostasis 
1.1.1 FXR Gene and Protein 
Farnesoid X Receptor (FXR/ NR1H4) is a well-characterized type II nuclear 
receptor (NR) belonging to the NR superfamily. NRs are ligand-activated transcription 
factors responding to enteral and external metabolites, including steroids, vitamins, 
dietary lipids, etc. (Mangelsdorf et al. 1995, Chawla et al. 2001). The NRs have been 
shown to play important roles involved in many aspects of mammalian physiology 
and/or pathology when they are deregulated. In 1995, FXR was initially cloned in yeast 
and shown to heterodimerize with retinoid X receptor alpha (RXRα) (Seol, Choi and 
Moore 1995). Later the same year, the mouse homologue was cloned and subsequently 
named FXR upon the finding that supra-physiological concentrations of farnesol could 
activate this NR. Four years afterwards, bile acids (BAs) were confirmed as the 
endogenous ligands of FXR by several groups simultaneously (Makishima et al. 1999, 
Wang et al. 1999, Parks et al. 1999).  
There were two FXR genes in humans and rodents, FXRα (NR1H4/Nr1h4) and 
FXRβ (NR1H5/Nr1h5). FXRβ is expressed in rodents while it is a pseudogene in 
humans (Otte et al. 2003). Only limited information exists regarding the ligands and 
functions of FXRβ. Four transcript isoforms are encoded by the single FXRα/Fxrα gene 
in both humans and mice, named FXRα1 to FXRα4, resulting from two different 
transcription start sites (TSSs) (5’ promoter for exon 1 and 3’ promoter for exon 3) and 
subsequent alternative splicing (exon 5) (Huber et al. 2002, Zhang, Kast-Woelbern and 
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Edwards 2003). The four FXRα proteins differ slightly regarding the amino acid 
sequences and all four share critical NR features (Huber et al. 2002, Zhang et al. 2003). 
Studies have only shown slight functional differences among the four FXRα isoforms in 
terms of expression patterns and transactivation activities (Modica, Gadaleta and 
Moschetta 2010). The majority of the in vivo and in vitro experimental technologies that 
biologists have applied to study the function of FXR, will not differentiate the four 
isoforms, such as gene knockout, mRNA expression, antibody recognition, etc. In this 
regard, FXR will be used in this dissertation unless otherwise specified. 
FXR is highly expressed in tissues in which BA homeostasis is tightly regulated, 
including the liver, intestine and kidney. FXR is also expressed moderately in the 
adrenal gland and minimally in the heart and adipose tissues (Zhang et al. 2003). FXR 
protein features classic NR structure characteristics (Figure 1.1), which includes a N-
terminal ligand independent activation motif (AF1), a highly conserved DNA binding 
domain (DBD) containing two cysteine-coordinated Zn2+ finger motifs, a hinge region 
followed by a moderately conserved C-terminal ligand binding domain (LBD), and a 
ligand-dependent activation motif (AF2) in the C-terminus (Zhang et al. 2003). It is well 
acknowledged now that FXR forms heterodimer with RXRα and binds to DNA prior to 
ligand binding, mediated by the DBD with the two Zn2+ finger motifs (Modica et al. 2010). 
Our genome-wide FXR chromatin binding results also support this theory (Thomas et al. 
2010). Previous studies obtained from the association of FXR with individual FXR target 
genes and recent genome-wide studies confirmed that FXR/RXR heterodimer mainly 
bind to the IR1 DNA motif (inverted repeat of canonical A/GGG/TCA separated by one 
nucleotide) (Modica et al. 2010, Thomas et al. 2010, Chong et al. 2010). Other FXR 
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response elements (FXRRE) include DR-1 (direct repeat separated by one nucleotide) 
and ER-8 (everted repeat separated by eight nucleotides), etc (Modica et al. 2010). As 
underlined by the moderately conserved sequence, the LBD of FXR presents a classic 
NR structure of a 12-α helix bundle, as well as a hydrophobic pocket suitable for 
accommodating lipophilic molecules such as BAs (Downes et al. 2003). Upon ligand 
binding, the LBD of FXR undergoes conformational changes, which trigger the release 
of common NR corepressors and the recruitment of transcriptional coactivators 
(Downes et al. 2003). Two protein methyl transferase, coactivator associated arginine 
(R) methyl transferase-1 (CARM-1) and protein arginine (R) methyl transferase-1 
(PRMT-1), as well as common NR coactivators, steroid receptor coactivator 1 (SRC-1), 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and 
vitamin D-interacting protein 205 (DRIP-205) have been shown to be FXR coactivators 
(Modica et al. 2010, Savkur et al. 2005, Ananthanarayanan et al. 2004, Rizzo et al. 
2005, Pineda Torra, Freedman and Garabedian 2004, Bauer et al. 2002, Zhang et al. 
2004). Besides modulations by ligands, FXR itself has been shown to be dynamically 
regulated by the protein acetylase p300 and its counterpart sirtuin-1 (SIRT1), a NAD+-
dependent deacetylase (Kemper et al. 2009). Acetylation at residue lysine 217 in the 
hinge region of FXR increases its protein stability, but inhibits its ability to 
heterodimerize with RXRα, resulting in inhibition of DNA binding and subsequent 
suppression of the target genes. 
 
1.1.2 BAs, the Endogenous Ligand of FXR 
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BAs are amphipathic molecules synthesized from cholesterol in the liver by two 
major pathways, the classic and alternative pathways (Russell 2003). The chemical 
structures of major BAs are shown in Figure 1.2. Cytochrome P450, family 7, subfamily 
A, polypeptide 1 (CYP7A1, also known as cholesterol 7 alpha-hydroxylase), which is 
located on the endoplasmic reticulum membrane, is the first and the rate-limiting 
enzyme in the classic pathway (Russell 2003). CYP7A1 and multiple downstream 
enzymes convert cholesterol into cholic acid (CA) and chenodeoxycholic acid (CDCA). 
The alternative pathway is initiated by mitochondrial cytochrome P450, family 27, 
subfamily A, polypeptide 1 (CYP27A1) and followed by cytochrome P450, family 7, 
subfamily B, polypeptide 1 (CYP7B1) to generate CDCA. Therefore, both CA and 
CDCA are primary BAs in humans. While CYP7A1 regulates the total amount of BA, 
cytochrome P450, family 8, subfamily B, polypeptide 1 (CYP8B1, also known as sterol 
12-alpha-hydroxylase) determines the ratio of CA: CDCA in the BA pool and CA is less 
hydrophobic than CDCA. In rodents, most CDCA undergoes hydroxylation at the 6β-
position to form α-muricholic acid (α-MCA) (Russell 2003). α-MCA can be further 
converted to β-muricholic acid (β-MCA) by epimerization of its 7α-OH into 7β-OH 
(Botham and Boyd 1983). Therefore, CA and α- and β-MCA are the major primary BAs 
in rodents. Hepatic BA synthesis is also responsible for a major fraction of daily 
cholesterol turnover in humans.  
Primary BAs then undergo multiple biotransformation steps in the liver and during 
the enterohepatic circulation. Primary BAs are first transformed and activated into CoA-
thioesters by the BA CoA synthase (BACS) in the liver. Activated BAs become the 
substrates for the BA-CoA:amino acid N-acetyltransferase (BAAT) enzymes, which 
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catalyze the glycine or taurine conjugation of primary BAs (Ridlon, Kang and Hylemon 
2006). The conjugation process is highly efficient and the conjugated BAs are referred 
to as “bile salts”. Compared to primary BAs, the bile salts are more hydrophilic, less 
cytotoxic and more readily to be secreted into the bile through the canalicular 
transporting system. Upon postprandial stimulus, BAs are actively secreted from the 
gallbladder through gallbladder contraction into the small intestine, to allow the 
absorption of lipophilic nutrients. In the intestine, BAs undergo a second round of multi-
step biotransformation mediated by the resident gut bacteria (Ridlon et al. 2006). In the 
small and large intestines, bacterial bile salt hydrolases can de-conjugate some bile 
salts into free BAs. In the large intestine, bacterial 7α-dehydroxylase converts CA to 
deoxycholic acid (DCA), and CDCA to lithocholic acid (LCA), respectively, by removing 
a hydroxyl group from C-7 (Figure 1.2). DCA and LCA are termed secondary BAs and 
are highly toxic, mainly due to their high level of hydrophobicity compared to CA and 
CDCA (Figure 1.2). DCA is mainly reabsorbed in the large intestine via passive 
absorption, followed by detoxification in the liver to form taurodeoxycholic acid (TDCA). 
LCA, on the other hand, is mostly sulfated for fecal excretion, and only a small amount 
(~1%) will be passively absorbed. In the liver, LCA undergoes either sulfation or 
hydroxylation to reduce its toxicity. Detoxified LCA will be efficiently secreted into 
circulation for renal excretion. In human liver microsomes, LCA can be hydroxylated to 
form hyodeoxycholic acid (HDCA), murideoxycholic acid (MDCA), and CDCA (Li and 
Chiang 2014).  
Among all the natural BA species in humans and rodents, CDCA has been 
shown to be the most potent FXR activator, mainly due to the optimal interaction 
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between the 7α-OH group of CDCA and FXR LBD (Modica et al. 2010). The EC50 of 
CDCA and its glycol- and tauro-conjugates was shown to be 50 μM and 10 μM for 
murine and human FXR, respectively (Makishima 1999). On the contrary, BAs without a 
7α-OH group, such as DCA and LCA, are more likely to be partial agonist. In addition, 
due to the presence of a 12α-hydroxy group, which cannot accommodate with the FXR 
LBD, CA and DCA actually have relatively low affinity for human FXR (Makishima 1999). 
It is worth noting that FXR LBD is not completely the same between humans and mice. 
The mouse FXR LBD has been found to be much more responsive to CA than the 
human one (Cui et al. 2002). In results, CA becomes more physiological important in 
mice in terms of FXR activation, since CDCA is converted into α- and β-MCA in mice.  
Ursodeoxycholic acid (UDCA), another important natural BA, found 
predominately in bear, is currently the only FDA approved pharmacological therapy for 
the management of cholestasis. And it’s interesting that UDCA has been shown to be a 
very weak FXR agonist (Lew et al. 2004). 
 
1.1.3 Enterohepatic Circulation of BAs 
As illustrated in Figure 1.3, after synthesis and conjugation, primary BAs are 
actively secreted from hepatocytes into the bile canaliculus through trans-membrane 
transporter systems. ATP-binding cassette (ABC) family transporters, bile salt export 
pump (BSEP/ ABCB11) and multidrug related protein 2 (MRP2/ABCC2) are responsible 
for active secretion of monoanionic- and dianionic-conjugated BAs, respectively (Modica 
et al. 2010). BSEP specifically mediates the efflux of BAs while MRP2 also mediates the 
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transport of other organic substrates, such as bilirubin conjugates, glutathione, drugs, 
etc. Other major organic constitutes of bile include phospholipids and cholesterol, which 
form mixed micelles in bile to increase cholesterol solubility as well as to reduce BA 
cytotoxicity to the bile duct and gallbladder. In addition, normal secretion of phospholipid, 
mainly phosphatidylcholine (PC), is required for biliary BA secretion. The efflux of PC is 
mediated by a phospholipid flippase, the multidrug protein 3/2 (MDR3/ABCB4 in 
humans, MDR2/Abcb4 in mice).  
Upon postprandial stimulus, duodenum secretes cholecystokinin (CCK), which 
stimulates gallbladder contraction and the release of BAs into the small intestine. Along 
the small intestinal tract, BAs mainly function as detergents to facilitate the solubilization, 
digestion and absorption of lipophilic nutrients. In the distal ileum, conjugated BAs are 
actively reabsorbed by enterocyte sodium-dependent bile salt transporter 
(ASBT/SLC10A1) (Shneider et al. 1995), while unconjugated BAs are only partially 
absorbed by passive diffusion. After crossing the apical membrane of enterocytes, BAs 
are actively shuttled to the basolateral membrane upon binding to the ileal bile acid 
binding protein (IBABP) (Gong et al. 1994). BAs are then secreted into the portal blood 
through the heterodimeric organic solute transporter α/β (OST-α/β) (Lee et al. 2006). 
Once reaching the basolateral (sinusoidal) membrane of hepatocytes, conjugated and 
free BAs are actively re-absorbed into hepatocytes via Na+-dependent and -
independent mediators, respectively. The Na+-dependent taurocholate transporter 
(NTCP) is specific for the uptake of conjugated BAs, while several organic anion-
transporting polypeptides (OATPs) have substrate specificities for unconjugated BAs, 
including OATP1A2, OATP1B1 and OATP1B3 in humans (St-Pierre et al. 2001).   
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After the enterohepatic circulation, about 90-95% of total BAs are reabsorbed in 
the intestine with around 0.5 g/day of BAs are secreted into the feces. The loss in the 
feces will be replenished by the de novo BA synthesis in the liver. The BA pool size is 
defined as the total amount of BAs in the entire enterohepatic circulation. As mentioned 
earlier, BA compositions in humans and mice are very different. Human BA pool 
consists of about 40% each of CA and CDCA, and 20% DCA, thus is more hydrophobic. 
Mouse BA pool consists about 50% CA and 50% α- and β-MCAs, and is more 
hydrophilic. 
BAs are detergent-like molecules, so accumulation of high levels of BAs, 
especially secondary BAs, can be detrimental. BA cytotoxicity increases linearly with its 
hydrophobic index, with the order of increasing cytotoxicity being UDCA, CA, CDCA, 
DCA and LCA (Figure 1.2). In this regards, the concentration of intra- and extra- cellular 
BAs are regulated in multiple levels under normal physiology to ensure BA homeostasis.  
 
1.1.4 FXR as the BA Sensor 
As a transcription factor, FXR mainly functions to induce and to a much lesser 
extent, suppress the transcription of its direct target genes. The combined effects from 
direct and indirect transcriptional regulation by FXR play a major role in maintaining BA 
homeostasis. By inducing the expression of its target genes, small heterodimer partner, 
(SHP/NR0B2) in the liver, and fibroblast growth factor 15/19 (FGF15 in mice, FGF19 in 
humans) in the intestine, FXR activation indirectly suppresses the expression of 
CYP7A1 and CYP8B1 in the liver (Kong et al. 2012b). Both SHP and FGF15/19 are 
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unique in their corresponding superfamilies. Specifically, SHP, an atypical nuclear 
receptor, lacks the classical NR DNA-binding domain and mainly functions as a 
transcriptional repressor by heterodimeric interaction with various transcriptional 
regulators, including many NRs (Garruti et al. 2012). SHP has been shown to suppress 
the gene expression of CYP7A1 and CYP8B1 by interfering with the transactivation 
activity of liver receptor homolog-1 (LRH-1) in vitro (Goodwin et al. 2000). FGF15/19, 
unlike most FGFs, lacks a heparin-binding site and FGF15/19 acts like hormones and 
binds to the cell surface fibroblast growth factor receptor 4 (FGFR4) to initiate the 
downstream signaling events (Inagaki et al. 2005). Using novel genetic modified mouse 
models, the most recent in vivo studies suggest that the intestinal FXR-FGF15 pathway 
plays a major role in suppressing the gene expression of Cyp7a1, whereas the hepatic 
FXR-SHP pathways is less important for Cyp7a1 suppression in mice (Kong et al. 
2012a). In addition, both pathways are suggested to be critical in suppressing Cyp8b1 
expression (Kong et al. 2012a).  
Following BA synthesis in the liver, FXR regulates BA homeostasis through direct 
targeting. First, FXR regulates BA amidation by positively regulating the gene 
expression of BAAT and BACS (Pircher et al. 2003). Second, FXR activation directly 
induces the expression of BA transporters BSEP (Ananthanarayanan et al. 2001) and 
MRP2 (Kast et al. 2002) to facilitate BA export from the hepatocytes. FXR also directly 
regulates the PC transporter MDR2 (Liu et al. 2003) and the cholesterol transporters 
ATP-binding cassette, sub-family G, member 5 (ABCG5) and ATP-binding cassette 
sub-family G, member 8 (ABCG8) to maintain coordinated biliary secretion of BAs, 
cholesterol and phospholipids (Li et al. 2011). NTCP and OST-α/β are also expressed in 
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the liver, and mediate BA transport across the basolateral membrane. FXR activation 
down-regulates the liver BA uptake transporter NTCP via induction of SHP (Denson et 
al. 2001), as well as by direct up-regulation of OST-α/β to facilitate BA efflux to the 
systemic circulation (Lee et al. 2006). The combined effects of FXR on NTCP and OST-
α/β in the liver help to decrease the intracellular levels of BAs in hepatocytes. In the 
intestine, FXR activation could indirectly suppress the expression of the uptake 
transporter, ASBT, as well as directly induce the sinusoid efflux transporters, OST-α/β, 
to protect the enterocytes from intracellular BAs build-up. The inhibition of ASBT by 
FXR was first shown by induction of SHP after FXR activation in human intestinal cell 
lines (Neimark et al. 2004). Later on, intestinal FGF15/19 was shown to mediate the 
inhibition of ASBT in different human and mouse cell lines as well (Sinha et al. 2008). 
Finally, inside the enterocytes, FXR activation induces IBABP through direct promoter 
binding (Grober et al. 1999).  
Similar to the liver and intestine, FXR also regulates the active transport of BAs 
in the kidney and bile duct. In both sites, ASBT mediates the uptake of conjugated BAs,  
in the canalicular membrane of cholangiocytes and the apical membrane of proximal 
renal tubular cells (Craddock et al. 1998). While multidrug related protein 3 
(MRP3/ABCC3) and OST-α/β are involved in BAs efflux back to bile from 
cholangiocytes in the biliary tract, OST-α/β is responsible for renal secretion of BAs 
back to systemic circulation in the kidney (Ballatori et al. 2005). The proper functions of 
ASBT and OST-α/β could ensure the sensing of normal BA levels in the circulation as 




1.1.5 Cholestasis and FXR  
The coordinated function of the molecular machinaries involved in the 
enterohepatic circulation of BAs maintain the proper levels of intra- and extra- cellular 
BAs to avoid BA cytotoxicity. And disruption of the normal BA homeostasis could lead to 
cholestasis. Cholestasis is defined as the retention of BAs in the hepato-biliary tract 
(Trauner, Meier and Boyer 1998). There are many causes of cholestasis. Depending on 
whether the cause is inside or outside the liver, cholestasis is classified mainly as intra- 
or extra- hepatic. The cause of Extrahepatic cholestasis occurs outside the liver and can 
be caused by bile duct tumors, stones in the common bile duct, pancreatitis, pressure 
on the bile ducts due to a nearby mass or tumor, primary sclerosing cholangitis (PSC), 
etc.. In these cases, the normal bile flow from the gallbladder into the intestine is 
disrupted. Intrahepatic cholestasis occurs inside the liver and can be caused by genetic 
mutations, alcoholic liver disease, bacterial abscess in the liver, total parenteral nutrition, 
lymphoma, pregnancy, primary biliary cirrhosis (PBC), viral hepatitis, etc.. And in these 
cases, the normal bile flow from the liver into the gallbladder is disrupted. Intrahepatic 
cholestasis will be the primary focus in this dissertation. 
Mutations in several genes, which encode the various transporters involved in BA 
circulation as mentioned above, have been linked to a class of genetic diseases, 
progressive familial intrahepatic cholestasis (PFIC). Currently, there are three known 
types of PFIC: PFIC-1, PFIC-2, and PFIC-3. PFIC-2 is linked to mutations in the major 
human BA transporter BSEP, which is also linked to intrahepatic cholestasis of 
pregnancy (ICP) (Song et al. 2014). PFIC-1 and PFIC-3 are linked to the genes 
encoding phospholipids transporters, ATPase, aminophospholipid transporter, class I, 
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type 8B, member 1 (ATP8B1) and MDR3 (ABCB4, MDR2/Abcb4 in mice), respectively 
(Groen et al. 2011). ATP8B1, also called FIC-1, is a P-type ATPase. In complex with the 
accessory protein transmembrane protein 30A (TMEM30A), FIC-1 flips PC from the 
outer to the inner leaflet of plasma membrane, whereas MDR2/3 flops PC in the reverse 
direction (Groen et al. 2011). Deficiency in MDR2/3 leads to the absence of PC in bile. 
PCs function as BA chaperones, preventing BA toxicity to the biliary epithelium. The 
free or "unchaperoned" BAs in the bile of patients with MDR3 deficiency cause 
cholangitis. Therefore, unlike PFIC-1 or PFIC-2, PFIC-3 is associated with markedly 
elevated serum levels of γ-glutamyl transferase (GGT), a marker of biliary injury (Li and 
Chiang 2014). Finally, the inheritance pattern of all these three forms of PFIC is 
autosomal recessive. These genetic disorders underline the importance of these 
transporters involved in the enterohepatic circulation of BAs.  
Clinically, biochemistry and histology examinations are commonly used to 
diagnose cholestasis and identity the etiology. Serum biomarkers of cholestasis include 
elevated levels of total serum bile acids (TSBA), bilirubin, alkaline phosphatase (ALP), 
and GGT (Li and Crawford 2004). Evaluation of these biomarkers alone could not 
provide a definitive diagnosis of the cause of cholestasis. Therefore, histological 
examination of the liver is often required for a more accurate diagnosis. Histological 
markers for cholestasis include bilirubin pigment accumulation that gives hepatocytes a 
reddish brown color, hepatocellular degeneration, bile duct proliferation, the presence of 
inflammatory cells typically in periportal regions, and at later stages, peribiliary fibrosis 
(Li and Crawford 2004).  
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While many genetic and non-genetic causes could lead to cholestatic liver 
diseases, UDCA is currently the only pharmaceutic drug approved by the FDA for the 
treatment of cholestasis regardless of the etiology. Although PBC patients treated with 
UDCA showed an improvement in liver biochemistry, jaundice, and ascites, UDCA did 
not decrease mortality or requirement of liver transplantation (Gong et al. 2008). And 
overtime, if the underlying cause of cholestasis is not resolved, the disease will progess 
to fibrosis, and eventually cirrhosis. 
In this regard, various animal models of cholestasis have been developed to 
study the molecular and cellular pathologenesis of cholestasis, in order to discover 
novel treatment for the disease (Rodriguez-Garay 2003). For intrahepatic cholestasis, 
the most commonly used animal models are genetic deficency-induced, estrogen-
induced, endotoxin-induced and drug-induced cholestasis (Rodriguez-Garay 2003). 
Several genetic engineered mouse models have been developed to mimic the human 
PFICs. Cholestatic liver abnormalities have been recapituated well in mice with deficient 
ATP8B1, BSEP and MDR2 protein, respectively (Shah et al. 2010, Groen et al. 2011, 
Zhang et al. 2012b). Interestingly, the severity of cholestatic disorders in mutant mice 
also depends on the genetic background, i.e., the mouse strains. For both Atp8b1 and 
Abcb11 mutants, C57BL/6J mice have shown greater liver injury than other stains 
(Zhang et al. 2012b, Shah et al. 2010). For extrahepatic cholestasis, common bile duct 
ligation is mostly used. In the later part of this disseration, a special type of intrahepatic 
cholestasis, named parenteral nutrition associated cholestasis (PNAC), will be 
discussed in detail.  
14 
 
The improtance of FXR involved in BA homeostasis and cholestasis has been 
further confirmed by studies using various genetic modified mouse models. Unlike mice 
with deficient ATP8B1 or MDR2, FXR whole body knockout mice (FXR-WBKO) didn’t 
show severe cholestatic phenotypes in early age under normal feeding condition (Sinal 
et al. 2000). Nevertheless, FXR-WBKO mice have elevated levels of serum BAs and 
triglycerides, featuring hepatic steatosis, which eventually lead to spantaneous 
hepatocellular carcinogenesis (Kim et al. 2007). And upon challenge with diet containing 
1% CA, FXR-WBKO mice developed severe hepatotoxicity even with only 5 days of 
treatment (Sinal et al. 2000). Using gain-of-function strategies, recent studies have 
shown that intestinal FXR activation protected mice from both cholestasis and 
spontaneous hepatocellular carcinogenesis (Modica et al. 2012, Degirolamo et al. 2014). 
Modica et al showed that constitutive intestinal FXR activation protected mice against 
obstructive extrahepatic cholestasis following bile-duct ligation or administration of α-
naphthylisothiocyanate (ANIT), as well as intrahepatic cholestasis from MDR2 defiency 
(Modica et al. 2012). As expected, liver damage was further exacerbated in FXR and 
MDR2 double knockout (DKO) mice. Furthermore, they also showed that FGF19 
administration protected the mice from obstructive extrahepatic cholestasis through the 
reduction of total BA pool size without further induction of adaptive hepatic responses 
(Modica et al. 2012). Using similar strategy, by crossing FXR-WBKO mice with intestinal 
specific transgenic iVP16FXR mice, the same group showed that constitutive intestinal 
FXR activation was able to rescue FXR-WBKO mice from BA overload, and to prevent 
hepatocarcinogenesis (HCC) formation by maintaining BA homeostasis via restoration 
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of intestinal FXR-FGF15 signaling, limiting hepatic inflammation and proliferation while 









From left to right: N-terminal activation motif (AF1), DNA binding domain (DBD), hinge 
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Figure 1.3 Enterohepatic Circulation of BAs 
 




1.2 FXR beyond the BA Sensor 
1.2.1 FXR Regulation of Triglyceride/Cholesterol Metabolism 
As mentioned above, FXR-WBKO mouse exhibited a potential proatherogenic 
serum lipoprotein profile (Lambert et al. 2003). In detail, under normal feeding, FXR-
WBKO mice had markedly elevated serum levels of cholesterol, cholesterol esters, 
triglycerides, and phospholipids (Sinal et al. 2000). Besides, serum levels of very low-
density lipoprotein (VLDL), LDL, and high-density lipoprotein (HDL) were increased in 
FXR-WBKO mice. In the liver, hepatic triglyceride levels were also increased 
significantly in FXR-WBKO mice, while hepatic cholesterol levels were similar to control 
mice (Sinal et al. 2000).  
Triglyceride accumulation in our body is mainly derived from two sources, dietary 
absorption in the intestinal tract and de novo synthesis in the liver. In the intestinal 
lumen, dietary triglycerides are emulsified by BAs and then hydrolyzed by lipase, 
generating a mixture of free fatty acids (FAs) and monoglycerides, which then enter into 
the enterocytes where they are re-esterified to form triacylglycerol. The triacylglycerol is 
the major component of chylomiron. After entering the systemic circulation, 
chylomicrons exchange components with HDL to receive apolipoprotein C-II (APOC-II) 
and apolipoprotein E (APOE). APOC-II is the cofactor for lipoprotein lipase (LPL) activity. 
Once the triglycerides are distributed, the chylomicron returns APOC-II to HDL and 
keeps APOE. While chylomiron is mainly responsible for absorption of exogenous lipid 
nutrients, VLDL functions as the internal mechanism of lipid circulation by transporting 
endogenous triglycerides, phospholipids, cholesterol, and cholesteryl esters. Once in 
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the blood stream, VLDL also picks up APOC-II and APOE from HDL. Then VLDL will 
encounter LPL in the capillary beds in the body, which removes triglycerides from VLDL 
for storage or energy production. VLDL then meets HDL again, transferring APOC-II 
back and keeping APOE, whereas HDL transfers cholesteryl esters to VLDL in 
exchange for phospholipids and triglycerides, mediated by the cholesterylester transfer 
protein (CETP). Excessive triglyerides are primarily cleared by FA metabolism through 
β-oxidation. 
FXR activation regulates BA synthesis in the liver, suggesting that FXR activation 
could indirectly regulate lipid emulsion and subsequent triglyceride absorption in the gut, 
leading to increased levels of triglycerides in the body. For de novo synthesis of 
triglycerides, studies have shown that FXR suppresses sterol regulatory element-
binding protein-1c (SREBP-1c) and microsomal triglyceride transfer protein (MTP), 
again through its important target, SHP (Watanabe et al. 2004, Hirokane et al. 2004). 
SREBP-1c is a master transcription factor involved in de novo FA synthesis in the liver, 
and regulates the expression of many critical genes in lipogenesis (Brown and 
Goldstein 2009). MTP is a microsomal transport protein facilitating VLDL efflux from the 
liver (Wetterau, Lin and Jamil 1997). In terms of triglyceride clearance, it has been 
shown that FXR activation could induce APOC-II and syndecan-1 (Kast et al. 2001, 
Anisfeld et al. 2003), whereas suppress APOC-III, angiopoietin-like protein 3 (ANGPTL3) 
and carbohydrate-responsive element-binding protein (ChREBP) (Claudel et al. 2003, 
Watanabe et al. 2004). Syndecan-1 is a transmembrane herpain sulfate proteoglycan 
involved in the clearance of lipoprotein remnants (Anisfeld et al. 2003). Unlike APOC-II, 
APOC-III inhibits LPL and hepatic lipase, therefore inhibiting hepatic uptake of 
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triglyceride-rich particles (Claudel et al. 2003). ANGPLT3, a member of the 
angiopoietin-like family of secreted factors, also inhibits LPL and thus increases plasma 
triglyceride levels. Finally, ChREBP is a glucose-activated transcription factor, which 
induces the expression of hepatic glycolytic and lipogenic genes. In summary, the 
combined effects of FXR activation on these target genes involved in triglyceride 
homeostasis suggest a beneficial role of FXR activation for lowering the plasma 
triglyceride levels. 
The role of FXR modulation in cholesterol homeostasis has been studied 
extensively as well. In FXR-WBKO mice, serum cholesterol levels increased 
significantly, whereas hepatic cholesterol levels were not (Sinal et al. 2000). A follow-up 
study showed more detailed plasma cholesterol profiles in these mice. 1st, FXR-WBKO 
mice had increased plasma HDL levels and markedly decreased plasma HDL 
cholesterol ester clearance. 2nd, FXR-WBKO mice had increased plasma non-HDL 
cholesterol and APOB-containing lipoprotein synthesis. 3rd, intestinal cholesterol 
absorption was elevated in FXR-WBKO mice. 4th, biliary cholesterol elimination was 
also increased in FXR-WBKO mice (Lambert et al. 2003). It was first shown in this study 
that FXR-WBKO mice exhibited reduced expression of hepatic genes involved in 
reverse cholesterol transport (RCT), especially scavenger receptor B1 (SR-B1). In the 
liver, SR-B1 mainly functions in facilitating the uptake of cholesteryl esters from 
circulating HDLs. This process drives the transport of cholesterol from peripheral tissue 
towards the liver for fecal excretion and is defined as the RCT. RCT is a protective 
mechanism against the development of atherosclerosis. Several studies have confirmed 
that FXR activation would induce the gene expression of mouse Sr-b1 (Zhang et al. 
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2006a, Zhang et al. 2010, Chao et al. 2010). A most recent study confirmed that FXR 
directly regulates Sr-b1 gene expression via intron binding (Li et al. 2012b). In terms of 
cholesterol secretion, BA activation of FXR was shown to induce the levels of ABCG5 
and ABCG8 in mouse livers, through a common FXRRE located in the intergenic 
promoter shared by Abcg5 and Abcg8 (Li et al. 2011). Using HepG2 cells, it was shown 
that FXR activation could repress the gene expression of the proprotein convertase 
subtilisin/kexin type 9 (PCSK9). PCSK9 is a recently discovered LDL receptor (LDLR) 
inhibitor, which binds to the epidermal growth factor-like repeat A (EGF-A) domain of 
the LDLR, resulting in LDLR degradation and decreased clearance of LDL cholesterol. 
Therefore, PCSK9 inhibition has been proposed to be a powerful weapon to lower LDL 
cholesterol levels (Steinberg and Witztum 2009). 
On the contrary, using DKO strategies, studies have shown that FXR deficiency 
actually reduced the development of atherosclerosis in LDLR-KO mice and/or APOE-
KO mice (Zhang et al. 2006b, Guo et al. 2006). In line with this, guggulsterone 
[4,17(20)-pregnadiene-3,16-dione], a nature product extracted from the resin of guggul 
tree, was shown to decrease LDL cholesterol in humans (Urizar et al. 2002). 
Guggulsterone was shown to be a highly effective antagonist of FXR (Urizar et al. 2002). 
The same year, another study showed that FXR activation could suppress APOA-I 
production in mice (Claudel et al. 2002). APOA-I is the major protein component of HDL 
in plasma. Overall, FXR activation in the liver induces SR-BI to enhance HDL uptake, 
whereas suppresses APOA-I to lower HDL production. In genetic deficient animal 
atherosclosis models, additional KO of FXR could help alleviate the desease 
progression during intial disease development. But in long-term high fat fed mice, FXR 
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deficiency caused hypertriglyceridemia may override the beneficial effects and further 
amplify the desease progression due to high fat feeding itself. While the research about 
FXR and cholesterol homeostasis from different animal models is still under debate (Li 
and Chiang 2014), more patients guided translational studies may provide better 
understanding of the function of FXR in humans. 
 
1.2.2 FXR Regulation of Glucose Metabolism 
The role of FXR in controling glucose homeostasis has also been studied 
extensively (Modica et al. 2010, Li and Chiang 2014).In diabetic mouse models, 
activation of FXR represses the expression of the genes encoding three rate-limiting 
enzymes involved in gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK), 
glucose-6-phosphatase (G6Pase) and fructose 1, 6-bis phosphatase (FBP1) (Cariou et 
al. 2006, Ma et al. 2006). Consistently, FXR-WBKO mice had elevated levels of 
circulating and muscle free FAs (Ma et al. 2006), whereas FXR activation decreased 
free FA levels and increased insulin sensitivity in mice (Zhang et al. 2006a). Another 
important FXR target, FGF15/19, has been shown to repress hepatic glucose 
production and promote glycogen synthesis, without induction of lipogenesis (Kir et al. 
2011). FGF15 defient mice failed to properly maintain blood concentrations of glucose 
and normal postprandial synthesis of liver glycogen. It was shown that FGF15/19 
downregulated the expression of genes involved in gluconeogenesis through 
dephosphorylation and inactivation of the transcription factor cAMP regulatory element-
binding protein (CREBP) (Kir et al. 2011). This in turn decreased the expression of Pgc-
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1α and other genes involved in hepatic glucose metabolism. Translational studies 
further showed that patients with non-alcoholic fatty liver disease (NAFLD) and/or 
insulin resistance had decreased levels of fasting FGF19 or impaired response to 
FGF19 signaling (Schreuder et al. 2010, Wojcik et al. 2012). In line with these studies, 
FXR activation in mice was associated with decreased free FA levels and increased 
insulin sensitivity (Zhang et al. 2006a). These studies linked FXR indirectly with glucose 
homeostasis, mainly through FXR-SHP, FXR-FGF15/FGF19, FXR-BAs pathways.  
In addition, most recent studies also implicate a direct regulation between FXR 
and glucose homeostasis. It was shown that glucose flux in hepatocytes could regulate 
FXR through direct post-translational modification (Berrabah et al. 2014). In this study, 
FXR was shown to interact with and be O-GlcNAcylated by O-GlcNAc transferase in its 
N-terminal AF1 domain. Increased FXR O-GlcNAcylation enhanced both FXR gene 
expression and protein stability. Elevated glucose levels thus increased FXR O-
GlcNAcylation, its protein stability and transactivational activity. In fast-refed mice, FXR 
was undergone O-GlcNAcylation in fed conditions, which was associated with increased 
expression of direct FXR target genes and decreased liver BA content (Berrabah et al. 
2014). In other studies, FXR was found to be expressed in both human and murine 
pancreatic β cells and may be involved in glucose-dependent insulin secretion (Popescu 
et al. 2010, Renga et al. 2010, Dufer et al. 2012), while the underlying mechanism is still 
under investigation. 
 
1.2.3 FXR in Tumorigenesis and Liver Regeneration 
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As mentioned above, FXR is critically involved in BA, lipid and glucose 
metabolism, so it is not surprising that animals with FXR modulation are used to study 
tumorigenesis. However, only until seven years after the initial report of FXR-WBKO 
mice, it was first reported that FXR deficiency would lead to spantaneous HCC 
formation (Kim et al. 2007). In detail, at 12 months of age, both male and female FXR-
WBKO mice showed a high prevalence of degenerative hepatic lesions, altered cell foci 
and liver tumors, including hepatocellular adenoma, carcinoma and 
hepatocholangiocellular carcinoma. At 3 months of age, FXR-WBKO mice had 
increased mRNA levels of the proinflammatory cytokine interleukin-1beta (IL-1β) and 
elevated protein levels of β-catenin and its target c-myc. Cell proliferation was also 
increased in these mice. Once again, FXR-dependent and independent pathways were 
speculated to play a role in the HCC formation. As mentioned earlier, combining FXR-
WBKO and transgenic expression of FXR specifically in the intestine, Degirolamo et al 
showed that intestinal FXR re-activation was enough to prevent the spontaneous HCC 
formation in the FXR-WBKO background (Degirolamo et al. 2014). In detail, intestinal 
selective FXR re-activation normalized the enterohepatic circulation of BAs by up-
regulation of the FXR-FGF15 signaling cascade and subsequent reduction of hepatic 
BA synthesis in FXR-WBKO mice. In addition, cellular proliferation and hepatic 
inflammation were also attenuated in these mice, indicated by reduced levels of 
cyclinD1 and signal transducer and activator of transcription 3 (STAT3) activation, 
respectively. These findings suggest, once again, the beneficial role of selective 
activation of intestinal FXR versus hepatic FXR against liver damage. 
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Similar to HCC formation, normal liver re-growth is also critically linked with intact 
FXR function.  Huang et al first showed that FXR-dependent BA signaling is critical for 
liver regeneration after 2/3 partial hepatectomy (PHX) (Huang et al. 2006). PHX has 
been commonly used as a model to study liver regeneration since it was first 
introducted in rodents in 1931 (Higgins and Anderson 1931). The entire process of PHX 
and liver regeneration consists of several well-orchestrated phases, starting with rapid 
induction of proliferative factors activating the quiescent hepatocytes and priming their 
subsequent proliferation, followed by re-establishment of normal liver size, and finally 
the re-established quiescence. Later on, using albumin promoter drived hepatocyte-
specific FXR KO (FXR-hepKO) mice, Borude et al showed that deficiency of hepatic 
FXR did not completely inhibit but delayed liver regeneration after PHX (Borude et al. 
2012). The overall lanscape of liver regrowth in FXR-hepKO mice was unaffected, 
whereas a delay in peak hepatocyte proliferation from day 2 to day 3 after PHX was 
observed. Moreover, decreased levels of cyclin D1 and its association with cyclin-
dependent kinase 4 (CDK4) were detected in FXR-hepKO mice after PHX compared to 
control mice, correlating with decreased phosphorylation of the retinoblastoma (Rb) 
protein and eventually, delayed cell proliferation in the livers. In the mean time, another 
paper further showed that induction of forkhead box protein m1b (FOXM1B) was 
dramatically reduced in FXR-hepKO mice, but not affected in enterocytpe specific FXR 
KO (FXR-entKO) mice after liver injury (Zhang et al. 2012a). Together these data 
indicate the requirement of a cell autonomous mechanism for hepatic FXR to activate 
FOXM1B and potentially other factors that are critically involved in regulating cell cycle 
in the liver. Detailed profiles of liver regeneration/repair after PHX in FXR-entKO mice 
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were presented in the later study (Zhang et al. 2012a). As expected, defective liver 
regeneration were observed in FXR-entKO mice in either PHX model or CCl4-induced 
liver injury model (Zhang et al. 2012a). In addition, induction of intestinal FGF15 was 
blocked in FXR-entKO mice. Finally, ectopic expression of FGF15 rescued the defective 
liver regeneration in both FXR-entKO and FXR-WBKO mice. It was proposed that the 
protective roles of FGF15 in these liver injury models was resulted from not only its 
important role in maintaining BA homeostasis, but also its mitogenic activities. Indeed, 
mice with FGF15 deficiency (FGF15-KO) showed marked liver injury and mortality after 
PHX (Uriarte et al. 2013). Protein abundance of CYP7A1 increased dramatically during 
early phase of liver regeneration after PHX (6 to 24 hours (hrs)) in FGF15-KO mice, 
resulting in persistent elevation of intrahepatic BA levels. Treating the FGF15-KO mice 
with adenovirally delivered FGF15 or BA sequestrant cholestyramine dramatically 
reduced hepatic BA levels and significantly prevented the lethal outcome from PHX 
(Uriarte et al. 2013). In addition, adenoviral-FGF15 treatment also reduced mortality 
after extensive PHX in WT littermate control mice. While CA feeding in WT mice 
induced liver injury, proliferation of hepatocytes and cholangiocytes was significanlty 
reduced in CA-fed FGF15-KO mice. Kong et al further showed that FGF15-KO mice 
had much weaker activation of those important signaling pathways involved in liver 
regeneration after PHX, including STAT3, nuclear factor-kappa B (NF-kB), and mitogen-
activated protein kinase (MAPK) signaling pathways (Kong et al. 2014). In WT mice, 
PHX induced the expression of many immediated-early responses genes and growth 
factors at early time points (10min and 30min) after PHX. However, the induction of 
these genes in the liver was reduced or delayed in the FGF15-KO mice. In summary, 
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both hepatic and intestinal FXR are critical for liver regeneration/repair. It is also 
important to note that FGF19 is generally considered as a tumor promoter and FGF19 
has been shown to regulate and promote the proliferation of liver cells (Desnoyers et al. 
2008). 
 
1.2.4 Genome-wide Study of FXR in Mice 
Other than the critical roles of FXR involved in BA, lipid and glucose homeostasis, 
it is suggested that FXR activation may also play a role in anti-inflammation by 
antagonizing the NF-kB signaling in the liver (Wang et al. 2008). To this point, the roles 
of FXR plays in many cellular processes have been studied in depth. And in order to 
comprehensively understand the functions of FXR in a genome-wide scale, chromatin 
immunoprecipitation coupled with massive parallel DNA sequencing (ChIP-seq) was 
first performed for FXR, in mouse livers and intestines in our laboratory (Thomas et al. 
2010). This study first showed the globally tissue specific FXR binding, with only 11% of 
total binding sites shared between mouse livers and intestines. FXR binding sites were 
widely distributed in upstream (defined as 0-10 kilobase (kb) upstream of transcription 
start site (TSS) of the associated RefSeq gene), intragenic, downstream (0-10 kb 
downstream of 3’ end of the gene), and intergenic of the genes retrieved. Novel binding 
sites were identified within known FXR target genes. Novel and tissue specific FXR 
binding motifs were also discovered, indicating possible involvement of tissue specific 
chromatin modifications and transcription factors in modulating FXR function. Finally, 
pathway analysis obtained from the Database for Annotation, Visualization and 
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Integrated Discovery (DAVID), indicates a much wider roles of FXR in cellular 
metabolism than previously appreciated (Thomas et al. 2010). The same year, using 
similar technique, another genome-wide study also showed the existence of a 
asymmetric IR1 motif for FXR binding, and the involvement of LRH-1 in co-regulating 
several FXR target genes (Chong et al. 2010). Two years later, genome-wide study for 
LRH-1 in the liver were reported by the same group (Chong et al. 2012). This study 
extended the co-regulation of FXR and LRH-1 in lipid metabolism in a global scale. 
Furthermore, genome wide co-regulation of FXR and hepatocyte nuclear factor 4 alpha 
(HNF4α) were reported (Thomas et al. 2013). In this study, FXR was found to have 
direct protein-protein interaction and cooperative binding with HNF4α. And genes co-
bound by the two NRs were highly enriched in the pathways of complement and 
coagulation cascades, and drug metabolism. These studies add another level of 
complexity involved in FXR function, pathway specific coordination/modulation of FXR 
transactivation. Finally, studies of genome-wide binding sites of hepatic FXR in both 
healthy and dietary obese mice suggest that FXR-binding sites are likely functionally 
inactive in obesity (Lee et al. 2012). Among the binding sites detected, a large 
proportion were found to be unique in healthy or obese mice. Most surprisingly, direct 
gene repression by FXR activation was suggested to be common, when increased 
occupanies of FXR and RXRα to the selected FXR target genes were correlated with 
decreased expression levels of those genes. And the authors suggest that FXR could 
mediate direct gene repression by binding to the DNA as a FXR/RXRα heterodimer or 
as a FXR monomer or homodimer (Lee et al. 2012). In summary, genome-wide studies 
of NRs not only revealed the global picture of their global gene regulation network, but 
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also could lead to the discoveries of novel and complex underlying mechanisms of how 
they function. 
 
1.3 Parenteral Nutrition Associated Liver Diseases 
1.3.1 Parenteral Nutrition and the Associated Liver Diseases 
Most recently, FXR was shown to play an important role in a special type of liver 
disease, parenteral nutrition associated liver disease (PNALD), especially PN 
associated cholestasis (PNAC) in neonates (El Kasmi et al. 2013). Parenteral nutrition 
(PN), also known as intravenous feeding, which was first introduced by Dudrick et al in 
1967 (Dudrick et al. 1968), is a method to obtain nutrition into the body through the 
veins. PN is mainly used for patients who cannot or should not obtain their nutrition 
through eating, and therefore is essential for them to maintain nutritional status and/or 
growth. To replace the enteral route of feeding, PN normally contains a combination of 
nutrients, including carbohydrates (dextrose) for energy, proteins (amino acids), lipids 
(fat), electrolytes, and trace elements. In 2002, a statement from the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK) summarized that 20,000 patients 
in the United States were supported by PN due to intestinal failure 
(www2.niddk.nih.gov/NR/rdonlyres/9CCC34A3-3CFE-4D89-93DF-1ADEE3AA3E32/ 
0/DDICC_June_25_2002_Minutes.pdf). Without PN therapy, patients with intestinal 
failure mostly died from malnutrition (Dorney et al. 1985). However, long-term PN 
feeding will lead to a spectrum of hepatobiliary diseases, including cholestasis, steatosis, 
fibrosis, and end stage liver complication, cirrhosis, summarized as PNALD (Kumpf 
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2006). Among these, there are 3 major types of PN associated hepatobiliary disorders: 
steatosis, cholestasis, and gallbladder sludge/stones, while overlap can exist (Kumpf 
2006). As mentioned in the 1st and 2nd parts of this chapter, FXR is critically involved in 
all these three clinical conditions. Therefore, these three abnormalities will be the 
primary focus in this 3rd part. 
Like other liver diseases, liver functional tests (LFTs) are normally used to 
assess the liver health/damage in PNALD patients. LFTs are a range of blood tests that 
provide information about liver health. Common serum biomarkers tested include 
activities of liver enzymes, such as alanine transaminase (ALT), aspartate transaminase 
(AST), ALP and GGT, as well as levels of albumin, bilirubin (direct and indirect), 
prothrombin time (PT), and activated partial thromboplastin time (aPTT), etc. Elevated 
levels of these serum markers are associated with potential damage to the hepatobiliary 
tract. Among these, albumin is specifically made in the liver. ALT and AST are mainly 
made by the parenchymal cells. Very smaller amounts of ALT are also present in the 
heart, kidneys, muscles, and pancreas, whereas AST is also found in red blood cells 
(RBCs), cardiac and skeletal muscles. Therefore, ALT and AST are not specific to the 
liver. The ratio of AST to ALT is sometimes useful in differentiating the causes of liver 
injury. If both elevated amounts of ALT and AST are found in in the blood, liver damage 
is most likely present. ALP is an enzyme mainly found in the cells lining the biliary ducts, 
also in bone and placental tissues. Measurement of bilirubin includes both unconjugated 
(indirect) and conjugated (direct) bilirubin. Unconjugated bilirubin is generated by the 
normal breakdown of heme, which is a part of hemoglobin in the RBC. Unconjugated 
bilirubin in the blood is taken up into hepatocytes, and is highly insoluble in water. 
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Therefore, it is made water-soluble by UDP-glucuronyl-transferase (UGT) in the liver 
and subsequently secreted into bile, which is mediated by the ATP-dependent 
transporter MRP2. Accumulation of bilirubin or the conjugates in the body causes 
jaundice. High levels of free, unbound bilirubin are especially toxic to newborns as it can 
pass through the partially developed blood brain barrier (BBB), causing bilirubin 
encephalopathy, which can result in permanent neurological damages in the newborns. 
GGT is a critical enzyme that is present in the cell membranes in many tissues. PT and 
aPTT are parameters of the blood coagulation cascades associated with normal liver 
function since coagulation factors are predominantly produced in the liver. These tests 
and liver biopsies followed by histological exams are the major clinical assessments to 
analyze the development and progression of PNALD, as well as many other liver 
diseases. 
PN associated steatosis, or hepatic fat accumulation, is found predominantly in 
adults and is generally benign (Kumpf 2006). Mild to moderate elevations of serum 
transaminase levels are commonly seen, with less pronounced elevations of serum ALP 
and bilirubin concentrations. Elevations of these serum biomarkers generally occur 
within 2 weeks after patients start to receive PN therapy and may return to normal even 
when PN therapy is continued (Kumpf 2006). Most adult patients are asymptomatic. 
Overfeeding may be the cause of steatosis and is therefore likely not as common now 
because the estimated calorie requirements for PN have decreased accordingly 
compared to the practices in more than 15 years ago (Kumpf 2006). Though steatosis is 
generally considered as a non-progressive lesion, long-term PN may lead to the 
progression to fibrosis or even cirrhosis (Craig et al. 1980, Cavicchi et al. 2000). The 
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prevalence of liver diseases in adults was evaluated in a group of 90 patients enrolled 
from 1985 to 1996, receiving home PN due to permanent intestinal failure in France 
(Cavicchi et al. 2000). Among them, 57 patients had liver biopsies followed by 
histological evaluations. The Kaplan-Meier method was used to determine the 
occurrence of chronic cholestasis and other PNALDs (bilirubin level ≥ 60 µmol/L [3.5 
mg/dL], portal hypertension, liver encephalopathy, ascites, gastrointestinal bleeding, 
and histologically identified fibrosis or cirrhosis). Analyzed results showed that 65% 
patients (58) developed chronic cholestasis (median duration of PN was 6 months with 
the range from 3 to 132 months), and 41.5% (37) developed complicated PNALDs 
(median duration of PN was 17 months with the range from 2 to 155 months) (Cavicchi 
et al. 2000). Among these, extensive fibrosis was found in 17 patients (median duration 
of PN was 26 months with the range from 2 to 148 months) and cirrhosis was found in 5 
patients (median duration of PN was 37 months with range from 26 to 77 months). The 
prevalence of PNALDs was 26% ± 9% after 2 years and 50% ± 13% after 6 years of 
home PN therapy, respectively. Among all patients with PNALD, 6 died from liver 
diseases. Multivariate analysis showed that chronic cholestasis was significantly 
associated with a PN-independent risk for liver disease (for example, alcohol use or viral 
hepatitis), a bowel remnant shorter than 50 cm in length, and infusion of lipid content 
equal to or more than 1 g/kg of body weight per day (g/kg/day). Complicated home 
PNALD was significantly associated with chronic cholestasis and infusion of lipid 
content equal to or more than 1 g/kg/day. Despite that the number of total patients 
enrolled in this study is relatively small plus 15 of them had pre-existing risks for liver 
diseases, the study did show a strong implication that liver complications were common 
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in patients receiving long-term PN therapy. In addition, pre-existing risk factors for liver 
diseases increased the risk for PNALD, leading to increased risk for progression to 
severe liver disorders.  
PN associated cholestasis (PNAC) is a special type of cholestasis occurs 
predominantly in children but may also occur in adult patients after receiving long-term 
PN as mentioned above (Peyret et al. 2011). PNAC is defined as cholestasis in the 
setting of PN therapy once all other causes of cholestatic liver diseases have been 
excluded (Kumpf 2006). Elevated concentration of serum conjugated bilirubin is typically 
considered as the primary indicator of cholestasis in clinics, defined as the 
concentration > 2 mg/dL. Elevated concentrations of serum ALP and GGT are often 
present in cholestasis as well, whereas serum ALT and AST may or may not be 
elevated. ALP and GGT are sensitive markers for hepatobiliary diseases, but not as 
specific as conjugated bilirubin. The prevalence of PNALD in neonates was well 
documented in one particular large historic cohort study published in 2007 (Christensen 
et al. 2007). From 2002 to 2006, a total of 1366 neonatal patients received PN therapy 
for ≥ 14 days in the neonatal intensive care unit (NICU) in the Intermountain Healthcare 
system. The incidence of PNALD increased along with prolonged PN duration. In detail, 
the incidence of PNALD in neonates receiving PN were 14% for 14-28 days, 43% for 
29-56 days, 72% for 57-100 days, and 85% for >100 days of PN therapy. Highest risk 
factors for developing PNALD in these patients include low birth weight (<750 g), 
gastroschisis and jejunal atresia. Among patients who developed PNALD, death rate 
after 28 days of PN therapy was much higher in those who had the highest serum levels 
of conjugated bilirubin and liver transaminase (p<0.0001) (Christensen et al. 2007). 
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Combining liver biopsies and LFTs, a subsequent study reported additional risk factors 
for neonatal populations receiving long-term PN (Peyret et al. 2011). Between January 
1998 and December 2007, 42 infants received PN for more than 2 years in an approved 
home parenteral center in France (Peyret et al. 2011). The median age of PN onset was 
1.5 ± 0.5 (SEM, standard error of the mean) years, and the median duration of PN was 
7.9 ± 0.8 (SEM) years. None of these patients died from hepatic complications or from 
direct complications of PN. Among them, 24 patients (57%) developed biochemical 
abnormalities in a median length of 2.9 ± 0.4 (SEM) years after commencement of PN 
therapy. Risk factors for biochemical abnormalities identified were younger age when 
PN therapy initiated, longer duration of PN, higher rate of catheter-related infections, 
and higher volume and calorie content of PN. It is also important to note that the 
reported median frequency of catheter-related infections was 1.1 ± 0.2 (SEM) infections 
per patient per year of PN, which corresponded to a high incidence of 7.5 ± 1.2 (SEM) 
infections for each patient during the entire PN duration. 43% of patients with median 
age of 3.2 ± 0.9 years had undergone liver biopsies. Histological analysis revealed high 
incidence of liver fibrosis in these children (94%), which was significantly associated 
with a shorter bowel remnant and a longer duration of PN therapy. While the only risk 
factor identified for cholestasis was the percentage of total energy intake from lipid 
contribution, no risk factor was identified for steatosis (Peyret et al. 2011). Unpublished 
data from follow-up histological studies mentioned in the paper also revealed critical 
indications: steatosis was stable or decreased during the 10-year period for most 
patients; cholestasis primarily depended on individual patient with large variety; and 
most strikingly, fibrosis was stable or increased but never showed any sign of decrease 
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(Peyret et al. 2011). In line with this finding, another study aiming to define predictive 
factors for the progression of PN associated liver fibrosis (PNALF) for children with short 
bowel syndrome (SBS) concluded that, biochemically confirmed cholestasis (direct 
bilirubin ≥ 2 mg/dL) could not reflect the presence or degree of biopsy-confirmed PNALF 
(Fitzgibbons et al. 2010). In summary, all these studies suggested that after discharge 
from PN therapy, follow-up with refined diagnosis and hepato-protective management 
should be performed routinely for the identified high-risk populations (Fitzgibbons et al. 
2010). 
Finally, prolonged gallbladder stasis after long-term PN therapy may progress 
into gallbladder sludge or gallstones, with subsequent development of cholecystitis 
(Kumpf 2006). Cholecystectomy, due to cholecystitis, is generally considered as 
detrimental and not recommended for patients receiving long-term PN due to intestinal 
failure (Sitzmann et al. 1990). Formation of gallbladder sludge/stones can occur in both 
adult and pediatric patients and is generally considered to be associated more with the 
lack of enteral stimulation than PN itself (Kumpf 2006). As mentioned before, entero-
hormone CCK is responsible for mediating gallbladder contraction and BA secretion 
upon postprandial stimulus. Therefore, the lack of oral stimulus during PN therapy will 
lead to decreased release of CCK and impaired bile flow and gallbladder contractility. It 
has been reported that CCK secretion decreased significantly in severe SBS patients 
receiving long-term PN, even after the stimulation from a liquid diet (Ling et al. 2001). It 
was first reported in a well-designed, randomized, double-blind controlled study, that 
intravenous administrations of cholecystokinin-octapeptide (CCK-OP) prevented the 
formation of biliary sludge in adult patients receiving long-term PN (Sitzmann et al. 
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1990). In this study, patients who had received PN therapy for more than 21 
consecutive days were recruited. For each patient, ultrasound was performed weekly 
followed by a final volume and empty assessment of the gallbladder in response to the 
assigned treatment. The study was concluded even after randomization of 15 of the 
total patients, as statistical significance was achieved (Sitzmann et al. 1990). Ultrasound 
showed that none of the patients in CCK-OP group developed sludge whereas 5 of the 
8 patients in the placebo group had sludge (p-value ≤ 0.02). In addition, volume and 
emptying studies showed significant contraction of the gallbladder in patients receiving 
intravenous CCK-OP but not saline control (Sitzmann et al. 1990). However, the same 
type of treatment didn’t reach significant improvement in a later trial with neonatal 
patients (Tsai et al. 2005). PN associated gallstones were detected in 10% of children in 
the study, while most were asymptomatic. CCK-OP prophylaxis was shown ineffective 
in preventing gallstone formation in children receiving long-term PN (Tsai et al. 2005). In 
addition, UDCA was shown also ineffective for dissolving gallstones in these patients, 
once detected (Tsai et al. 2005).  
 
1.3.2 Etiology and Management of PNALD 
Intestinal Failure and Lack of Enteral Stimulation 
It is well accepted now that the most effective treatment for PNALD is enteral 
stimulation, even in a very small amount (Ziegler and Leader 2006). It is suggested that 
the underlying mechanisms may involve the induction of endogenous gut mucosal 
growth factors, increased splanchnic blood flow, stimulation of enterohepatic circulation 
38 
 
and subsequent BA homeostasis, and several others (Ziegler and Leader 2006, Kumpf 
2006).  Nevertheless, for patients with permanent intestinal failure, clinical management 
is still challenging. The cause of intestinal failure related to PNALD can be divided into 
two major categories: 1st, actual or effective decrease of the gut mucosal surface area, 
such as massive small bowel reduction caused SBS; 2nd, diseases of gut mucosal, such 
as inflammatory bowel disease (IBD) (Ziegler and Leader 2006). As discussed, shorter 
length of bowel remnant due to intestinal failure is associated with higher risk of 
developing PNALD, in both adult and pediatric patients. Unfortunately, patients with 
SBR are dependent on long-term PN and options are very limited when liver failure 
happens, after which combined liver and bowel transplantations are often required. 
 
Prematurity and Low Birth Weight 
As mentioned, PNAC is predominantly found in neonates. In one PN study 
involved in 62 premature newborns with birth weight less than 2,000 g, cholestasis was 
identified in 50% of the newborns with very low birth weight < 1000 g, but only 7% if 
birth weight was > 1500 g (Beale et al. 1979). On one hand, prematurity and/or low birth 
weight may be independent or associated risk factors for PNALD, since many neonates 
demanding PN therapy are those with prematurity and low birth weight. Though it is well 
accepted now that longer duration of PN will lead to higher incidence of PNALD, no 
correlation was found between the duration of PN therapy with the onset of cholestasis 
in this study (James, Hendry and MacMahon 1979). On the other hand, the immature 
neonatal liver may be the bona fide reason for the increased incidence of PNAC since 
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jaundice and temporary elevation of serum indirect bilirubin levels are commonly found 
even in more than half of the full-term babies. In preterm infants, the enterohepatic 
circulation is not well-established as reflected by diminished levels of both hepatic 
uptake and synthesis of BAs (Kumpf 2006). In this regard, BA cytotoxicity may not be 
the direct cause of the so called PNAC, indicated by jaundice and elevated serum levels 
of direct bilirubin. It is possible that the hepatic system for bilirubin metabolism and/or 
transport is not fully functional in these preterm infants. It is also suggested that the 
premature liver is more susceptible to BA cytotoxicity due to the reduced rate of 
sulfation of primary and secondary BAs (Kumpf 2006). In this regard, maintaining and/or 
improving normal liver development could be a putative and more direct therapeutic 
strategy for PNALD management. 
 
Infections 
There are two major causes of infections in patients receiving long-term PN: 1st, 
sepsis due to bacterial and/or fungal infection related to the central venous catheter 
system; 2nd, bacterial overgrowth in the small intestine (Kumpf 2006). Bacterial and 
fungal infections are highly associated with PNAC (Kumpf 2006). Jaundice and elevated 
serum concentration of total bilirubin can occur within several days after the initial insult 
from infection (Kumpf 2006). Endotoxins, such as bacterial lipopolysaccharide (LPS), 
could activate liver Kupffer cells to stimulate the release of pro-inflammatory cytokines 
in the liver, leading to systemic liver inflammation and exacerbating PNALD. Good 
clinical practice is needed to minimize catheter related infections. It is also important for 
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the patients to maintain proper handling and aseptic techniques, as well as minimize 
manipulations of the catheters in home PN settings.  
Small intestine bacterial overgrowth (SIBO) occurs when large amounts of 
resident bacteria in the lower small intestine and/or colon colonize the upper small 
intestine. Reduced enterohepatic circulation caused by SBS, and intestinal stasis 
caused by motility abnormalities such as chronic intestinal pseudo-obstruction, 
predispose PN patients to SIBO (Kumpf 2006). It is suggested that the bacteria 
originated from the lower bowel and colon may produce and retain hepato-toxins in the 
small intestine, such as LCA, which is predominantly found in the large intestine and 
readily excreted into feces under normal conditions. Intestinal stasis and/or dysplasia 
could also lead to bacterial translocation and subsequent release of endotoxins into the 
portal vein, causing hepatic inflammation. 
 
Cycling of PN  
Cyclic PN infusion is common in the current clinical practice due to two major 
reasons. First, it’s more convenient for the patients, especially long-term, to receive the 
infusion in the evening during their sleep, as well as to maintain their regular physical 
activity during the daytime. Second, it has been shown that continuous PN infusion was 
associated with hyperinsulinemia and fat deposition in the liver, leading to steatosis and 
increased risks for the development of other liver complications (Kumpf 2006). In 




Basic PN Components and Improvements  
 Since PN was first introduced into clinic, many side effects, which are associated 
with the lack or excess of certain nutrients in the PN formulations, have been reported. 
And over the course of more than 50 years of clinical practice, many PN related 
abnormalities due to nutrient deficiency/overload have been resolved. Early dextrose-
based PN formulations, which contain little or no fat, were implicated in the development 
of PN associated steatosis (Kumpf 2006). Dextrose-based PN formulation may lead to 
the development of essential FA deficiency (EFAD), which not only will impair normal 
neurodevelopment but may also lead to impaired lipoprotein production and triglyceride 
secretion (Kumpf 2006). Thus, excessive carbohydrates in the dextrose-based PN may 
induce lipogenesis and subsequent fat deposition in the liver. The combined effect could 
result in hepatic steatosis. In line with this, later studies suggested that excess calorie 
intake, either individual or combined, regardless of source (dextrose, fat, amino acid, 
etc.), could contribute to the development of PN associated steatosis (Kumpf 2006). It is 
suggested that overfeeding, regardless of the type of nutrient in PN, could stimulate 
insulin release followed by induction of lipogenesis and suppression of FA oxidation 
(Kumpf 2006). 
Amino acid components in early PN were derived from protein hydrolysates. 
Later clinical studies found significant aluminum contamination in this type of protein 
source (Klein et al. 1984). Animal studies also linked high levels of aluminum 
contamination to the development of cholestasis (Kumpf 2006). In this regard, protein 
hydrolysates were subsequently replaced by crystalline amino acid, which though 
doesn’t contain cysteine and taurine in the standard formulation. In adults or older 
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infants, cysteine and taurine can be synthesized from methionine but not in the 
premature infants. As mentioned before, taurine is critically involved in BA conjugation 
and solubilization. In early clinic practice, taurine deficiency was indeed found in 
premature infants, as well as both pediatric and adult patients after long-term PN 
therapy (Geggel et al. 1985). In these patients, taurine deficiency may contribute directly 
to the development of PNAC. In one study mentioned earlier, which was designed to 
assess the potential beneficial effect of CCK-OP in PNALD patients (Tsai et al. 2005), 
the potential beneficial effect of taurine supplementation in PN was also evaluated. 
Using multivariate analysis, taurine supplementation was shown to reduce the incidence 
of PNAC, with markedly and significantly decreased serum levels of conjugated bilirubin 
in preterm infants (p-value < 0.07) and in infants with necrotizing enterocolitis (p-value < 
0.01), respectively (Spencer et al. 2005). Thanks to these studies, specialized neonatal 
amino acid formulation has become a standard and essential component of the current 
neonatal PN regimen. Tremendous efforts have also been made in recent years in order 
to refine the lipid components in PN solution, which will be discussed in detail in the 
next section. 
Patients receiving long-term PN may also develop choline deficiency as choline 
is not considered essential and therefore not contained in the crystalline amino acid 
solution, which does contain methionine. While choline can be synthesized 
endogenously from methionine, it was suggested that this conversion might be less 
efficient when methionine was given intravenously than normally absorbed in the gut 




Intravenous Fat Emulsion 
 In the United States, there are currently only two FDA-approved lipid emulsions 
for PN therapy, Intralipid, a soybean oil based lipid emulsion (SOLE), and Liposyn II, a 
mixture of half soybean oil and half safflower oil based lipid emulsion. Intralipid mainly 
contains linoleic acid (LA, 53%), oleic acid (OA, 24%), as well as less amount of palmitic 
acid (PA), α-linoleic acid (ALA) and stearic acid (SA), but lacks of long-chain 
polyunsaturated FA (LC-PUFA) eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA). LA is a polyunsaturated omega-6 FA (ω-6 FA), and the precursor for the 
biosynthesis of arachidonic acid (AA). The metabolism of AA predominantly results in 
the formation of the pro-inflammatory eicosanoids, including 2-series prostaglandins, 2-
series thromboxanes and 4-series leukotrienes (Calder 2007). These eicosanoids 
mediate multiple pro-inflammatory pathways, including the release of pro-inflammatory 
cytokines such as interleukin-6 (IL-6), initiation of leukocyte chemotaxis, vasodilation, 
and the stimulation of pain pathways (Calder 2007). It is also important to note that LA 
and its derivative γ-linolenic acid (GLA) are also precursors for the production of 
epoxyeicosatrienoic acids (EETs) and 1-serial prostaglandins, respectively. EETs, 
produced by cytochrome P450 epoxygenase, are considered as anti-inflammatory 
mediators due to their ability to decrease the activity of cyclooxygenase and platelet 
aggregation (Spector et al. 2004). Nevertheless, the potential beneficial roles of EETs 
and GLA in PNALD have not been documented.  
Other components contained by SOLE, which are also critically linked to PNALD, 
are the high levels of phytosterols, including plant sterols and stanols. Plant sterols are 
structurally similar to cholesterol, but differ from cholesterol by the presence of an extra 
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ethyl group (sitosterol and stigmasterol) or methyl group (campesterol) at C-24 of the 
sterol side chain (Othman, Myrie and Jones 2013). Plant stanols are saturated sterols, 
which are less abundant in nature compared to plant sterols. Extremely elevated levels 
of plant sterols in the plasma and tissue, will lead to the development of sitosterolemia 
(STSL, also known as phytosterolemia). STSL is a rare autosomal recessive genetic 
disease caused by homozygous or compound heterozygous mutations in the genes 
encoding either one of the two ABC family transporters, ABCG5/8, resulting in 
xanthoma and premature atherosclerotic disease (Othman et al. 2013). Functional 
ABCG5/8 in the liver and mainly in the intestinal, will rapidly remove the absorbed plant 
sterols out from the hepatocytes and enterocytes for fecal excretion, respectively 
(Othman et al. 2013). In vitro studies using hepG2 cells and cultured mouse 
hepatocytes isolated from WT or FXR-WBKO mice showed that, stigmasterol and its 
derivative stigmasterol acetate, were FXR antagonists (Carter et al. 2007). Beta-
sitosterol (β-sitosterol), the most abundant plant phytosterol, however, didn’t show any 
inhibitory effect to the transactivation activity of FXR in this in vitro study (Carter et al. 
2007). in 1993, Clayton el al first reported that plasma levels of phytosterol were 
positively associated with the severity of PNAC in children receiving PN therapy 
(Clayton et al. 1993). In this study, plasma concentrations of sterols were measured by 
gas chromatography-mass spectrometry (GC-MS) in 29 children receiving PN with age 
range from 2 months to 9 years as well as in 29 age-matched controls. Among the 29 
children receiving PN, 5 developed severe PNAC (bilirubin > 100 µmol/L; AST > 200 
IU/L). The elevated plasma concentrations of phytosterols and sitostanol in these 5 
children (around 1500 µmol/L) were as high as those found in STSL patients (total 
45 
 
phytosterols, 1300-1800 µmol/L). Besides, all these 5 children had intermittent 
thrombocytopenia. In 2 of the 5 patients, a subsequent reduction of lipid intake to less 
than 50 mL/kg/wk was associated with decreased plasma phytosterol concentrations 
and improved outcome from LFTs and platelet counts. Finally, the serum levels of 
phytosterol in the children with mild cholestasis and the age matched controls were 
approximately 300 and 40 µmol/L, respectively. It was then proposed that 
phytosterolemia might contribute to the pathogenesis of PNALD. However, it is still 
debatable that the increased serum levels of phytosterols seen in this study could result 
from the severe cholestatic liver complications, which possibly were partially caused by 
and could lead to the impaired hepatic transporting system, since adult patients 
receiving higher amount of SOLE in their PN normally don’t develop cholestasis in 
short-term. Another recent study also reported significant higher levels of phytosterols in 
16 SBS patients receiving PN therapy (SBS-PN) compared to 8 SBS patients (SBS-only) 
and 21 healthy controls without PN (Ellegard, Sunesson and Bosaeus 2005). Serum 
levels of phytosterols plus cholesterol, and markers for BA and cholesterol synthesis, 
were quantified by gas or liquid chromatography (GC/LC). In addition, patients in both 
SBS-PN and SBS-only groups showed lower serum levels of cholesterol, higher levels 
of lathosterol (824, 808, and 228 µmol/100mmol cholesterol for SBS-PN, SBS-only, and 
controls, respectively) and significantly higher levels of 7α-hydroxy-4-cholesten-3-one 
(C4) (207, 191, and 18 nmol/L in SBS-PN, SBS-only and controls, respectively. p-value 
<0.05, between controls and SBS). Therefore, SBS alone could be a contributing factor 
of higher levels of cholesterol and BA synthesis compared to controls.  
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As mentioned, SOLE also contains small amount of ALA, another essential ω-3 
FA. ALA is the precursor for the production of long change PUFAs (LC-PUFAs), EPA 
and DHA, which are critical for normal human physiology, especially neurodevelopment 
in infants during the critical period. Though EPA can be synthesized from ALA in 
humans, the relative efficiency is very low. EPA can also give rise to DHA, catalyzed by 
similar enzymes involved in the formation of EETs from AA, but the efficiency is even 
lower. In contrary to AA, EPA and DHA are precursors for the production of 3-series 
prostaglandins, 3-series thromboxanes and 5-series leukotrienes (Calder 2007). These 
mediators are generally considered less pro-inflammatory and some anti-inflammatory. 
EPA and DHA are also precursors for the synthesis of the recently discovered resolvins, 
which are involved in resolution of cellular inflammation by inhibiting the production and 
transportation of inflammatory cells and mediators to the inflammation sites (Serhan et 
al. 2002).  
In contrary to SOLE, a new generation of fish oil based lipid emulsion (FOLE), 
Omegaven (Fresenius Kabi, Bad Homburg, Germany), contains relatively large 
amounts of EPA and DHA, median amount of OA as well as small amounts of AA, ALA, 
LA, PA and SA (El Kasmi et al. 2013). In addition, there is no phytosterols in FOLE. The 
beneficial roles of FOLE in alleviating PNALD have been shown recently in many 
clinical studies with different underlying mechanisms proposed.  
One prospective, randomized, and double-blind study, which was reported 2 
years ago by researchers from Taiwan, particularly evaluated the overall effects of ω-3 
FAs on immune and inflammatory modulations in patients receiving PN therapy (Han et 
al. 2012). Thirty-eight patients were randomized into 2 groups with PN regimen 
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containing equal volume and calorie contributions from glucose, nitrogen, and lipid from 
2 different lipid emulsions for 7 days. One group (n=12) received a 50:50 mixture of 
SOLE and another vegetable oil, which is rich in MCT (SOLE/MCT, also commonly 
known as MCT/LCT (long chain triglycerides), indicating the mixture of MCT in the other 
vegetable oil and LCT in SOLE). The other group (n=18) received a combination of 
SOLE and FOLE (SOLE/FOLE). Test results of blood inflammatory cytokines showed 
significant differences in the two groups in regards to serum concentrations of 
interleukin-1 (IL-1), interleukin-8 (IL-8), and interferon-γ (IFN-γ) on postoperative day 4 
(p-value < 0.05), as well as IL-1, IL-8, IFN-γ, IL-6, and tumor necrosis factor alpha (TNF-
α) on postoperative day 7 (p-value < 0.05). A trend toward reduced serum levels of 
inflammatory cytokines was identified in the SOLE/FOLE group compared to the 
SOLE/MCT group. Insignificant results also linked the usage of FOLE to reduced 
incidence of postoperative liver dysfunction and infections (Han et al. 2012). Another 
single-center, randomized, placebo-controlled trial compared the effects of different 
intravenous fat emulsions in patients receiving PN therapy due to systemic inflammatory 
response syndrome (SIRS) and sepsis in a university hospital (Sungurtekin et al. 2011). 
The patients were assigned to receive SOLE/MCT mixture or FOLE based PN infusion 
for over 7 days. In the group of patients with sepsis, those receiving SOLE/MCT had 
significantly higher levels of hepatic steatosis, measured by ultrasound on days 7 and 
10, whereas in the group of SIRS patients, no significant differences in inflammatory 
markers were observed. Nevertheless, the significant differences found in the sepsis 
group demonstrated both hepato-protective and anti-inflammatory effects of FOLE 
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(Sungurtekin et al. 2011). These studies suggest that FOLE may be associated with 
decreased liver injury, mainly due to the anti-inflammatory effects of the ω-3 FAs. 
FOLE has also been shown to reverse PNALD in patients previously received 
SOLE based PN. In 2011, Le et al reported the significant reverse of PNAC in 79 
pediatric patients switched from SOLE to FOLE, as indicated by reduction of median 
serum levels of total and direct bilirubin from 7.9 and 5.4 mg/dL into 0.5 and 0.2 mg/dL, 
respectively (p-value < 0.0001). In addition, serum levels of triglyceride, total cholesterol, 
LDL, and VLDL significantly decreased by 51.7%, 17.4%, 23.7%, and 47.9%, 
respectively, after the replacement of SOLE by FOLE. Though FOLE only contains low 
levels of the essential ω-3 FAs (ALA) and ω-6 FAs (LA), none of the patients in this 
study developed EFAD. Hence, FOLE was proposed by the authors to be the preferred 
lipid emulsion for patients receiving PN who developed PNAC and/or dyslipidemia. In 
line with these findings, a number of other studies also showed that parenteral fish oil as 
monotherapy could prevent EFAD in PN-dependent patients (Gura et al. 2008, de 
Meijer et al. 2009, Le et al. 2011, de Meijer et al. 2010). 
Most recently, replacement of SOLE with combinations of lipid emulsions were 
also reported. A recent randomized, double-blind, controlled study evaluated the 
potential beneficial effects of using SMOFlipid (Fresenius Kabi, Bad Homburg, Germany) 
versus Intralipid in 53 preterm infants (gestational age < 34 weeks) receiving PN for at 
least 7 days (Rayyan et al. 2012). SMOFlipid is a mixture of 30% soybean oil, 30% 
MCTs, 25% olive oil, and 15% fish oil. Serum levels of total and direct bilirubin 
decreased significantly in the SMOFlipid group than the Intralipid control group. In 
addition, in the plasma and RBCs, levels of EPA and DHA were significantly higher, and 
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the ratio of ω-6/ω-3 FAs was significantly lower in the SMOFlipid group (p-value < 0.05 
vs control). These alterations of lipid profiles were considered beneficial for the preterm 
infants. Another study tested the combination of 1:1 ratio of Omegaven and ClinOleic 
(Baxter, Maurepas, France), an olive/soybean oil based lipid emulsion, in five premature 
infants (gestational age ≤ 35 weeks) with SBS and cholestasis (Lilja et al. 2011). 
ClinOleic has higher ω-9 monounsaturated FAs (ω-9 FAs) and lower ω-6 FAs than 
Intralipid. After receiving FOLE/ClinOliec based PN therapy for the time periods ranging 
between 7 and 17 months, direct bilirubin levels normalized in all the patients receiving 
based PN. In addition, none of these patients developed irreversible intestinal failure-
associated liver disease (IFALD), though all the patients were preterm, had gone 
through multiple major surgical operations, and had experienced more than one episode 
of sepsis. Finally, the mixture of FOLE/ClinOliec didn’t cause any adverse effect in 
these preterm infants, and all of them grew and developed well with normal liver 
function with 2 extremely premature infants (gestational age 23–26 weeks) had signs of 
delayed development (Lilja et al. 2011). The safety and efficacy outcomes of the mixture 
of FOLE/ClinOliec versus ClinOliec-only was also compared in another large 
retrospective study in PN patients in Poland (Pawlik, Lauterbach and Hurkala 2011). 
152 preterm infants (gestational age < 32 weeks) with very low birth weight (< 1500 g) 
received the same FOLE/ClinOliec mixture in their PN, whereas185 matched preterm 
infants with very low birth weight received ClinOleic-only based PN. All these patients 
started their corresponding PN therapy on the 1st day of lives. The newborns in the 
FOLE/ClinOliec group had significantly lower incidence of cholestasis (0.66%) versus 
those in the ClinOleic-only group (4.86%) (p-value < 0.025). Besides regular histological 
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and biochemical tests, plasma and erythrocytes DHA concentrations were also 
determined in these newborns with a high-performance LC-MS method (Pawlik et al. 
2011). It was also showed that the risk for the preterm infants to develop retinopathy, 
which required laser therapy, was markedly lower in patients in the FOLE/ClinOlei group, 
though it was not statistically significant. 
In the US, FOLE (Omegaven) is currently approved by the FDA only under 
compassionate use for the treatment of PNALD and is dosed as a 10% lipid emulsion at 
1 g/kg/day. In contrast, Intralipid is administered as a 20% lipid emulsion at up to 3 
g/kg/day. Despite the mounting evidence for the beneficial impact of FOLE on 
improvement and reversal of PNALD, it has also been suggested that the impact may 
simply result from the reduced administration of lipid content (Cowan, Nandivada and 
Puder 2013), rather than the distinct properties of FOLE as discussed above. To resolve 
this debate, Nehra et al asked the question that whether a reduction of SOLE in PN 
solution from 2-3 g/kg/d into 1 g/kg/d is associated with a reduced incidence of PNAC. 
The hypothesis was tested by a retrospective study of the medical records of 61 
neonatal patients (Cowan et al. 2013). These patients, based on the amount of SOLE 
intake mentioned above, were divided into 2 groups (n=29, 1 g/kg/d group; n=32, 2-3 
g/kg/d group). Baseline characteristics, including overall enteral intake, the duration of 
PN, the number of surgical procedures and catheter related infections were all similar 
between the 2 groups. Analyzed results showed that there was no difference in terms of 
the incidence of PNAC (51.7% for 1 g/kg/d group, 43.8% for 2-3 g/kg/d group, p-value = 
0.61), nor the time towards the development of PNAC (32.6 ± 24.1 days for 1 g/kg/d 
group, 27.7 ± 10.6 days for 2-3 g/kg/d group, p-value = 0.48) between the 2 groups. In 
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addition, among all the patients developed PNAC, 44.8% made successful transition 
from PN feeding into full enteral feeding, whereas 55.2% had to switch into the FOLE-
PN, after which serum levels of direct bilirubin normalized in all patients.  
 
1.3.3 Study of PNALD in Animal Models 
To understand the underlying mechanisms of the pathogenesis of PNALD, and to 
seek novel management and treatment strategies, studies of PNALD in various animal 
models have been reported, including mice, rats, rabbits, guinea pigs, pigs, and dogs 
(Puiman and Stoll 2008). Compared to the large amount of clinic reports related to 
PNALD, literatures about PNALD in animal models are, however, still limited. Majority of 
literatures are based on mice, rats and pigs, especially newborn piglets, and these will 
be discussed in detail in this chapter. 
As mentioned, PN with no or very little amount of lipid content could induce 
hepatic steatosis. An early study well-recapitulated this clinic issue in a rat PN model 
(Hall et al. 1984). Adult rats were assigned to receive lipid-free dextrose-PN (Dex-PN, 
other major nutrients were included) or PN with lipids (PN). Hepatic triglyceride levels 
increased around threefold in Dex-PN rats and twofold in PN rats (p-value < 0.02). 
Endogenous FA synthesis in the liver also elevated, as reflected by the fourfold and 
twofold increase of the activity of hepatic acetyl-coenzyme A carboxylase (ACC) in Dex-
PN and PN rats, respectively, when compared to controls. And the elevated levels of 
hepatic triglyceride correlated positively with the increased activity of hepatic ACC (R2 = 
0.82). However, activities of hepatic microsomal enzymes involved in lipid synthesis 
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were similar in the two groups. In addition, both PN regimens inhibited hepatic 
triglyceride secretion, which negatively correlated with total hepatic lipid contents (R2 = -
0.89). Hepatic uptake of a radiolabeled triglyceride emulsion and hepatic lipase activity 
were both increased in the Dex-PN rats, whereas both decreased in PN rats (Hall et al. 
1984). On the contrary, the levels of adipose and cardiac lipase were lower in Dex-PN 
rats and higher in PN rats, respectively. Dex-PN also significantly suppressed 
triglyceride FA oxidation, which was less suppressed in the PN rats. Finally, 
suppression of free FA oxidation was only seen in Dex-PN rats (Hall et al. 1984). These 
results suggested that enhanced hepatic FA synthesis and reduced triglyceride 
secretion were likely the underlying causes of hepatic steatosis in Dex-PN rats (Hall et 
al. 1984). In another study published the same year, Wood et al showed that isocaloric 
substitution of PN glucose with lipid by 60% would not exacerbate the hypercalciuria 
condition observed in Dex-PN rats. It was mainly because of these early studies that PN 
with lipid administration became standard practice (Kumpf 2006). Though rat is a good 
rodent model to study PNALD in adult settings, it is still difficult to use infant rats to 
mimic human neonatal conditions. In 1989, newborn rabbit PN models were reported by 
two different groups (Gleghorn et al. 1989, Hata et al. 1989). Gleghorn et al showed that 
PN rabbits had higher percentage of LCA, unconjugated bilirubin and total calcium in 
their gallbladder bile content (Gleghorn et al. 1989). In addition, elevated serum markers 
of liver injury as well as histologically mild steatosis and edema were observed in the 
livers of these PN rabbits. Hata et al showed that excessive amount of non-protein 
calories in PN rabbits was correlated with increased occurrence of histology-proven 
cholestasis (Hata et al. 1989). Subsequently, study of PNALD in non-human primates 
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was also reported (Friday and Lipkin 1990). Due to the relative high maintenance 
requirement, it’s not a popular model for PN study. 
 
Study of PNALD in Pigs/Piglets 
More than two decades ago, it was already suggested that infant and pediatric 
piglets were excellent animal models for the study of PNALD, due to their relatively 
large body sizes readily accessible for surgical manipulations, and more importantly, 
their high levels of similarities to human neonates, in terms of development and 
nutritional requirements (Borum 1993). In 1985, Goldstein et al first reported a study, 
using piglets to evaluate the effect of PN during the phase of rapid intestinal growth and 
development in three 6-week-old weaned piglets (Goldstein et al. 1985). PN fed piglets 
had the same total body weight gain but reduced growth of the stomach, small bowel 
and pancreas compared to chow fed controls (Goldstein et al. 1985). Gallbladder sludge 
was replicated in PN piglets in a later study (Truskett et al. 1987). Five female piglets 
receiving lipid-free PN (Dex-PN) developed “sludge” in their gallbladder, had decreased 
basal bile flow and bile salt secretion, and responded weakly to bile salt stimulation, 
when compared with age-matched controls. LFTs and liver histology, however, didn’t 
show any obvious abnormalities (Truskett et al. 1987). In 1996, Duerksen el al first 
demonstrated that the newborn piglet was a valid model to study neonatal PNAC 
(Duerksen et al. 1996). Eight newborn piglets, receiving PN therapy for 3 weeks, had 
significantly lower rates of both BA-dependent and BA-independent bile flow compared 
to 9 milk-fed newborn controls (Duerksen et al. 1996). BA secretions in PN piglets were 
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less than 50% of the control values, whereas total cholesterol and phospholipid 
secretions were less than 5% of the control values. Intravenous administration of 
taurocholic acid (TCA) failed to stimulate bile flow in the PN piglets compared to orally 
fed animals. PNAC was validated by the elevated levels of both liver and serum bilirubin 
in these newborn piglets (Duerksen et al. 1996).  
In 1997, Van Aerde et al first evaluated the effects of different lipid emulsion in 
PN, on the lipid compositions and function of the intestinal brush border membrane 
(BBM) and the enterocyte microsomal membrane (EMM) (van Aerde et al. 1997). Major 
membrane phospholipid contents in the jejunal and ileal BBM and EMM, including 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE), were evaluated. Different 
compositions of the four major FAs (LA, OA, PA, and SA) were detected in both PC and 
PE in the BBM and EMM of the jejunums and ileums in 21-day-old milk-fed piglets, 
when compared to those in newborn animals. Different compositions of membrane FAs 
were also detected among the three groups of animals, fed by milk orally, lipid-free PN 
(Dex-PN), or PN with SOLE, respectively. In addition, FOLE was also tested in this 
study. Compared to PN with SOLE, PN with FOLE or SOLE/FOLE altered the FA 
contents in BBM and EMM. It was therefore proposed that the lipid composition of PN 
regimen could potentially modify the membrane lipid content and the related functions in 
other organs as well. In 1998, Dudley et al showed that parenterally fed 3-day-old 
piglets had significant lower rate of absolute total mucosal protein synthesis (the amount 
of protein synthesized per gram of mucosa) than enterally fed animals (Dudley et al. 
1998). However, the absolute synthesis rate of the important gut enzyme lactase 
phlorizin hydrolase (LPH) was shown unaffected by the route of nutrient administration 
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in this study (Dudley et al. 1998). These studies suggest that PN feeding could alter 
basic cellular functions in the lipid and protein levels. 
In 2002, Sangild et al reported an interesting study comparing the effect of PN 
feeding and enteral feeding in both preterm (gestation age, 107d, delivered by 
caesarean section (C-section) and term (gestation age, 115d) piglets (Sangild et al. 
2002). These piglets were fed with either intravenous PN or enteral sow’s milk for 6 
days after birth. Upon delivery, preterm piglets had lower blood pH, reduced oxygen 
saturation and neutrophil granulocyte function, impaired intestinal uptake of 
immunoglobulin G from colostrum, and altered relative weights of visceral organs (small 
intestine, liver, spleen, pancreas, and adrenals) compared to term piglets. Both preterm 
and term piglets had increased pancreatic weight (30-75%) and amylase activity (0.5- to 
13-fold) after the 6 days of feeding period, but much more in milk-fed than in PN-fed 
piglets (p-value < 0.05). Compared to oral feeding, 6 days of PN feeding was associated 
with significant intestinal weight lost for both age groups (60% of the values in milk-fed 
piglets, p-value < 0.001). For PN term piglets, intestinal weight was even lower than at 
birth (-20%, p-value < 0.05). And only did PN term piglets have increased intestinal 
maltase activity and decreased absorption of glucose and proline compared to other 
groups. Compared to milk-fed piglets, lactase activity was seen increased in preterm 
piglets (up 50%, p-value < 0.05). For both age groups, the relative mRNA levels of LPH 
and sodium-coupled glucose transporter 1 (SGLT-1) were increased in PN-fed animals. 
These valuable results obtained in preterm piglets suggest that PN feeding may induce 
GI atrophy and modify postnatal maturation of many GI functions in preterm infants as 
well (Sangild et al. 2002). The same group subsequently showed that PN also affected 
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gut barrier function in the neonatal piglets (Kansagra et al. 2003). Jugular venous and 
bladder catheters were planted in the colostrum-deprived newborn piglets under general 
anesthesia. After 6 days of feeding with either oral formula or intravenous PN, all piglets 
were gavaged with a mixed solution of lactulose, mannitol, and polyethylene glycol 4000 
(PEG 4000). Urine samples were collected over the next 24 hrs. After that, small bowel 
samples were harvested for functional analysis. Peripheral organ tissues, especially 
intestinal contents were used for bacterial culture and identification. PN-fed piglets had 
significantly higher urinary recovery (%dose) of lactulose (2.93 vs. 0.18) and PEG 4000 
(12.78 vs. 0.96) (p-value < 0.05 for both), whereas recovery of mannitol (53 vs. 68) was 
similar. Incidence of bacterial translocation was similar in the two feeding groups. 
Jejunal myeloperoxidase activity increased significantly in PN-fed piglets compared to 
controls (p-value < 0.001), and was, however, weakly correlated with the urinary recover 
of lactulose (R2 = 0.32) and PEG 4000 (R2 = 0.38). Among the tight junction proteins 
analyzed, PN only increased the protein levels of claudin-1. In summary, it was 
suggested that PN induced dysfunction of the gut barrier was associated with increased 
intestinal permeability, rather than bacterial translocation (Kansagra et al. 2003).  
In 2006, Wang et al reported detailed morphological and molecular analysis of 
PN induced liver injury in neonatal piglets (Wang et al. 2006). Seven newborn piglets 
were included in each group (PN or enteral nutrition (EN). Liver histology showed 
prominent steatosis (grade >2) in 6 of the 7 PN piglets, whereas only 2 EN piglets had 
minimal steatosis (grade ≤ 1). Gel electrophoresis showed strong signals of DNA 
fragmentation in cultured primary piglet hepatocytes from PN but not EN piglets. Test 
results showed significantly lower levels of ATP and higher activation of caspase-3 
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activity (9.9 fold) in the livers of PN piglets. Western blot showed markedly increased 
cleavage of apoptotic markers, including poly (ADP-ribose) polymerase (PARP), 
caspase-7, -8, and -9 in the livers of PN piglets. Protein levels of Bax, Fas and cytosolic 
cytochrome c were also up-regulated whereas Bcl-2 and proliferating cell nuclear 
antigen (PCNA) were slightly down-regulated in the livers of PN piglets. However, levels 
of markers of the endoplasmic reticulum-mediated apoptosis, including caspase-12 and 
binding immunoglobulin protein (BiP, also known as 78 kDa glucose-regulated protein, 
or GRP78), were similar between the two feeding groups. These results indicated that 
short-term PN in neonatal piglets could induce hepatic steatosis and oxidative stress, 
triggering mitochondrial and Fas pathways mediated apoptosis in the liver. In 2010, Stoll 
et al further showed that prolonged PN feeding in neonatal piglets could induce hepatic 
inflammation, steatosis, and even insulin resistance (Stoll et al. 2010). In this study, 
newborn piglets were fed with either enteral formula (EFor) or intravenous PN for 17 
days. After PN feeding for 7 or 13 days, fasting i.v. glucose tolerance tests (IVGTT) 
were performed and evidence of insulin resistance were shown in PN piglets. PN 
animals also had higher levels of fasting plasma glucose and insulin than EFor piglets. 
On day 17, 1hrbefore tissue harvesting, low-dose hyperinsulinemic-euglycemic clamps 
(CLAMP) were performed and results showed that PN piglets had markedly decreased 
insulin sensitivity, compared to EFor piglets. Western blot showed that PN piglets had 
significantly reduced protein abundance of insulin receptor (IR), insulin receptor 
substrate 1 (IRS1), and phosphatidylinositol 3 kinase (PI3K) in the livers and skeletal 
muscles. Relative mRNA levels of many hepatic pro-inflammatory genes, 
phosphorylation of c-Jun-N-terminal kinase 1 (cJNK1), and plasma protein levels of IL-6 
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and TNF-α were all higher in PN piglets compared to controls. These detailed analysis 
linked chronic PN feeding to the development of insulin resistance, hepatic steatosis 
and inflammation in newborn piglets (Stoll et al. 2010). In a later study, Jain et al 
showed that PN-fed newborn piglets had dramatically decreased plasma levels of HDL, 
FGF19, glucagon-like peptide (GLP)-1 and GLP-2, and increased plasma triglyceride 
levels (Jain et al. 2012). One group of PN piglets also received CDCA infusion through 
additional duodenal catheter (PN+CDCA). CDCA treatment significantly improved 
conjugated bilirubin levels compared with the PN-only piglets. Normalized levels of total 
serum BAs and liver triglyceride were seen in the PN+CDCA piglets. ELISA showed that 
CDCA treatment significantly induced plasma levels of FGF19, GLP-1 and GLP-2. This 
study suggested that enteral CDCA treatment not only could resolve PNALD, but also 
could improve intestinal atrophy by induce GLP-2 (Jain et al. 2012). This study in part 
revealed the underlying mechanism by which minimal enteral intake could improve 
PNALD in patients.  
In 2014, the same group reported another important study and showed that not 
only new generation lipid emulsions, FOLE and SMOFlipid, could reverse but also 
prevent PNALD in chronic PN-fed preterm pigs (Vlaardingerbroek et al. 2014). 
Compared to SOLE based PN (SOLE-PN), preterm piglets fed with FOLE based PN 
(FOLE-PN) or SMOFlipid based PN (SMOF-PN) for 14 days had significantly decreased 
serum levels of total bilirubin, conjugated bilirubin and GGT, though still higher than EN-
fed piglets. Liver BA pool was increased in both SOLE-PN and FOLE-PN, but not 
SMOF-PN piglets. Plasma TSBA levels were highest in SOLE-PN, median high in 
FOLE-PN, and low in SMOF-PN piglets (similar to EN piglets). Liver triglyceride levels 
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were only increased in the SOLE-PN group, and with statistical significance. Among the 
hepatic genes tested, mRNA levels of ABCB11, CYP7A1, FXR and MRP3 were down-
regulated in all PN groups, whereas mRNA levels of OST-α was up-regulated only in 
SOLE-PN group. CYP7A1 protein levels increased only in the FOLE-PN group, yet 
plasma C4 concentration decreased significantly in all PN groups compared with EN 
group. Most importantly, PN with FOLE or SMOFlipid were able to maintain similar 
plasma level of FGF19, but not with SOLE when compared with EN group. Though in 
vitro data in this study still supported the idea that plant phytosterols may cause liver 
injury due to the suppression of FXR signaling, in vivo data contradicted the theory, 
mainly supported by the protective effect from SMOF-PN, which also contains 
considerable amounts of phytosterol.  
As mentioned, PN rat model has also been used extensively to study the 
underlying mechanism of PNALD. In fact, studies conducted in rats and pigs (piglets) 
showed extensively overlapping findings in many aspects. In this regard, only studies 
obtained in pigs/piglets are discussed in detail here. 
 
Study of PNALD in Mice 
Unlike piglets and rats, surgical operations and subsequent PN infusion in 
newborn mice are still technically challenging. However, the well-established genetic 
engineering techniques in mice have provided indispensable opportunities for biologist 
to study the underlying mechanistic and genetic mechanisms for all sorts of human 
diseases, including PNALD.  
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Early PN studies conducted in adult mice mostly focused on the interplay 
between PNALD and the associated intestinal dysfunctions. Kiristioglu et al first showed 
that 7 days of PN infusion in mice was associated with significantly increased incidence 
of bacterial translocation to the mesenteric lymph node in the gut (40% in PN mice vs. 
12.5% in controls) (Kiristioglu and Teitelbaum 1998). PN infusion significantly 
decreased the subpopulations of CD4+, CD8-; CD4+, CD8+; and CD8+, CD44+ gut 
intraepithelial lymphocytes (IEL) (p-value < 0.05), which were stained for CD4, CD8, 
and CD44 and counted by flow cytometry. Relative mRNA levels of IFN-γ increased 53% 
(p-value < 0.05), whereas levels of TGF-β1 decreased 75% (p-value = 0.1) in the 
isolated gut IELs of PN mice when compared with controls. In cultured intestinal 
epithelial cells (IEC), it was shown that increase of IFN-γ and decrease of TGF-β1 was 
associated with loss of intestinal tight junction (Madara and Stafford 1989). It was then 
suggested that these alterations in the IELs might affect the tight junctions between the 
IECs, and thus subsequently damage the integrity of the gut epithelial layer, leading to 
bacterial translocation (Kiristioglu and Teitelbaum 1998). In a later study reported in 
2002, it was shown that the subpopulation of thymus-derived CD8αβ+ IELs declined by 
92% (p-value < 0.01), whereas proliferation of IELs also declined significantly 
(Kiristioglu et al. 2002). In 2003, PN studies in IFN-γ KO mice showed that measured 
intestinal permeability in the KO mice was significantly lower than in PN-fed WT mice, 
though still higher than saline-infused control mice, suggesting that additional factors 
(cytokines) may also contribute to PN-associated gut epithelial barrier dysfunction 
(Yang, Finaly and Teitelbaum 2003). In 2007, this group further showed that PN infusion 
significantly diminished the expression of IEC-derived IL-7 (Yang et al. 2007), which 
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together with the IL-7 receptor (IL-7R), have been found in both thymic and intestinal 
epithelial cells (Watanabe et al. 1995, Watanabe et al. 2003, Yamazaki et al. 2003). IL-7 
has been shown to play an essential role for the homeostatic proliferation and survival 
of naive peripheral T cells (Tan et al. 2001). Indeed, administration of exogenous IL-7 to 
PN mice significantly attenuated PN-associated IEL alterations, whereas blocking IL-7 
receptor (IL-7R) with an exogenous anti-IL-7R antibody in normal chow-fed mice led to 
similar alterations in the IELs seen in PN mice. In 2008, subsequent studies obtained 
from transgenic mice showed that intestinal specific overexpression of IL-7 significantly 
attenuated many phenotypic and functional alterations of the IELs seen in PN mice 
(Yang, Gumucio and Teitelbaum 2008). The same year, Sun et al reported that PN 
infusion induced significant decline of the expression of IEL-derived cytokine interleukin-
10 (IL-10) (Sun et al. 2008), which has been found to be a central modulator of the gut 
mucosal immune system in mice (Berg et al. 2002). Sun et al also showed that PN 
administration decreased the expression of several tight junction molecules, including 
zonula occludens-1, E-cadherin, and occluding when compared to controls (Sun et al. 
2008). Convincingly, as demonstrated, administration of exogenous IL-10 partially 
attenuated the intestinal alterations observed in vehicle treated PN mice (Sun et al. 
2008). In 2010, Feng et al reported the potential beneficial role of the PI3K/phospho-Akt 
(PI3K/Akt) signaling pathway in reversing intestinal atrophy observed in PN mice (Feng, 
McDunn and Teitelbaum 2010). A head-to-tail peptide dimer of the Akt-binding domain 
of the T-cell lymphoma-1 protein (TCL-1) was administered to activate the PI3K/Akt 
pathway in PN mice. PN mice treated with the effective peptide (PN+TCL-1) had 
increased protein abundance of p-Akt (Ser473) in the jejunal epithelial cells compared 
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to control peptide treated (PN+Ctrl). Phosphorylation of downstream effectors, including 
β-catenin and glycogen synthase kinase-3β (GSK-3β), were also decreased in PN+Ctrl 
mice but not in PN+TCL-1 mice. TCL-1 treatment also prevented the decline of gut 
epithelial cell proliferation and partially decreased the levels of apoptosis observed in 
PN+Ctrl mice. Similar activity reduction was also detected for the mammalian target of 
rapamycin (mTOR) pathway in PN+Ctrl mice, and subsequently corrected by TCL-1 
treatment (Feng et al. 2010). These results suggest a potential strategy to maintain gut 
integrity in PN patients by regaining proliferation as well as retaining apoptosis of IECs 
through activation of the PI3K/Akt signaling pathway. In 2013, Feng et al reported 
another study showed that the loss of gut epithelial barrier function presented in PN 
mice was almost fully prevented in TNF-α receptor 1 (TNFR1) and TNFR2 DKO mice 
(TNFR1R2-DKO) and partially prevented in TNFR1-KO mice but not in TNFR2-KO mice 
when received intravenous PN feeding (Feng and Teitelbaum 2013). In addition, PN 
TNFR1R2-DKO mice had similar expression levels of intestinal gap junctional proteins 
to those found in saline-infused controls. Blockade of TNF-α signaling also prevented 
intestinal epithelial dysfunction and loss of junctional proteins in PN mice. Though these 
studies in various mouse models have linked PN therapy with intestinal dysfunction, 
none has provided valid data to directly correlate intestinal dysfunction to the 
development of PN associated liver injury, which is seen strongly in patients with 
intestinal failure as mentioned in the sections of clinical studies. 
To fill this missing gap, one groundbreaking study published in 2012 in 
Hepatology  by El Kasmi et al showed that liver toll-like receptor 4 (TLR4) signaling was 
critically involved in the pathogenesis of PNALD in adult mice with preexisting intestinal 
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injury induced by dextran sulphate sodium (DSS) pretreatment (El Kasmi et al. 2012). 
DSS, a chemical agent, was shown to induce intestinal damage followed by increased 
intestinal permeability. DSS pretreatment is a common research strategy to induce 
intestinal inflammation in animals to mimic human clinical conditions such as NEC and 
SBS, while the underlying mechanism is not completely known yet (Laroui et al. 2012). 
In the study, 6-8 weeks old adult mice were pretreated with 2.5% DSS in water or saline 
control for 4 days (El Kasmi et al. 2012). Pretreated mice were then put on continuous 
infusion with SOLE-PN or saline control for 7 (PN7d/DSS, PN7d/Saline) or 28 
(PN28d/DSS, PN28d/Saline) days. In contrary to many early published studies using 
mice and those using rats and piglets, SOLE-PN infusion alone in this study only 
caused mild increase of serum levels of ALT, AST, and bilirubin in the PN7d/Saline and 
PN28d/Saline mice. There was indeed a trend towards development of liver injury in 
these mice as shown by the significantly increased levels of portal vein LPS and TSBAs 
(more than 2 fold for both). These findings are more consistent with the clinical 
observations in adult patients, for which short-term PN will not likely cause severe liver 
injury when compared to neonates. However, SOLE-PN induced dramatic liver injury in 
DSS pretreated mice, demonstrated by significantly elevated serum markers, including 
ALT, AST, bilirubin, GGT, and TSBA, as well as increased gene expression of Il6, Tnf-α, 
and Il-1β in purified primary mouse Kupffer cells (KCs) but not in whole liver 
homogenates. PN28d/DSS mice were associated with much more severe liver injury, 
including increased expression of Il6, Tnf-α, and Il-1β from even whole liver 
homogenates, as well as prominent KC hypertrophy and hyperplasia, associated with 
neutrophils recruitment, hepatic inflammatory infiltrates, hepatocyte apoptosis, and 
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parenchymal peliosis (El Kasmi et al. 2012). Next, the PN7d/DSS model was tested in 
the TLR4 mutant mice (PN7d/DSS-TLR4-KO), which had impaired LPS-TLR4 signaling 
(El Kasmi et al. 2012). Most strikingly, liver injury and cholestasis were both significantly 
attenuated in PN7d/DSS-TLR4-KO mice. ALT and AST levels decreased significantly 
(p-value < 0.05), whereas serum bilirubin and TSBA levels also decreased dramatically 
in PN7d/DSS-TLR4-KO mice. This study suggests that the combination of diminished 
enteral stimulus due to PN infusion, plus additional intestinal dysfunction/dysmotility 
(DSS pretreatment, NEC, SBS, etc.), together could promote intestinal bacterial 
overgrowth, which will lead to exacerbated intestinal inflammation and compromised gut 
barrier function. These eventually increased gut absorption and subsequent liver 
exposure to TLR agonists, such as bacterial endotoxins, and further exacerbated liver 
injury caused by PNALD. 
As mentioned in previous sections of this chapter, studies obtained from both 
patients and newborn piglets have shown that new generations of lipid emulsion have 
been proven to be extremely beneficial and effective to both prevent and reverse 
PNALD. El Kasmi et al again used the PN/DSS mouse model to study the underlying 
mechanisms. Indeed, FOLE-PN mice had significantly attenuated liver injury compared 
to SOLE-PN mice (El Kasmi et al. 2013). By adding selected stigmasterols to the FOLE-
PN (FOLE-PN-Stig/DSS), they were able to replicate the liver injury in DSS pretreated 
mice infused with FOLE-PN-Stig. In addition, hepatic mRNA expression of Abcb11, 
Abcb2, Fxr and liver X receptor (Lxr) decreased significantly in SOLE-PN/DSS but not 
FOLE-PN/DSS mice, whereas expression of Abcg5 and Abcg8 increased significantly in 
FOLE-PN/DSS but not SOLE-PN/DSS mice when compared with saline-infused 
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controls (El Kasmi et al. 2013). The relative low levels of ABCG5/8 transporters in 
SOLE-PN mice will aid in accumulation of plant sterols in the liver, whereas decreased 
protein abundance of BSEP and MRP2 will further promote the development of 
cholestatic liver diseases, especially in newborn populations in which the premature 
livers are even more vulnerable to PNALD. Indeed, mice with TLR4 deficiency or mice 
treated with antibiotics had significantly lower incidence of cholestasis and liver injury, 
as well as restored expression of Abcb11, Abcc2, Lxr and Fxr (El Kasmi et al. 2013). It 
was also proposed that stigmasterols might activate macrophages and synergize with 
intestinal endotoxins to promote the development and progression of PNALD in patients 
who had intestinal failure (El Kasmi et al. 2013). 
 
1.4 Significance of the Studies of FXR and BA signaling Involved in Human Liver 
Functions 
1.4.1 Genome-wide Studies of FXR in PHHs 
As discussed throughout this chapter, there are limitations in biological research 
conducted in animal models in terms of studying human diseases, mainly due to 
species differences and technical challenges. Though extensive studies of the functions 
of FXR have been reported by using in vitro cell culture and in vivo animal models, how 
FXR function exactly in humans, are not yet fully investigated. To partially fill this gap, 
we performed genome-wide binding and RNA profiling analyses in PHHs and HepG2 
cells, to compare and contrast FXR function in human hepatocytes versus in mouse 
livers on a global scale. 
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1.4.2 Studies of FXR Regulated BA Homeostasis in PNALD 
As mentioned, both FXR gene expression and FXR regulated pathways were down-
regulated in the livers of PN-fed piglets and PN/DSS mice. The down-regulation of liver 
FXR signaling and the lack of enterohepatic circulation caused by PN could potentially 
disrupt the normal BA homeostasis in patients receiving PN as well. To data, the 
potential contributions of BA cytotoxicity involved in the development and progression of 
PNALD is not yet studied. To address these questions, and to further study the 
mechanisms underlying the pathogenesis of PNALD, we developed a mouse PN model 
and characterized valuable signatures for the PN mice. These results will also be critical 




Chapter 2: Materials and Methods 
2.1 Genome-wide Studies in PHHs and HepG2 cells 
Cells and Treatment  
Primary human hepatocytes (PHHs) used in this study were obtained through the Liver 
Tissue Cell Distribution System from the University of Pittsburgh (Kostrubsky et al. 1999, 
Li et al. 2012a). Only diagnostic and demographic information were obtained and 
provided by the supplier, no identifier was obtained. Comprehensive information of the 
PHH donors received in this study was listed in Table 3.1. PHHs were cultured in 37 °C, 
5% CO2 upon arrival. Three hs later, medium were refreshed with serum-free HMM 
Hepatocyte Maintenance Medium supplemented with dexamethasone, insulin, and GA-
1000 (Lonza, Switzerland). Next morning, cells were treated with 5 μM GW4064 
(Thomas et al. 2010), a synthetic FXR agonist, or control vehicle, DMSO. Cells were 
collected for chromatin and RNA isolation at 1 or 24 hrs after the treatment, respectively. 
HepG2 cells were obtained from ATCC (Manassas, VA). To obtain chromatin and RNA 
samples, same treatments and procedures as for PHHs were performed for HepG2 
cells when the cells reached 95% confluence. RNA was isolated using TRI Reagent 
(Invitrogen, CA), according to the manufacture’s instructions. FXR activation was 
confirmed by the induction of known human FXR target genes using Reverse 






Onehrafter GW4064 treatment, cells were fixed in 1% formaldehyde for 10 minutes 
(mins), followed by quenching with glycine and rinsing with cold PBS. Afterwards, cells 
were collected and lysed. Nuclei were released and sonicated into 200-700 base-pair 
(bp) DNA fragments. Aliquot chromatin was incubated overnight with 5 μg anti-FXR 
antibody (1:1 mixture of sc-1204x and sc-13063x, ChIP grade) (Santa Cruz 
Biotechnology, CA), or control rabbit immunoglobulin G (rIgG, sc-2027) (Santa Cruz 
Biotechnology, CA). Chromatin-antibody complex were pulled down with prewashed 
Dyna beads (Invitrogen, CA), washed and eluted. DNA fragments associated with FXR 
or control antibodies were eluted and purified. Input genomic DNA was obtained 
through similar elution and purification procedures. Quality of ChIP assay was 
confirmed by qPCR with primers amplifying known FXRREs of human FXR target 
genes (promoter regions of BSEP (bile salt export pump) and OST-β (organic solute 
transporter beta) as well as the negative control (promoter region of IL-8 (interleukin-8). 
Primer sequences are listed in Table 2.1. PHH samples from four donors, with good 
FXR activation and pull-down efficiency, were selected to pool together for the 
generation of sequencing libraries (Table 3.1). For HepG2 cells, only chromatin 
samples obtained from GW4064 treated cells were used for sequencing library 
preparation. Primer sequences used for qPCR followed by ChIP experiments (ChIP-
qPCR) are listed in Table 2.1. 
 
Sequencing Library Preparation for ChIP-seq and RNA-seq 
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Equal amounts of chromatin from the selected four PHH donors were pooled together, 
followed by ChIP assay to generate DNA for ChIP-seq library preparation. Equal 
amounts of RNA from the selected PHHs were pooled together as well for RNA-seq 
library preparation. DNA and RNA sequencing libraries were prepared using the 
Illumina TrueSeqTM DNA and RNA Sample Prep Kit (Illumina, CA), respectively. The 
quality of all library samples was confirmed by Agilent Bioanalyzer (Agilent 
Technologics, CA) before the sequencing reactions. For ChIP-seq, purified library DNA 
ranging from 400 to 500 bp was fractionated on an agarose gel, followed by extraction 
and purification before sequencing. All libraries were sequenced 100 bp paired-end on 
Illumina HiSeq2000 sequencing system. 
 
ChIP-seq Data Analysis 
Genome Analyzer Pipeline Software (Illumina, CA) were used for both primary image 
data files processing and base calling. All sequenced paired-end reads were aligned to 
Homo sapiens version 19 (hg19) reference genome using bowtie (version 0.12.7) 
(Langmead et al. 2009). Only uniquely mapped reads were included. Regions with read 
enrichment were detected using Model-based Analysis of ChIP-Seq (MACS v 1.4.1) 
method (Zhang et al. 2008). By comparing with the rIgG background, non-specific 
peaks with false discovery rate (FDR) greater than 0.1 were eliminated. Identified peaks 
were further split by Mali Salmon's Peak Splitter 
(http://www.ebi.ac.uk/bertone/software.html) and filtered by p-value of Poisson 
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distribution lower than 10-5. Peaks were annotated using R packages (http://www.r-
project.org) based on the ENSEMBL version 65 human genes. 
Motif Analysis for ChIP-seq 
For each ChIP-seq dataset, the sequences for the summit regions (201 bp), spanning 
100 bp up and downstream from the summit of each peak, were retrieved. The top 500 
sequences with the highest peak score were selected for motif analysis based on 
MEME (Multiple Em for Motif Elicitation) (Bailey et al. 2009). 
 
ChIP-seq Validation 
To validate the ChIP-seq results, we first identified the IR-1 site for each peak, which 
was located inside the peak summit regions (201 bps) used for motif analysis. Then the 
genome sequences spanning the IR-1 sites were retrieved to design qPCR primers. 
ChIPed DNA from individual donors and pooled samples were used for qPCR validation. 
The primer sequences are listed in Table 2.1.  
 
Microarray for GW4064 and Vehicle Control Treated C57BL/6J Mice 
C57BL/6J (hereafter referred to as wild type (WT) mice (n=3) were treated with either 
GW4064 (100 mg per kg body weight) or vehicle three times as previously described 
(Kong et al. 2012b) (first dose at 8 am, second dose at 6 pm, third dose at 8 am the 
second day). Mice were fasted overnight starting from the second dose and liver tissues 
were collected at 2 hrs after the third dose. All mice used for microarray study were 
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maintained in pathogen-free animal facilities in the Laboratory of Animal Research, 
under a standard 12-h light/dark cycle (6:00AM/6:00PM) with free access to standard 
chow and autoclaved tap water. Animal protocols and procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University of Kansas 
Medical Center. Total RNA from livers was prepared with TRIzol Reagent (Invitrogen, 
CA), and the whole transcription expression levels were determined using Mouse Gene 
1.0 ST Array system manufactured by Affymetrix, Inc.. Microarray data were analyzed 
using the Affymetrix Power Tools (http://www.affymetrix.com). 
 
RNA-seq Data Analysis 
For RNA-seq in PHHs, RNA was pooled from selected PHH donors. After sequencing, 
the obtained reads were aligned to the Homo Sapiens reference genome (hg19) using 
TopHat (version 2.0.0) (Trapnell et al. 2012).The resulted alignments were then 
assembled into transcripts using Cufflinks (version 2.0.2). Cuffdiff, a component of the 
Cufflinks package, was used to estimate FPKM (fragments per kilobase of exon model 
per million mapped fragments) and identify differentially expressed transcripts. Finally 
the Baggerley’s test was used to perform the differential expression analysis. 
 
Pathway Analysis for ChIP-seq and RNA-seq 
Functional genes from ChIP-seq and RNA-seq were selected and analyzed using the 
Functional Annotation Tool in DAVID (http://www.david.niaid.nih.gov). For a pathway or 
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process to be defined, the threshold count was set at 2 with a minimum EASE 
(Expression Analysis Systematic Explorer) score, a modified Fisher Exact Test, of 0.1. 
Categories from DAVID with false discovery rates (FDRs) less than or equal to 0.1 were 
considered as statistically significant.  
 
Data Files Access for ChIP-seq and RNA-seq 
All sequencing data files discussed in this publication have been deposited in NCBI's 
Gene Expression Omnibus (Edgar, Domrachev and Lash 2002) and are accessible 




For RT-qRCR experiments for PHHs, due to the difficulty of repeating sample collection 
from individual PHH donors, PHHs from different donors served as experimental 











2.2 Studies of PNALD in Animal Models 
Animals and Surgery 
All animal protocols and procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC) of the Rutgers University. Unless otherwise specified, 
all mice used for the PNALD study were maintained in the pathogen-free animal 
facilities in the Comparative Medicine Resources at the Nelson Animal Facility at 
Rutgers University, under a standard 12-h light/dark cycle (6:00AM/6:00PM) with 
temperature-, humidity- controlled conditions. Mice were fed at ad libitum with standard 
mouse chow and autoclaved tap water. C57BL/6J (WT) mice used in this study were 
obtained from the Jackson Laboratory (Bar Harbor, ME) 
For the surgery of jugular vein catheterization, mice were anesthetized with 
80mg/kg ketamine and 10 mg/kg xylazine via intraperitoneal injection, followed by 
placement of a central venous catheter (polyurethane tubing, 1F in O.D., ) (SAI Infusion 
Technologies, IL) into the right jugular vein. After inserting the catheter into the right 
atrium of the mouse, the patency was verified by carefully withdrawing minimal amount 
of blood from the jugular vein. Once the correct insertion was confirmed, the saline 
solution in the catheter was replaced by heparin/glycerol catheter lock solution (SAI 
Infusion Technologies, IL) followed by securing the proximal end of the catheter with a 
stainless steel plug (SAI Infusion Technologies, IL), to maintain the catheter patency 
during the post-operative recovery period. The proximal end of the catheter was then 
tunneled subcutaneously and exited between the shoulder blades. The outside part of 
catheter was secured with a wound clip on the back of the mouse to prevent potential 
damage from the surgical mouse. On the next day, the fully recovered surgical mouse 
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was placed in a plastic harness (SAI Infusion Technologies, IL) and the catheter was 
flushed with saline. Catheter patency was confirmed with blood withdraw again before 
connecting the catheter to an infusion pump (Harvard Apparatus, MA) through the 
extension line (SAI Infusion Technologies, IL). Mice were then kept on intravenous 
infusion of normal saline (NS, 0.9%) at an initial rate of 6mL/d and had free access to 
mouse chow (Rodent Diet 5001; LabDiet) and water. The next day, PN mice started to 
receive intravenous PN infusion prepared by CAPS, Inc. (Englewood, NJ), and still had 
free access to water but not mouse chow. One day after, the infusion rates for both 
saline and PN mice were increased to 8mL/d, and kept as 8mL/d throughout the study 
period with the PN solution providing a caloric intake of 10.62 kcal/24 hrs (detailed list of 
nutrients in PN solution was presented in Table 2.2). It has been reported and well-
accepted in the research field, that graded infusion period is necessary for the mice to 
adapt to the continuous infusion of fluid and nutrients (Omata et al. 2013). All saline 
control and PN mice were housed individually in metabolic cages to prevent PN mice 
from coprophagia. 
At the end of the study period, blood was collected from the retro-orbital plexus 
and kept in heparin coated anti-coagulant tubes. Blood samples were then centrifuged 
at 8,000g for 10min to collect plasma. Tissues were quickly collected and snap frozen in 
liquid nitrogen for future analysis.  
 
Serum Biochemical Analysis 
Commercially available testing kits were used to measure serum levels of 
biomarkers, including alanine transaminase (ALT), aspartate transaminase (AST), and 
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alkaline phosphatase (ALP) (Pointe Scientific, MI), and total serum bile acids (TSBA) 
(Diazyme Laboratories, CA). Procedures were scaled up or down based on the 
manufacturer’s instructions. 
 
RNA Isolation, RT-qPCR and Microarray Analysis 
For RNA isolation, frozen mouse tissues were homogenized for 30 seconds 
(secs) in TRI reagent (Invitrogen, CA) with a polytron homogenizer, then undergone the 
isolation procedures according to the manufacturer’s instructions. Live gene expression 
was analyzed by RT-qPCR. After rigorous analysis of gene expression in saline and PN 
mice, RNA samples (n=3) obtained from saline and PN mouse livers were pooled, 
respectively, for microarray analysis (Microarray-PN/Saline). Whole liver transcription 
expression levels were then determined using Mouse Gene 2.0 ST Array system 
manufactured by Affymetrix, Inc. Microarray data were analyzed using the Affymetrix 
Power Tools (http://www.affymetrix.com). Data retrieved from the microarray analysis 
were further validated by RT-qPCR analysis. All the primer sequences for mouse genes 
are listed in Table 2.3. 
 
Histological Analysis 
Mouse liver and intestinal tissues were removed at sacrifice, fixed in 10% neutral 
phosphate buffered formalin. Fixed livers were processed by the University of 
Connecticut Veterinary Medical Diagnostic Laboratory (Storrs, CT), where tissues were 
embedded in paraffin, sectioned into slides, and stained with hematoxylin and eosin 
(H&E) according to standard staining protocols. 
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Organic Extraction and Ultra Performance Liquid Chromatography/Mass 
Spectrometry (UPLC/MS) Profiling of Serum BAs 
For simple protein precipitation, 900uL of pre-chilled acetonitrile (ACN) was 
added to 90uL of plasma samples with 20uL of internal standards, followed by vortex 
and centrifugation at 11,000 x g for 10min at 4oC. The supernatant was then transferred 
to a fresh tube, completely dried under a vacuum evaporator, and reconstituted in 50:50 
methanol/water (v:v). Further purification is done by centrifugation with a 10 kDa 
molecular size exclusion membrane. The final BA extracts were introduced to the 
Thermo Finnigan Ultra Performance Liquid Chromatography (UPLC) system (Thermo 
Fisher Scientific, MA) coupled with a Thermo Finnigan LTQ XL Ion Trap Mass 
Spectrometer (Thermo Fisher Scientific, MA). An Electrospray (ESI)/ITMS was operated 
in multiple MS/MS and SRM (Selective Reaction Monitoring) modes for simultaneous 
determination of 23 bile acid including: CA, CDCA, DCA, LCA, UDCA,TCA, T-CDCA, 
TDCA, taurolithocholic acid (TLCA), tauroursodeoxycholic acid (TUDCA), glycocholic 
acid (GCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), 
glycolithocholic acid (GLCA), and glycoursodeoxycholic acid (GUDCA),  β-MCA, α-MCA, 
ω-muricholic acid (ω-MCA), tauro-β-muricholic acid (T-β-MCA), tauro-α-muricholic acid 
(T-α-MCA), tauro-ω-muricholic acid (T-ω-MCA), HDCA, taurohyodeoxycholic acid 
(THDCA), and glycohyodeoxycholic acid (GHDCA). 
For BA standards, CA, CDCA, DCA, LCA, UDCA, glycocholic acid hydrate, 
taurocholic acid sodium salt hydrate, sodium glycochenodeoxycholate, sodium 
taurochenodeoxycholate, sodium glycodeoxycholate,  sodium taurodeoxycholate 
hydrate, sodium taurolithocholate, and sodium tauroursodeoxycholate, were purchased 
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from Sigma-Aldrich (St. Louis, MO); sodium glycolithocholate, GUDCA, sodium 
tauroursodeoxycholate, β-MCA, α-MCA, ω-MCA, tauro-β-muricholate, tauro-α-
muricholate, tauro-ω-muricholate, HDCA, THDCA, and GHDCA were purchased from 
Steraloids, Inc. (Newport, RI). For internal standards, chenodeoxycholic-2,2,4,4-d4acid 
(2H4-CDCA) and glycochenodeoxycholic-2,2,4,4-d4 acid (
2H4-GCDCA) were purchased 
from C/D/N Isotopes, Inc. (Pointe-Claire, Quebec, Canada). 
 
Statistical Analysis 
 Student’s t-test was used to compare the data obtained from the saline and PN 
groups. P-value < 0.05 was considered statistically significant. 
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Table 2.2 Components of Parenteral Nutrition per 100 mL 
Component Amount Unit 
Concentrated amino acid * 4 g 
Dextrose 25.5 g 
Lipid 
#
 3 g 
Sodium phosphate 1.34 mM 
Potassium chloride 1.6 mEq 
Sodium chloride 3.2 mEq 
Potassium acetate 12 mEq 
Magnesium sulphate  0.8 mEq 
Calcium gluconate 1.32 mEq 
Multitrace®-5 concentrate 
§
 0.1 ml 
Heparin 500 U 
Multi-vitamin 
¥
 2 ml 
Protein content (amino acid) 4 g 
Nitrogen content  0.632 g 
Non-protein calorie 116.7 kcal 
Carbohydrate calorie 86.7 kcal 
Lipid calorie 30.0 kcal 
Protein calorie 16 kcal 
Total calorie 132.7 kcal 
 
* Clinisol 15%, obtained from Baxter International Inc., Deerfield, IL.                                    
# Intralipid 20%, obtained from Baxter International Inc., Deerfield, IL.                                 
§ Multitrace®-5 concentrate, contains zinc, copper, manganese, chromium, and 
selenium, obtained from American Regent, Inc. Shirley, NY.                                          
¥




Table 2.3 List of qPCR Primers Used for Mouse PN Studies 
 
  
Gene Forward Primer Sequence (5' - 3') Reverse Primer Sequence (5' - 3') 
β-actin GCGTGACATCAAAGAGAAGC CTCGTTGCCAATAGTGATGAC 
Fxr TCCGGACATTCAACCATCAC TCACTGCACATCCCAGATCTC 
Bsep CTGCCAAGGATGCTAATGCA CGATGGCTACCCTTTGCTTCT 
Ost-α GTCTCAAGTGATGAACTGCCA TTGAGTGCTGAGTCCAGGTC 
Ost-β GTATTTTCGTGCAGAAGATGCG TTTCTGTTTGCCAGGATGCTC 
Mrp3 AGAGCTGGGCTCCAAGTTCT TGGTGTCTCAGGTAAAACAGGTAGCA 
Ntcp GGCCACAGACACTGCGCT AGTGAGCCTTGATCTTGCTGAACT 
Fgf15 GCCATCAAGGACGTCAGCA CTTCCTCCGAGTAGCGAATCAG 
Shp CGATCCTCTTCAACCCAGATG AGGGCTCCAAGACTTCACACA 
Cyp7a1 AACAACCTGCCAGTACTAGATAGC GTGTAGAGTGAAGTCCTCCTTAGC 
Cyp7b1 CAGCTATGTTCTGGGCAATG TCGGATGATGCTGGAGTATG 
Cyp8b1 AGTACACATGGACCCCGACATC GGGTGCCATCCGGGTTGAG 
Cyp27a1 GCCTCACCTATGGGATCTTCA TCAAAGCCTGACGCAGATG 
Cyp2b10 GACTTTGGGATGGGAAAGAG CCAAACACAATGGAGCAGAT 
Cyp17a1 TGGCTTTCCTGGTGCACAATC GGAGGTGAGTCCGGTCATTGAA 
Abcg5 TGGATCCAACACCTCTATGCTAAA GGCAGGTTTTCTCGATGAACTG 
Abcg8 CCGTCGTCAGATTTCCAATGA GGCTTCCGACCCATGAATG 
Fas GCTGCGGAAACTTCAGGAAAT AGAGACGTGTCACTCCTGGACTT 
Srebp1c GGAGCCATGGATTGCACATT GCTTCCAGAGAGGAGGCCAG 
Nurr77 AGCTTGGGTGTTGATGTTCC AATGCGATTCTGCAGCTCTT 
Lxrα GGGAGGAGTGTGTGCTGTCAG GAGCGCCTGTTACACTGTTGC 
Lpl AGGACCCCTGAAGACAC GGCACCCAACTCTCATA 
Abcd2 CACAGCGTGCACCTCTAC AGGACATCTTTCCAGTCCA 
Lepr-b GCATGCAGAATCAGTGATATTTGG CAAGCTGTATCGACACTGATTTCTTC 
Marco GCACTGCTGCTGATTCAAGTTC AGTTGCTCCTGGCTGGTATG 
Nocturnin ACCAGCCAGACATACTGTGC CTTGGGGAAAAACGTGCCT 
Acc TGACAGACTGATCGCAGAGAAAG TGGAGAGCCCCACACACA 
Scd1 CCGGAGACCCCTTAGATCGA TAGCCTGTAAAAGATTTCTGCAAACC 
Cd36 GATGACGTGGCAAAGAACAG TCCTCGGGGTCCTGAGTTAT 
Sult1e1 GTGGAAAAATGCAAGGAGGA GGGTGGCAGGTGAGTTTTTA 
Pgc-1α CGGAAATCATATCCAACCAG TGAGGACCGCTAGCAAGTTTG 
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Chapter 3: Genome-wide Binding and Transcriptome Analysis of Human FXR in 
PHHs and HepG2 Cells 
(Portions of this section are adapted from Zhan et al. (2014), PLoS ONE 9(9): e105930. 
doi:10.1371/journal.pone.0105930 (Zhan et al. 2014))  
 
3.1 Introduction 
Farnesoid X receptor (FXR, NR1H4) is a ligand activated transcription factor 
belonging to the nuclear receptor (NR) superfamily (Forman et al. 1995), and is highly 
expressed in the liver, intestine, and kidney, both in humans and rodents (Zhang et al. 
2003). Bile acids (BAs) are the endogenous ligands of FXR (Makishima et al. 1999). 
FXR mainly functions as the BA sensor by regulating genes that are critically involved in 
BA homeostasis, including BA biosynthesis, conjugation, and enterohepatic circulation 
(Sinal et al. 2000). In addition, it has been shown that FXR is also involved in lipid and 
glucose homeostasis, inflammation, and tumorigenesis (Sinal et al. 2000, Ma et al. 
2006, Wang et al. 2008, Kim et al. 2007). FXR normally forms a heterodimer with 
retinoid X receptor alpha (RXRα) and binds to DNA elements as FXR response 
elements (FXRREs) (Forman et al. 1995). The most common DNA motif bound by FXR 
is an inverted repeat separated by one nucleotide (IR1). Upon ligand activation, the 
heterodimer normally activates the expression of its target genes.  
Chromatin immunoprecipitation - deep sequencing (ChIP-seq) analysis has been 
widely used to study the functions of various NRs, including androgen receptor (AR), 
estrogen receptor alpha (ERα), glucocorticoid receptor (GR) etc. (Jia et al. 2008, Gao et 
al. 2008, John et al. 2008). This approach has aided in discovering novel pathways 
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regulated by these NRs. We and others have reported the genome-wide binding 
analysis of FXR in mice (Thomas et al. 2010, Chong et al. 2010, Lee et al. 2012). These 
studies suggest broad functions of mouse FXR as well as novel molecular mechanisms, 
by which FXR regulates its target genes. First of all, FXR could bind to multiple sites 
within a known FXR target gene. For example, FXR binds to both the promoter and 3’ 
gene regulatory regions of the Nr0b2 gene, which encodes small heterodimer partner 
(SHP) (Thomas et al. 2010), and this pattern of binding likely enhances chromatin 
interaction and subsequent gene expression (Li et al. 2010). Secondly, many new target 
genes of FXR are identified in the liver and/or intestine, including the Sqstm1 gene, 
which encodes the protein p62, an important component of autophagy (Williams et al. 
2012).  Thirdly, FXR cooperates with other transcription factors, most likely orphan 
nuclear receptors, to modulate transcription of genes involved in specific biological 
processes. For exp., FXR and LRH-1 (liver receptor homolog-1) co-regulate genes 
involved in lipid homeostasis (Chong et al. 2012, Thomas et al. 2013).  Fourthly, FXR 
elicits tissue-specific binding patterns, indicating differential regulation of chromatin 
structures as well as FXR functions among different organs/cells. Lastly, FXR binding 
could suppress gene expression, which could be altered during disease state, such as 
obesity (Lee et al. 2012). Taken together, these studies suggest that FXR may regulate 
diverse physiological and pathological processes in mice, underlying that tissue- or 
even pathway-specific modulations of FXR may provide better treatment strategies to 
various lipid- and BA-associated diseases. Indeed, recent literatures have highlighted 
FXR as a potential therapeutic target for different metabolic diseases, such as 
parenteral nutrition associated cholestasis (El Kasmi et al. 2013), vertical sleeve 
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gastrectomy (Ryan et al. 2014), and more commonly nonalcoholic steatohepatitis 
(NASH) (Deng et al. 2013, McMahan et al. 2013), while only limited treatment options 
are currently available for these diseases. 
To date, the binding of human FXR in primary human hepatocytes (PHHs) or 
hepatoma cell lines has been characterized to limited genes, including ABCB4 (ATP-
binding cassette, sub-family B, member 4), ABCB11, FGF19 (fibroblast growth factor 
19), ICAM1 (intercellular adhesion molecule 1), and NR0B2 (Ananthanarayanan et al. 
2001, Sinal et al. 2000, Holt et al. 2003, Huang et al. 2003, Qin et al. 2005). However, 
the genome-wide FXR binding profile in humans is not yet available. More importantly, 
little information is known about species similarities and differences in terms of FXR 
binding between humans and mice, which are needed urgently to determine to what 
degree the murine models can be used to study the role of FXR in various physiological 
and/or pathological conditions. 
In this study, using ChIP-seq and RNA-seq techniques, we determined the 
genome-wide binding and transcriptome profiles of human FXR in PHHs, as well as 
genome-wide binding profiles in HepG2 cells. We compared and contrasted the binding 
patterns and gene regulation profiles of FXR between human and mouse livers, as well 
as between PHHs and HepG2 cells. 
 
3.2 Results 
FXR Activation in PHHs 
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To identify genome-wide FXR binding sites in primary human hepatocytes, we 
first validated FXR activation in the PHHs obtained in this study. Upon 24 hrs of 
GW4064 treatment, mRNA levels of classic FXR target genes (BSEP, OST-β) were 
induced in PHHs from individual donors (Figure 3.1 A). Pooled chromatin samples, 
which were collected after 1hrGW4064 treatment, showed significant enrichment of 
FXR binding to known FXR targets (promoter regions of BSEP and OST-β), but not the 
negative control (promoter region of IL-8) (Figure 3.1 B). ChIPed-DNA, generated from 
pooled chromatin from selected donors (Table 3.1), as well as pooled RNA was then 
used to generate DNA and RNA sequencing libraries. Indeed, many known human 
FXRREs were detected with relatively high peak values in this study, in both DMSO and 
GW4064 treated PHHs (Table 3.2). Again, multiple FXR binding sites were found in the 
NR0B2 and OST-β gene in our datasets (Table 3.2), which resembled the binding 
patterns of FXR to these genes in mice (Thomas et al. 2010).  
In ChIP-seq, the peak summit of each peak (binding site) was a single bp 
position within the peak with the highest coverage given by the MACS analysis. Due to 
the relatively large size of fragmented library DNA obtained in this study (average 350 
bp for ChIP-seq), and the subtle differences in the local chromatin environment in 
different samples, we saw slightly different peak width and peak summit values for the 
same binding sites in the two datasets. For example, for the binding site located in the 
intron of FGF19 gene, the peak width was 1000 and 851 bps in the ChIP-seq datasets 
from DMSO treated PHHs (PHH-DMSO) and GW4064 treated PHHs (PHH-GW), 
respectively. And the peak summits in the two datasets were 3665 and 3695 bps 
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downstream from the TSS of FGF19, respectively. Nevertheless, these peaks were 
indicating the same binding site.  
 
Comparison of Global FXR Binding between PHHs and Mouse Livers 
When cut off score (CO score) for ChIP-seq data analysis was set as 20, a total 
of 2759 and 5235 FXR binding sites were identified from PHH-DMSO and PHH-GW, 
respectively. Human and mouse FXR binding profiles in livers were compared between 
these human data with our previous genome-wide mouse FXR binding data, which were 
obtained from WT mice treated with GW4064 (referred to as mLiver-GW, which was not 
normalized to the rIgG control though) (Thomas et al. 2010). The following results were 
obtained by comparing the global binding pattern in these datasets: 1st, genomic 
distributions of FXR binding sites were similar in PHHs compared to those in mice 
(Figure 3.2). Briefly, around 43% peaks were located in intergenic, 21% in upstream 0-
10 kb, 22% in introns, 10% in downstream 0-10 kb, 2% in 5’ untranslated region (UTR), 
1% in 3’ UTR, and 1% in coding DNA sequence (CDS) regions of their associated 
RefSeq genes in both PHH-DMSO and PHH-GW. This site-distribution pattern was 
similar to that in mice. Though in mouse livers, around 30% peaks were located in 
introns and 15% in upstream 0-10 kb region (Thomas et al. 2010). 2nd, the distribution 
patterns of total FXR binding sites relative to transcription start sites (TSSs) of the 
associated RefSeq genes, and FXR’s intron binding patterns were both similar to those 
in mice as well. The highest frequency of total binding events was located within 0-10 kb 
up and downstream of TSSs (Figure 3.3 A). Most intron binding events were located in 
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the 1st intron and the number of total binding events in individual intron decreased as 
the intron number increased (Figure 3.3 B). These patterns were almost identical to 
those in mice (Thomas et al. 2010). 
 
Motif Analysis of FXR Binding Sites in PHHs 
The most commonly reported FXR binding motif is an IR1 in both mice and 
humans. This motif has been reported in many human FXR target genes, such as 
ABCB11, FGF19, NR0B2, and OST-β (Holt et al. 2003, Ananthanarayanan et al. 2001, 
Goodwin et al. 2000). When we select the top 500 peaks from PHH-GW and PHH-
DMSO, the most common motif found in PHH-GW was an IR-1 with a putative nuclear 
half site, whereas in PHH-DMSO it was the IR1 motif (Figure 3.4). And interestingly, 
when we select the top 501-1000 peaks to run motif analysis, we only obtained the IR-1 
motif from both datasets (data not shown). The presence of IR-1 with nuclear half site 
was also similar to our previous motif analysis in mouse livers (Thomas et al. 2010).  
 
Validation of ChIP-seq and Novel FXR Targets in PHHs 
After motif analysis, we were able to precisely locate the IR-1 site associated with 
each peak summit for most peaks in our datasets. The subtle position difference (mostly 
around 50bp) from the IR-1 site to the peak summit for each FXR target was most likely 
caused by a combination of relatively large DNA fragments used for our sequencing 
analysis and the technical limitation of the sequencing processing and data analysis. 
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Since most classic FXR targets were presented correctly in the datasets (Table 3.2), we 
then focused on validating novel FXR targets.  
ChIP-qPCR was performed on chromatin samples from pooled PHH samples, as 
well as individual PHH donors. For many FXR targets, we were unable to detect valid Ct 
value from rIgG control from qPCR experiments for individual PHH donors, mainly due 
to limited quantity of chromatin samples. Nevertheless, we were able to confirm 
enhanced FXR pull-down from GW4064 treated PHHs comparing to DMSO control, for 
the promoter regions of BSEP and most selected novel targets, but not the negative 
controls. And for those FXR targets, of which FXR pull-down was not further enhanced 
upon GW4064 treatment, we were able to calculate their FXR pull-down efficiency after 
normalizing to rIgG control from pooled PHH samples (Figure 3.5 A, B). Without valid 
Ct values from the rIgG control pull-down, we couldn’t differentiate these FXR targets 
from the negative controls. For exp., the binding score for PNMT (phenylethanolamine 
N-methyltransferase) in PHH-DMSO and PHH-GW were 55 and 68, respectively, which 
were close. Indeed, ChIP-qPCR showed similar FXR pull-down efficiency from pooled 
PHH samples (Figure 3.5 B, around 3 fold for both control and treatment). The 
promoter region of OST-β showed the same trend as well (Figure 3.1 B).  
In this regard, to better illustrate FXR binding in both DMSO and GW4064 treated 
PHHs, only ChIP-qPCR data for pooled PHHs were presented. We were able to 
validate FXR pull-down for most selected novel targets with relatively high binding 
scores (9 out of 11 peaks were validated, with binding scores equal to or above 50 in 
either PHH-DMSO or PHH-GW (Figure 3.5). This trend was consistent with our 
previous findings in mouse livers (Thomas et al. 2010).  
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Microarray, RNA-seq and their Correlation with ChIP-seq Datasets 
Using microarray, we obtained a gene expression profile from WT mouse livers 
treated with GW4064 (M-mLiver-GW) normalized to vehicle control. When set cut off 
fold induction (CO fold) as 1.5 and p-value <0.05 (unpaired t-test), we obtained 102 
different genes with altered expression levels, up or down more than or equal to 1.5 fold. 
From RNA-seq for GW4064-treated PHHs (R-PHH-GW), which was normalized to 
DMSO control, we obtained 143 genes with log2 fold enrichment ≥2 (fold change ≥4, 
both up- and down- regulated) and p-value <0.05. The percentage of genes found in 
microarray and RNA-seq, which was also bound by FXR from ChIP-seq, was plotted in 
Figure 3.6 based on the fold induction from microarray and RNA-seq. Among all the 
genes found in M-mLiver-GW, over 50% were bound in mLiver-GW for both up- and 
down- regulated. However in R-PHH-GW, around 50% up-regulated genes were bound 
in PHH-GW, whereas only a few down-regulated genes were actually bound in PHH-
GW. Interestingly, FGF19 and cytochrome P450, family 7, subfamily A, polypeptide 1 
(CYP7A1) were the top up- and down-regulated FXR targets in R-PHH-GW, 
respectively.  
 
Pathway Analysis for ChIP-seq and RNA-seq for PHHs 
A major difference between the mLiver-GW dataset and the PHH-GW dataset 
was that, more than 5,000 genes and 10,000 peaks were found in mLiver-GW 
compared to 5,231 peaks identified in PHH-GW. The lack of IgG control for the mLiver-
GW may well explain this major difference as non-specific peaks may present in the 
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mouse FXR binding study. Another difference was that the majority of the peaks in 
mLiver-GW were associated with RefSeq genes, which encode proteins with known 
functions, whereas in PHH-GW only around 50% peaks were. In order to compare and 
contrast the functional detail of FXR binding in humans and mice, two major analyses 
from DAVID were performed, the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
and the Gene Ontology Biological Process (GO-BP) analysis. Similar to our previous 
study, functional genes associated with peaks located in the upstream 0-10 kb promoter 
regions were selected to run DAVID analyses. Overall, more categories were enriched 
in PHH-GW than PHH-DMSO. And most categories enriched in PHH-DMSO were also 
presented in PHH-GW. In this regard, only categories and their corresponding FXR 
targets from PHH-GW were presented and compared with mLiver-GW. All significantly 
enriched KEGG categories (with FDR <0.1) (Table 3.3 A), and the corresponding genes 
(Table 3.5 A) obtained were listed, whereas most non-redundant categories (with gene 
count >5) from GO-BP were presented (Table 3.3, 3.5 B). From DAVID analyses, we 
could see overall similar pathways enriched from mLiver-GW and PHH-GW, though the 
number of genes retrieved from PHH-GW was smaller. Nevertheless, the percentage of 
genes found in each category was similar between the two datasets. For R-PHH-GW, 
291 functional genes with log2 fold ≥1 (fold change ≥2, up- and down- regulated), and p-
value ≤0.05 were retrieved for KEGG and GO-BP analyses. Note that the cut off fold 
change used for pathway analysis is smaller than the cut off used for the ChIP-
seq/RNA-seq correlation analysis. For pathway analysis, the cumulative effect from 
many altered genes in a single pathway could be of functional importance as well, 
though the level of fold change for individual gene was relatively low. All categories from 
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KEGG and non-redundant categories from GO-BP, and the corresponding genes were 
presented (Table 3.4 A, B). In agreement with previous correlation study presented in 
Figure 3.6, both similar and different categories were enriched from R-PHH-GW. 
Interestingly, many genes involved in chemokine signaling pathway (KEGG) and 
chemotaxis (GO-BP) were enriched in R-PHH-GW (Table 3.4), and most of these were 
not directly bound by FXR. 
 
Genome-wide FXR Binding Profiles in HepG2 Cells 
As expected, common FXR targets were also identified in the ChIP-seq analysis 
for GW4064 treated HepG2 cells (HepG2-GW) (Table 3.1). Similar results in terms of 
FXR activation (Figure 3.1 A, B), genomic and functional distributions of FXR binding 
sites (Figure 3.2, Figure 3.3 A, B), and FXR binding motif (Figure 3.4) were obtained 
from the HepG2-GW as well. Similar to PHH-DMSO, the most common binding motif 
identified for HepG2-GW was also an IR1, without a nuclear half site.  
 
3.3 Discussion 
In this study, combining the widely used ChIP-seq and RNA-seq techniques, we 
have characterized the genome-wide FXR binding and transcriptome profiles upon 
ligand activation in selected PHHs and HepG2 cells. From the three datasets, we were 
able to detect almost all previously identified important human FXR targets, which have 
diverse physiological functions. Comparing the global FXR binding patterns, we showed 
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that the patterns in PHHs and HepG2 cells were very similar to those identified in 
mouse livers in terms of genomic distribution, intron binding pattern, and the association 
with TSSs of RefSeq genes. These phenomena were in agreement with the conserved 
function of FXR in transcriptional regulation.  
Most convincingly, the motifs found in this study were almost identical to those 
found in mice. Interestingly, the putative nuclear receptor half site was enriched 
significantly only from the top 500 peaks in PHH-GW, neither in the top 501 to 1000 
peaks nor the top 500 peaks from PHH-DMSO (Figure 3.4). In the chromatin level, the 
co-binding of FXR and other transcription factors to certain targets may potentially 
correspond to higher levels of pull-down from ChIP assay, leading to higher enrichment 
scores for these genes. Previous genome-wide binding analysis of LRH-1 in mice has 
shown that LRH-1 could bind to the nuclear half site next to IR1, and co-regulate 
transcription of FXR target genes involved in lipid metabolic processes in mice (Chong 
et al. 2012). The top 500 peaks identified in this study are associated with genes not 
only involved in lipid metabolism, but in diverse cellular processes. This could indicate a 
common mechanism of how FXR regulate gene transcription in different cellular 
processes, while with different cofactors involved. This type of co-regulation has been 
well studied for ERα (Lupien et al. 2008). Moreover, the presence of a nuclear receptor 
half site adjacent to the IR-1 in both PHH-GW and mLiver-GW indicates the similarities 
of FXR functions from mice to humans in a greater extent by indicating the existence of 
similar type of cofactors for FXR in different species. This mechanistic similarity 
implicates that tissue- and even pathway- specific FXR modulation in mice can be 
translated into therapeutic benefits in humans. 
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Using multiple pathway analysis tools (KEGG and GO-BP from DAVID), the 
current study predicts that human FXR could participate in the regulation of diverse 
physiological processes (Table 3.3, 3.4, 3.5). Furthermore, similar pathways were 
enriched from PHH-GW compared to mLive-GW. More genes were obtained from 
mLiver-GW than PHH-GW. As a result, more pathways were enriched in mLiver-GW 
(Thomas et al. 2010). Future studies are needed in order to determine to what degree 
the lack of IgG control contributes to the increased output from mLiver-GW. Overall, the 
comparison studies presented in this study will be valuable information for researchers 
in correlating and translating previous and future mouse FXR studies to human FXR 
functions. 
RNA-seq analysis for DMSO and GW4064 treated PHHs also further confirmed 
the reliability of GW4064 treatment and FXR activation in this study. Interestingly, 
FGF19 and CYP7A1 were the top up-regulated and down-regulated target genes in 
PHHs, respectively, whereas in mice Fgf15 is only found to be expressed and induced 
in the intestine (Kong et al. 2012b). 
When correlating the results from ChIP-seq with RNA-seq for PHHs, and 
microarray for mouse livers, different trends were observed for genes down-regulated 
following GW4064 treatment (Figure 3.5). In addition, only a small portion of target 
genes showed similar change in R-PHH-GW and M-mLiver-GW. This difference may be 
due to several reasons. First, there are different baseline regulatory network in different 
species, such as the different expression patterns of FGF19 in humans versus Fgf15 in 
mice. Besides, the genetic background of the PHH donors could be heterogeneous 
since we didn’t receive certain donor information upon tissue collection, such as races, 
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patient condition, etc. And the inbred C57BL6/J mice were relatively homogenous. 
Second, for many FXR target genes, the expression levels may be already high in 
control mice due to activation of FXR by the largely stable bile acid pool, while the levels 
of residual bile acids in PHHs could be very low. In this regard, GW4064 treatment 
wouldn’t further induce the expression of these genes in mice. In line with this, for many 
FXR target genes in mice, we detected similar FXR binding from ChIP assay when 
comparing GW4064 treated versus vehicle control treated mouse livers (data not 
shown). But we did see dramatic increase of FXR binding from GW4064 versus DMSO 
treated PHHs (see data in Table 3.2, Figure 3.1 and Figure 3.5). Indeed, both the 
magnitude of relative fold change levels and the number of altered genes were much 
larger in R-PHH-GW than M-mLiver-GW.  Third, gene expression in the mouse livers 
could be affected by whole body physiology, such as circadian rhythms, hormones, 
fast/feeding cycles, physical activity and energy level, etc. Fourth, for microarray study, 
we cannot completely rule out the contributions from other cell types in mouse livers, 
such as endothelial cells and liver Kupffer cells, while in the enriched PHHs, the number 
of other liver cell types was minimal. Finally, technical differences between RNA-seq 
and microarray could be another minor factor as well. Among all these factors, the first 
two that affecting the baseline expression levels of many FXR target genes, could be 
the major causes of the differences we saw between the in vivo and in vitro studies. 
While certain technical limitations existed, the correlation/comparison study still provides 
valuable information for human FXR function. For R-PHH-GW, mRNA level down-
regulation was observed for only a few FXR target genes found in ChIP-seq. But for M-
mLiver-GW, the percentage of up- and down- regulated genes also presented in ChIP-
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seq was similar. Lee et al have shown that direct gene suppression by FXR is common 
in mice (Lee et al. 2012). The correlation study presented here implicates that FXR may 
play less important roles in direct gene suppression in humans.   
When comparing HepG2 cells to PHHs, FXR bound to genes in overall similar 
pathways, even though the total number of peaks found in HepG2-GW was only half of 
that found in PHH-GW (data not shown). Previous studies in HepRG cells, another 
human hepatoma cells, showed overall more similar mRNA expression profiles than 
HepG2 cells, when compared to PHHs and human liver specimens, especially for drug 
metabolism genes (Hart et al. 2010). It is possible that for these genes, not only the 
signal regulation network was different in HepG2 cells, but the associated chromatin 
structures also changed. The altered FXR binding and gene expression of BSEP in 
HepG2 cells was an example to show the complexity of gene regulation. Nevertheless, 
to a greater extent, our data indicate that HepG2 cells represent PHHs well in terms of 
FXR binding. However, to study the role of FXR in drug metabolism, HepRG cells may 
be a better model. 
The FXR gene sequence is highly conserved across species, and the protein 
sequence is very similar between humans and mice (Maglich et al. 2003, Gardes et al. 
2013). This similarity indicates the overall conserved and important functions of FXR in 
different species, further confirmed by our genome wide binding studies. On the other 
hand, the differences between species, from genome landscape, cellular components, 
all the way to physiology and pathology could contribute to the differences identified in 
this study, especially for gene expression.  
95 
 
In summary, we have obtained valuable information of genome-wide binding and 
transcriptome analyses of human FXR in PHHs. Detailed analysis of the ChIP-seq data 
indicates that the global binding patterns of FXR in HepG2 cells and PHHs are similar to 
those in mouse livers. In addition, similar biological pathways were enriched from genes 
bound by FXR in PHHs compared to those enriched in mouse livers. We also identified 
and validated novel FXR target genes, with and without alteration of mRNA levels. 
Species differences were found for specific pathways and within gene families involved 
in similar pathways. In a major extent, mouse model is a suitable model for studying 





Figure 3.1 Validation of FXR Activation 
 
 (A) RT-qPCR analysis of relative mRNA levels of FXR and FXR targets (BSEP, OST-β) 
in the selected 4 PHH donors (1958, 1959, 1962, and 1974) and HepG2 cells upon 24 
hrs GW4064 treatments. For each PHH donors, we treated 3 wells of cells with 
GW4064, 3 with DMSO control. RNA from each well was collected and analyzed 
individually. Human 18S was used as the normalization control. Fold changes were 
normalized to DMSO control. 
(B) ChIP-qPCR analysis of FXR antibody pull-down for the promoter regions of BSEP, 
OST-β and IL-8 upon 1hr DMSO or GW4064 treatment for pooled chromatin from the 
selected 4 PHH donors and GW4064 treated HepG2 cells. Fold enrichment of FXR 




Figure 3.2 Genomic Distributions of FXR Binding Sites 
 
Percentage of FXR binding sites in the three datasets (HepG2-GW, PHH-DMSO, PHH-
GW) that were distributed to >10 kb from genes (intergenic), 0-10 kb upstream of genes 
(Up 0-10 kb), 5’UTRs, coding sequence (CDS), introns, 3’UTRs, and 0-10 kb 
downstream of genes (Down 0-10 kb) were shown. The cut off score for the data 




Figure 3.3 Distribution of Total FXR Binding Sites Relative to TSSs, and Intron 
Binding Profiles of FXR 
 
 
 (A) The left panel shows the frequency distribution of FXR binding. The number of 
binding events (y-axis) was plotted against the distance from TSSs in 10 kb increments 
(x-axis) for the three datasets. The PHH-GW/DMSO difference was generated by 
plotting the frequency distribution against the subtracted total binding events from the 
PHH-GW to PHH-DMSO. It is interesting that this pattern was similar to the other three 
as well.  
(B) The cumulative binding events of FXR distributed only to introns of RefSeq genes in 
the three datasets. The graph displays the total number of FXR binding peaks (y-axis) in 
PHH-DMSO and PHH-GW located within intron 1-9 of RefSeq genes (x-axis). Total of 
62.8%, 62.4% and 60.2% of intron binding events were located in the first introns in 




Figure 3.4 Motif Analysis 
 
The most commonly identified sequence motifs from the top 500 FXR binding sites in 
the three datasets using MEME. These motifs were found in totally 246, 247, 240 sites 
from the top 500 peaks in HepG2-GW, PHH-DMSO, and PHH-GW, respectively.  It is 
interesting that there is a putative nuclear half site next to the IR-1 site from PHH-GW, 




Figure 3.5 Validation of ChIP-seq in PHHs 
 
The location of FXR binding sites (second column on the left) and binding scores (the 
two columns on the right) for the selected novel FXR targets found in PHH-DMSO and 
PHH-GW were summarized in (A), and ChIP-qPCR results for these targets from 
pooled GW4064 or DMSO treated PHHs were presented in (B). FXR pull-down was 
normalized to rabbit immunoglobulin G control. Note that ACTBP11 is a pseudogene in 
humans. GW4064 treatment also induced the mRNA levels of AOC3, FABP3, PNMT 
and UROC1 in PHHs in RNA-seq (data not shown). *N/F stands for not found. Genes 
with their full names: ACTBP11 (actin, beta pseudogene 11), AOC3 (amine oxidase, 
copper containing 3), FABP3 (fatty acid binding protein 3), HS6ST1 (heparan sulfate 6-
O-sulfotransferase 1), GFOD2 (glucose-fructose oxidoreductase domain containing 2), 





Figure 3.6 Correlation of FXR Binding with Gene Expression Profiling 
 
The binding of FXR to its target genes were correlated with genes that showed altered 
mRNA expression levels in RNA-seq for PHHs (R-PHH-GW) and microarray for mouse 
livers (M-mLiver-GW). The x axis displays the divided range of fold induction in R-PHH-
GW or M-mLiver-GW. For RNA-seq, 143 altered genes with log2 fold change ≥2 (fold 
change ≥4, both up- and down- regulated), p-value <0.05 were used, whereas for 
microarray, 102 altered genes with fold change >1.5 (both up- and down- regulated), p-
value <0.05 were used. The total number of genes from microarray or RNA-seq analysis 
in each fold range was listed in parenthesis. The y axis displays the percentage of 
genes found in M-mLiver-GW and R-PHH-GW, which were also bound by FXR in PHH-
GW (top) and mLiver-GW (bottom). Note that for the y axis, the log2 fold change from 
RNA-seq data analysis was displayed for R-PHH-GW, while for M-mLiver-GW, the 




Table 3.1 Summary of PHH Donors 
 
* Selected PHH donors for ChIP-seq library preparation, which had enough chromatin 
yields to pool from both DMSO and GW4064 treatment. RNA samples from these four 
donors were also used and pooled for RNA-seq. Patient I.Ds, from 1956 to MSUD, was 
used by the tissue bank to record individual PHH. No personal identity information was 
obtained nor provided by the provider. 
 
§ N/A stands for not available. Due to limited quantity of cells, we didn’t detect valid Ct 
values for the positive controls (promoter regions of FXR target genes) from the ChIP-



















1st Female 58 N/A Good N/A § 
2nd Female 85 
Metastatic colon cancer and 
chemotherapy 
Good N/A § 
1956 Male Pediatric Donor, fatty Fair N/A § 
1958 * Female ~ 60 5-10% steatosis Good Good 
1959 * Male Mid age 
Metastatic cancer, prior 
chemotherapy 
Good Good 
1962 * Female ~ 40 
Adenocancer metastatic to 
liver 
Good Good 
1974 * Male 56 Organ donor Good Good 
1983 Male 70 Organ donor Good Fair 




Table 3.2 Selected Known Human FXR Target Genes Identified in This Study * 














ABCB11   -83 69 -103 319 
FGF19 3655 153 3665 89 3695 251 
ICAM1 58 65 58 91 88 111 
MIR122 -36961 321 -36936 89 -36941 294 
NR0B2 -128 116 -258 83 -178 112 
 3262 189 3252 41 3212 69 
OST-β -53 160 -48 67 17 68 
 10017 30 10087 67 10017 138 
PPARα -2819 161 -2839 126 -2789 203 
 
* “Distance To TSS” is the distance of the peak of the binding site to the transcription 
start site (TSS) of the corresponding RefSeq gene. Note that the peak identified from 
ChIP-seq analysis may not overlap exactly with the IR-1 motif found from motif analysis. 
The binding score is the FXR antibody pull-down score normalized to rIgG control 
antibody generated by the sequencing analysis processes. Note that for most FXR 
targets listed, the binding scores retrieved from HepG2-GW and PHH-GW dataset are 
much larger than the scores from PHH-DMSO for the same peak. This is a general 
trend for most shared FXR targets among the three datasets. Genes with their full 





Table 3.3 Comparison of DAVID Functional Annotation for PHH-GW versus 
mLiver-GW* 
A. KEGG analysis 
 
mLiver-GW  (Total 970 
genes) 
PHH-GW (Total 343 genes) 
Term Count % FDR Count % FDR 
Retinol metabolism 
   
12 2.84 0.000336 
Drug metabolism 23 1.82 0.000169 12 2.84 0.001458 
Complement and 
coagulation cascades 




18 1.42 0.030918 10 2.36 0.057414 
PPAR signaling 
pathway 
26 2.06 0.000004 7 1.65 15.843098 
B. GO-BP analysis 
 
mLiver-GW  (Total 970 
genes) 
PHH-GW (Total 343 genes) 
Term Count % FDR Count % FDR 
organic ether 
metabolic process 
11 0.87 3.117740 13 3.07 0.000010 
triglyceride metabolic 
process 
11 0.87 0.268143 12 2.84 0.000011 
glycerolipid metabolic 
process 
21 1.66 1.408123 19 4.49 0.000253 
lipid transport 26 2.06 0.001436 18 4.26 0.000258 
chemical homeostasis 45 3.56 0.750307 31 7.33 0.029556 
monocarboxylic acid 
transport 
8 0.63 0.387526 9 2.13 0.057257 
response to wounding 53 4.19 0.000434 30 7.09 0.138013 
oxidation reduction 86 6.80 0.000218 34 8.04 0.138493 
cholesterol metabolic 
process 
17 1.34 0.045242 11 2.60 0.187740 
homeostatic process 70 5.53 0.036206 37 8.75 0.291825 
steroid metabolic 
process 
41 3.24 0.000000 16 3.78 0.337117 
cellular amino acid 
derivative metabolic 
process 
29 2.29 0.001080 12 2.84 5.666095 
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fatty acid metabolic 
process 
41 3.24 0.000000 11 2.60 40.373990 
regulation of cellular 
ketone metabolic 
process 
8 0.63 1.457816 9 2.13 0.151048 
acute-phase response 14 1.11 0.000078 9 2.13 0.010223 
acute inflammatory 
response 
26 2.06 0.000000 10 2.36 1.440881 
coenzyme metabolic 
process 
30 2.37 0.000427 9 2.13 51.626240 
organic acid catabolic 
process 
27 2.13 0.000000 
   
glucose metabolic 
process 
32 2.53 0.000019 
   
cellular amino acid 
catabolic process 
19 1.50 0.000029 
   
hexose metabolic 
process 
35 2.77 0.000049 
   
monosaccharide 
metabolic process 
36 2.85 0.000351 
   
L-phenylalanine 
catabolic process 
6 0.47 0.018543 
   
pyruvate metabolic 
process 
10 0.79 0.059427 
   
 
*Binding sites that were associated with 0-10 kb upstream of RefSeq genes were 
selected for DAVID functional annotation analyses. The cut off score for ChIP-seq 
datasets was 20. Totally 970 and 343 RefSeq genes were retrieved from mLiver-GW 
and PHH-GW, respectively. The categories were listed based on the FDR values from 




Table 3.4 DAVID Functional Annotation for PHH RNA-seq* 
A. KEGG analysis 
Term % Genes 
Retinol metabolism 2.9508 
CYP1A1, CYP26B1, ADH1C, DHRS9, ADH1B, 




CXCL2, CX3CL1, EDAR, CCL15, CCL18, CXCL10, 
INHBB, CCL25, TNFRSF9, INHBA, TNFSF10, 








1.6393 HSD3B2, CYP1A1, CYP7A1, UGT2B10, SULT1E1 
Tryptophan 
metabolism 
1.3115 KYNU, CYP1A1, IDO2, CYP1A2 
Drug metabolism 1.3115 XDH, UPP1, CYP2A7, UGT2B10 
Tyrosine 
metabolism 




ADRB1, CYSLTR1, PHKA1, CACNA1H, BDKRB2, 




CCL25, CCL14, CCL20, CXCL13, CXCL2, CX3CL1, 
CCL15, CCL18, CXCL10 
B. GO-BP analysis 
Term % Genes 
chemotaxis 4.2623 
CYSLTR1, CXCL2, CX3CL1, CCL15, CCL18, CXCL10, 
CCL25, CCL14, CCL20, CXCL13, IL1B, LECT2, 
DEFB1, FGF2 
oxidation reduction 7.8689 
HSD3B2, XDH, ALDH8A1, STEAP4, ADH1C, ADH1B, 
BBOX1, CYP7A1, CYP26B1, HSD17B6, LOXL4, 
ALDH6A1, CYP1A1, IDO2, DHRS9, CYP26A1, 
CYP1A2, CYP27C1, DIO3, ALOX15B, HAO2, CYP2A7, 
RDH16, DCXR, AOC3 
ion homeostasis 5.2459 
KNG1, MCHR1, PPARD, CYSLTR1, ATP1A2, BDKRB2, 
CCL15, S1PR3, CCL14, RHCG, CXCL13, MT2A, LGI4, 
IL1B, NPPB, NEDD4L, MT3 
immune response 5.9016 
ICAM1, KYNU, IGHG4, AQP9, CXCL2, CX3CL1, 
CCL15, CCL18, CXCL10, CCL25, TNFSF10, 






KNG1, NUAK2, EEF1A2, BCL2A1, ACTN2, BDKRB2, 
SOX9, DAPK2, GDNF, INHBA, SERPINB9, TNFRSF9, 





*Functional genes with log2 fold enrichment ≥1 (fold change ≥2, both up- and down- 
regulated) and p-value <0.05 were selected for DAVID analysis, totally 291 RefSeq 
genes were retrieved from the PHH RNA-seq dataset (R-PHH-GW).  
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Table 3.5 Comparison of Genes from Selected Categories in DAVID Annotation 
for ChIP-seq* 
A. KEGG Analysis 
Category mLiver-GW PHH-GW 
Retinol metabolism 
 








CYP2D9, CYP3A25, CYP2A12, FMO5, 
GSTM3, UGT1A7C, ADH4, GSTK1, FMO3, 
GSTZ1, UGT1A@, GSTA2,GSTA4, 
CYP3A13, CYP3A11, GSTT1, GSTT2, 
CYP2E1, UGT1A1, UGT1A10, AOX1, 
CYP2D26, CYP2C38, CYP2C39, MGST1, 
GSTA3 
CYP3A4,  CYP2B6, 
CYP2C9, CYP2C18,  
ADH1B, CYP3A43, 







KNG1, MBL1, KNG2, HC, C3, C4B, CFB, 
SERPINA1E, PLG, PROC, 
SERPINF2,CFH, C2, CFD,  FGG, FGA, 
FGB, F2, SERPINE1, SERPINC1, CPB2 
F11, MBL2, 
SERPINA1, BDKRB2, 






GSTA2, GSTA3, GSTA4, CYP3A25, 
CYP3A13, CYP3A11, GSTT1, GSTT2, 
CYP2E1, UGT1A1, DHDH, UGT1A10, 
GSTM3, UGT1A7C, GSTK1, ADH4, 










ACOX2, PPARD,PPARA,  APOA2, 
APOA5,APOC3,PCK1(HepG2), CPT1A, 
CPT1B, FABP5, APOA1, ACSL1, CYP7A1,   
ACAA1B, ACSL5, ANGPTL4, SCD1, 
ACADM, DBI, ADIPOQ, CYP27A1, UBC, 
CYP4A14, SLC27A2, SCP2, SLC27A4 





CYP3A25, CYP3A13, HSD17B2, 
HSD17B1, CYP3A11, CYP21A1, UGT1A1, 
UGT1A10, CYP17A1, UGT1A7C, CYP7A1, 











CYP2J5, CYP3A25, CYP3A13, CYP3A11, 








CHPT1, GPD1, PEMT, PLA2G6, AGPAT2, 
AGPAT1, CRLS1, NAT6, PPAP2C, CHKB, 




B. GO-BP Analysis 
Category mLiver-GW PHH-GW 
organic ether 
metabolic process 
MOGAT2, G6PC, APOA5,  APOC1, LIPC, 
APOC3, SLC37A4, SLC22A4,  LIPE, 
PCK1, INSIG2, 
CYP1A1, IL6ST, 
APOC1, APOC2,  
AGPAT6,  DGAT1, 
APOE, G6PC, 
APOC3, APOA2, 
APOA4, APOA5, LIPC 
monocarboxylic acid 
transport 
CPT1B, PPARD, SLC6A6, ABCC3, 
SLC27A2, CROT, SLC10A1, SLC27A4 
MIP, SLC16A5,  
PPARA, CPT2, PLIN2, 
AQP8, FABP1, 
BDKRB2, SLC10A1 
regulation of cellular 
ketone metabolic 
process 
PPARA, HNF4A, INSIG2, AGT, MLXIPL, 
GNMT, ADIPOQ, BRCA1 






RBP4, OSBP, PPARD, LDLR, APOC1, 
APOC2, APOA4, APOA2, APOA1, APOE, 
LCAT, APOC4, APOC3, APOA5, ATP8B1, 
LBP, OSBPL5, CPT1B, ABCG8, NPC1, 
ABCG5, LIPC, SLC27A2, SCP2, CROT, 
SLC27A4 
PPARA,  LDLR, 
APOC1, APOC2,  
APOA4, APOA2, 
P2RX7,  APOE, 
APOC4, APOA5, 






MOGAT2, G6PC, INSIG2, APOA5, 
APOC3, SLC37A4, APOC1, SLC22A4, 









MOGAT2, ALDH5A1, CHKB, SLC37A4, 
APOC1, PTEN, CHPT1, PCK1, G6PC, 
INSIG2, PIGG, APOC3, APOA5, PEMT, 















SLC9A8, PPARD, GCLC, FTL1, LDLR, 
ATOX1, SLC37A4, NR3C2, AQP4, TTC7, 
TRF, ASGR2, APOA2, GCKR, SLC24A3, 
APOE, GRIN2C, PXMP3, APOA5, MT2, 
LGI4, MT1, EIF2B4, SCO1, PRKCA, IBTK, 
SLC8A1, STIM2, MLXIPL, BAD, CSRP3, 
ADIPOQ, PARK7, USF2, QK, ATXN1, 
ABCG8, NPC1, G6PC, TSC1, LYST, 
VEGFA, LIPC, NR5A2, CLN6 
FXYD1, GNA13, 





SAA1, APOE, AGT, 
APOC4, APOA5, 
SERPINE1, APOC3, 
TGM2, QKI, PPP3CA, 
IBTK, P2RX7, G6PC, 




SC5D, OSBP, LDLR, MVD, HSD17B2, 
HSD17B1, SLC37A4, STAT5B, APOC1, 
RDH9, ACBD3, APOA2, APOA1, INSIG2, 
APOE, SAA1, SERPINA6, CYP7A1, LCAT, 
PXMP3, SULT1A1, APOC3, ATP8B1, 
SRD5A1, SULT1E1, DHCR24, OSBPL5, 
CYP21A1, AMACR, ESR1, RDH1, AFP, 
NPC1, G6PC, CYP17A1, PON1, LIPC, 









fatty acid metabolic 
process 
PTGES3, ACOX2, PRKAG3, HACL1, 
PPARA, PPARD, SC5D, PRKAG2, 
STAT5B, ACOT5, ACOT4, ACOT3, PECR, 
APOA2, ACSL1, ELOVL5, FASN, 
ACOT12, ELOVL6, ACAA1B, ACSL5, 
SCD1, CPT1B, ACADM, ALDH5A1, 
EPHX2, ADIPOR2, LYPLA2, PHYH, 
ADIPOQ, CPT1A, BRCA1, QK, PTGDS, 





FASN, QKI, CYP4F3, 
LIPC, ACOT4 
oxidation reduction 
CYP2D9, ACOX2, CYP2J5, STEAP3, 
LDHA, SC5D, ALDH1L1, PRDX5, PDHB, 
GPX2, RDH9, PECR, CYP7A1, CPOX, 
SRD5A1, DHTKD1, DUS1L, SARDH, 
GFOD1, DHCR24, HPD, SQRDL, ACADM, 
CYP3A13, ALDH5A1, CYP3A11, CYCS, 
DECR2, QDPR, CYP26A1, RDH1, 
CYP2E1, GRHPR, CDO1, POR, DHDH, 
CYP27A1, H6PD, SLC37A2, CYP2D26, 
TXNRD2, DEGS1, CYP2U1, XDH, 
CYP3A25, NDUFB6, HSD17B2, HSD17B1, 
HSD17B13, AASS, MOSC2, EGLN2, KMO, 
PAH, ALDH3A2, PIPOX, CYP2A12, FMO5, 
ADH4, FMO3, HAAO, FASN, BDH1, 
BCKDHA, SCD1, CYP2G1, GPD1, CHDH, 
CYP21A1, HGD, PHYH, AKR1B7, 
CYP17A1, SLC25A13, LEPRE1, UOX, 

























PPARA, JUB, PPARD, TRPV1, CRP, 
TLR3, SAA2, GRIN2C, SAA1, TICAM1, 
PROZ, CFH, LBP, CFD, KNG1, C4B, 
SAA3, SAA4, PROC, SERPINF2, LYST, 
F2, CTSB, LCP1, MBL1, RTN4RL1, C3, 
CXCL2, NINJ1, ABHD2, ITGB2, TRF, 
AHSG, FGG, IL17B, FGA, FGB, MAP3K1, 
SERPINC1, C2, PAPSS2, B4GALT1, LIPA, 
CFB, HC, SAAL1, EPHX2, PLG, ORM1, 
C1RL, HBEGF, ORM2, AI182371 
GNA13, MBL2, 
PPARA, NMI, NDST1, 
TGFB3, ITGB3, 
BDKRB2, APOA2, 
FGG, FGA, FGB, 
SAA1, SERPINE1, 
APOA5, SERPINC1, 
SERPINA1, LBP, F11, 
CEBPB, CYP1A1, 
CCNB1, ORM1, 
P2RX7, SDC1, TSC2, 
F2, KDM6B, ORM2, 
AOC3 
cellular amino acid 
derivative metabolic 
process 
AHCY, GCLC, CHKB, STAT5B, AGMAT, 
AFMID, OAZ1, CSAD, GSTK1, SLC22A4, 
PEMT, ETNK2, GNMT, CHDH, P4HB, 
ACADM, ALDH5A1, NR4A2, GSTT1, 
GSTT2, GSTT3, CDO1, TPMT, CHPT1, 








SLC9A8, PPARD, LDLR, ATOX1, TRPV1, 
STAT5B, PRDX5, AQP4, TENC1, GPX2, 
ASGR2, APOA2, DNAJC16, SLC24A3, 
APOE, GRIN2C, PXMP3, APOA5, MT2, 
MT1, LGI4, FAS, EIF2B4, PRKCA, IBTK, 
SLC12A7, MLXIPL, STIM2, QK, NPC1, 
G6PC, LYST, VEGFA, PDGFRB, TXNRD2, 
CLN6, XDH, GCLC, FTL1, STK11, CSF1, 
SLC37A4, NR3C2, EGLN2, SFXN1, TTC7, 
HSPA1A, TRF, ZC3H8, GCKR, FH1, EPO, 
SCO1, P4HB, SLC8A1, LIPA, SMG6, BAD, 
CSRP3, ADIPOQ, PLG, USF2, PARK7, 
ATXN1, ABCG8, TSC1, ID2, RHOT1, 
NR5A2, LIPC 
FXYD1, GNA13, 
SIVA1, LDLR, IL6ST, 




NUBP1, APOE, SAA1, 
APOC4, AGT, 
APOA5, SERPINE1, 




G6PC, CCL14, F2, 




MVD, LDLR, APOC1, APOA2, APOA1, 
INSIG2, APOE, SAA1, LCAT, CYP7A1, 
APOC3, PON1, LIPC, CLN8, LIPE, CLN6, 
DHCR24 
APOA4, APOA2, 






TRPV1, SAAL1, CRP, SAA3, SAA4, TRF, 
AHSG, ORM1, SAA2, SERPINF2, SAA1, 
F2, LBP, ORM2 
ORM1, MBL2, 







MBL1, C3, TRPV1, CRP, TRF, AHSG, 
SAA2, SAA1, CFH, C2, LBP, CFD, 
B4GALT1, HC, CFB, C4B, SAAL1, EPHX2, 
SAA3, SAA4, ORM1, SERPINF2, F2, 
C1RL, ORM2, AI182371 
ORM1, MBL2, 
APOA2, CEBPB, 





ALDH1L1, GCLC, KMO, PDSS1, ACOT5, 
PIPOX, ACOT4, GCH1, ACOT3, GSTK1, 
ACOT12, HAAO, FH1, SUCLA2, NAPRT1, 
CES3, ALDH5A1, PDK4, GSTT1, GSTT2, 
ACLY, GSTT3, DLAT, HNF4A, PANK1, 




FTCD, ACLY, ACOT4 
organic acid 
catabolic process 
ACOX2, HACL1, BCKDK, PPARD, AHCY, 
AASS, PAH, FAH, AFMID, CSAD, GSTZ1, 
SARDH, HPD, BCKDHA, ACADM, HAL, 
FTCD, HGD, CDO1, TAT, ADIPOQ, PHYH, 





PTGES3, PRKAG3, RBP4, PPARA, LDHA, 
SLC37A4, CAR5A, PDHB, PPP1R3B, 
NISCH, GYS2, GNMT, DHTKD1, ENO1, 
GPD1, ALDH5A1, PDK4, BAD, DLAT, 
PPP1CC, ADIPOQ, CPT1A, PCK1, PGM2, 
PCX, G6PC, GBE1, H6PD, PYGL, SDS, 
MAPK14, FABP5 
 
cellular amino acid 
catabolic process 
BCKDHA, BCKDK, AHCY, HAL, FTCD, 
HGD, AASS, PAH, CDO1, TAT, FAH, 
AFMID, AMDHD1, CSAD, PRODH2, 




PTGES3, PRKAG3, RBP4, PPARA, LDHA, 
GNPDA1, SLC37A4, CAR5A, PDHB, 
PPP1R3B, NISCH, GYS2, GALE, GNMT, 
DHTKD1, ENO1, B4GALT1, GPD1, 
ALDH5A1, PDK4, BAD, DLAT, PPP1CC, 
ADIPOQ, CPT1A, PCK1, PGM2, PCX, 





PTGES3, PRKAG3, RBP4, PPARA, LDHA, 
GNPDA1, SLC37A4, CAR5A, PDHB, 
NISCH, PPP1R3B, UGT1A7C, GYS2, 
GALE, GNMT, UGT1A@, DHTKD1, ENO1, 
B4GALT1, GPD1, ALDH5A1, PDK4, BAD, 
DLAT, PPP1CC, ADIPOQ, UGT1A1, 
CPT1A, PCK1, PGM2, UGT1A10, PCX, 









RBP4, GPD1, PCX, G6PC, SDS, PDK4, 
CAR5A, DLAT, AGXT, PCK1  
113 
 
* Detailed list of genes retrieved from DAVID analyses for Table 3.3. For GO-BP 
analysis, the same categories are listed here as in Table 3.3. For KEGG analysis, 
categories with FDR > 0.1 are also included. The orders of the categories listed here 
are the same as in Table 3.3, based on the FDR values from PHH-GW dataset. Please 













Chapter 4: Study the Roles of FXR and BAs in Mouse Models of PNALD 
4.1 Introduction 
Parenteral nutrition (PN), also known as intravenous feeding, is an effective 
method to obtain sufficient nutrition into the body through the veins. PN is mainly used 
for patients who cannot or should not obtain their nutrition through eating, and therefore 
is essential for them to maintain nutritional status and/or growth. To replace the enteral 
route of feeding, PN normally contains a combination of nutrients, including 
carbohydrates (dextrose), proteins (amino acids), lipids (fat emulsion), electrolytes, 
vitamins, and trace elements. 
However, long-term PN feeding will lead to a spectrum of hepatobiliary diseases, 
including cholestasis, steatosis, fibrosis, and end stage liver complication, cirrhosis, 
summarized as parenteral nutrition associated liver diseases (PNALD) (Kumpf 2006). 
Among these, steatosis, cholestasis, and gallbladder sludge/stones are most common, 
while overlap can exist (Kumpf 2006). PN associated steatosis, or hepatic fat 
accumulation, is found predominantly in adults and is generally benign (Kumpf 2006). 
PNAC is a special type of cholestasis occurs predominantly in children but may also 
occur in adult patients after long-term PN therapy (Peyret et al. 2011). Prolonged 
gallbladder stasis after long-term PN therapy may progress to gallbladder sludge or 
gallstones, with subsequent development of cholecystitis (Kumpf 2006). In the clinic, the 
most effective treatment for PNALD is to increase enteral food intake (Ziegler and 
Leader 2006). Nevertheless, for patients with intestinal failure, clinical management is 
still challenging.  
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Currently, soybean oil based lipid emulsion (SOLE) is most commonly used in 
the world for the lipid components in PN solution (Waitzberg, Torrinhas and Jacintho 
2006). And SOLE has been shown to be associated with the development of PNALD 
based on multiple reasons, including the presence of plant phytosterols and relatively 
large amount of pro-inflammatory ω-6 polyunsaturated fatty acids (PUFAs), as well as 
the lack of anti-inflammatory ω-3 PUFAs in SOLE (Vlaardingerbroek et al. 2014). In 
recent years, new generations of lipid emulsion, including fish oil based lipid emulsion 
(FOLE), which mainly contain ω-3 PUFAs, and SMOFlipid (a mixture of soybean oil, 
medium chain triglycerides (MCTs), olive oil, and fish oil), have been shown to be 
beneficial to improve or even reverse PNALD in both pediatric and adult patients 
(Waitzberg et al. 2006).  
Most recent studies in animal models have made substantial progress in 
understanding the pathogenesis of PNALD, especially studies conducted in preterm 
piglets, which well-recapitulated the clinical symptoms found in preterm and neonatal 
patients (Vlaardingerbroek et al. 2014). To fully understand the underlying molecular 
mechanisms, mouse models are also valuable due to the well-established genetic-
manipulation technologies in mice. Indeed, using toll like receptor 4 (TLR4) knockout 
mice, El Kasmi et al showed that TLR4 signaling mediated immune responses were 
critically involved in PN induced liver injury when PN mice were pretreated with dextran 
sulphate sodium (DSS) (El Kasmi et al. 2012), a toxic chemical agent, to induce 
intestinal damage to mimic human clinical conditions. In a later study, El Kasmi et al 
also showed that plant sterols contained in SOLE, particularly stigmasterols, were 
associated with the cholestatic liver injury observed in DSS pretreated mice (El Kasmi et 
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al. 2013). However, the findings from these mouse studies and those obtained from 
preterm piglets were inconsistent about the roles of plant sterols in the development of 
PNALD. While it was proposed that stigmasterols were FXR antagonists (El Kasmi et al. 
2013), to dates, the roles of liver FXR and BA signaling pathways involved in the 
pathogenesis of PNALD are still poorly understood. In addition, recent studies have 
shown that intestinal FXR-FGF15 (fibroblast growth factor 15, FGF19 in humans) axis 
plays important roles in suppressing liver BA synthesis and protecting the liver from 
cholestatic liver injury, as well as inhibiting intestinal inflammation and maintaining 
intestinal barrier integrity (Modica et al. 2012, Gadaleta et al. 2011, Kong et al. 2012b). 
Nevertheless, the potential beneficial roles of the intestinal FXR-FGF15 pathway 
involved in the improvement and management of PNALD have not been explored. 
In this study, we aim to establish a valid mouse PN model, and to characterize 
the detailed serum BA and liver gene expression profiles, to aid in future studies of the 
potential roles of FXR and BA signaling, as well as other contributing factors involved in 
the development and management of PNALD. 
 
4.2 Results 
Body Weight and Liver Weight for PN Mice 
Upon flushing the catheters and connecting the mice to the infusion system, 
average body weight (B.W.) for both saline and PN mice were around 21.5 g (Figure 
4.1A). In a previous study, from which we obtained the setup of PN regimen (El Kasmi 
et al. 2012), the PN infusion rate was kept as 7 mL/d throughout the study, and the 
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calculated daily calorie intake was 8.4 kcal for the PN mice. We initially did administer 
the same PN solution to mice with similar initial body weight (B.W.) at the rate of 7 mL/d. 
However, after 8 days of PN infusion, these mice had an average of around 20% body 
weight (B.W.) loss. Therefore, we decided to increase the lipid content in the PN 
solution from 2 g per 100mL to 3 g per 100mL, as well as increase the infusion rate from 
7 mL/d to 8 mL/d, for mice with an initial B.W. around 22 g. After receiving continuous 
intravenous infusion of the modified PN for 8 to 10 days (6 mL/d for day1, 8 mL/d 
afterwards), average B.W. change for PN mice was -2.10 g (range 0.06 to -3.44 g 
Figure 4.1 A), whereas average B.W. change for saline control mice was -0.06 g (range 
1.28 to -2.02 g, Figure 4.1 A). PN mice had around 10% body weight loss (mean 10.0%, 
SEM 1.7%, Figure 4.1 B). This trend of B.W. change is similar to the trend reported 
previously (El Kasmi et al. 2012). In addition to body weight loss, liver weight decreased 
further in PN mice, as presented in Figure 4.1 C,D, with the ratio of liver weight (L.W.) 
to mouse B.W. further decreased in PN mice (mean 0.052, 0.038 and SEM 0.003, 0.004 
for saline and PN mice, respectively, p-value < 0.05) (Figure 4.1 D). Upon animal sac, 
the gallbladders in PN mice were substantially smaller than those found in saline control 
mice (data not shown).  
 
Liver Functional Tests 
Serum levels of ALT were similar between the saline and PN mice (Figure 4.2 A). 
However, PN mice had significantly increased serum levels of AST (Figure 4.2 B, p-
value < 0.005) and TSBA (Figure 4.2 D, p-value < 0.05), and significantly decreased 
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serum levels of ALP (Figure 4.2 C, p-value < 0.005), when compared to saline control 
mice. Decreased ALP levels and empty gallbladders observed in PN mice indicate that 
PN infusion was associated with diminished bile flow from the hepatocytes into the 
biliary tract. These data suggest that these PN mice may have increased risks of 
developing cholestatic liver dysfunction after long-term PN infusion, or when other risk 
factors are presented, such as intestinal damage caused by DSS pretreatment. 
 
Liver Gene Expression  
After 8 to 10 days infusion of PN at 8mL/d, liver mRNA levels of genes involved 
in BA homeostasis were quantified (Figure 4.3). Relative mRNA levels of Cyp7a1 
showed significant increase in the livers of PN mice compared to saline controls (around 
3 fold, p-value < 0.05) (Figure 4.3 A). Relative mRNA levels of cytochrome P450, family 
27, subfamily a, polypeptide 1 (Cyp27a1), Fxr, and bile salt export pump (Bsep) 
decreased 40% in PN mice (p-value < 0.05, 0.05, 0.005, respectively) (Figure 4.3 A). 
Relative mRNA levels of cytochrome P450, family 7, subfamily b, polypeptide 1 
(Cyp7b1) and multidrug related protein 3 (Mrp3) decreased more than 70% (p-value < 
0.005 for both), whereas relative mRNA levels of Cyp8b1 decreased more than 90% (p-
value < 0.005) (Figure 4.3 A). Expression of genes involved in cholesterol and lipid 
metabolism was also quantified. Relative mRNA levels of cluster of differentiation 36 
(Cd36) decreased 50% with statistical significance (p-value < 0.05), whereas relative 
mRNA levels of fatty acid synthase (Fas), lipoprotein lipase (Lpl) and sterol regulatory 
element-binding protein-1c (Srebp-1c) increased significantly in the livers of PN mice 
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compared to saline control mice (p-value < 0.005, 0.05, 0.005, respectively) (Figure 4.3 
B). 
 
Microarray Profiling of Liver Gene Expression in PN Mice 
Genes with fold change ≥ 4 (up-regulated) or ≤ -4 (down-regulated) obtained 
from the microarray analysis, with their full names and the corresponding fold changes, 
are presented in Table 4.1. The RT-qPCR was performed to validate the results 
obtained from the microarray analysis (Figure 4.4). Both up-regulated and down-
regulated genes were tested. Among these, the relative mRNA levels of ATP-binding 
cassette, sub-family d (ALD), member 2 (Abcd2), Nocturnin and macrophage receptor 
with collagenous structure (Marco) increased significantly in PN mice compared to 
saline controls (2.2, 5, and 6.8 fold, p-value < 0.0005, 0.05, 0.05, for Abcd2, Nocturnin, 
and Marco, respectively). Relative mRNA level of cytochrome P450, family 2, subfamily 
b, polypeptide 10 (Cyb2b10) decreased more than 20 fold in PN mice (p-value < 0.005). 
However, for the other genes tested, the means of fold changes were less than 2, and 
without significance (Figure 4.4).  
Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway analysis obtained 
from Database for Annotation, Visualization and Integrated Discovery (DAVID) also 
revealed additional alterations in the livers of PN mice (Table 4.3). Many genes, which 
are related to immune and inflammatory responses, were up-regulated, including genes 
involved in cytokine-cytokine receptor interaction (19 out of 28), Janus kinase-signal 
transducer and activator of transcription (JAK-STAT) signaling pathway (12 out of 15), 
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and natural killer cell mediated cytotoxicity (11 out of 15). And most genes in the 
category of fat digestion and absorption and biosynthesis of unsaturated fatty acids 
(FAs) were up-regulated (10 out of 11). On the contrary, majority of genes involved in 
metabolism of endobiotics and xenobiotics were down-regulated (13 out of 19 for drug 
metabolism - cytochrome P450, 10 out of 14 for retinol metabolism, 8 out of 12 for 
arachidonic acid metabolism, all the 8 for glutathione metabolism, and all the 6 for fatty 
acid metabolism).  
 
Serum BA Profiling by UPLC-MS 
Among all the 23 BAs, serum concentrations of GDCA, LCA, and GUDCA in both 
saline and PN samples were below the system detection limits. For the other 20 BAs, 
the analyzed concentrations for each BA in the serum of saline (n=4) and PN mice (n=5) 
were plotted in Figure 4.5, and the relative fold changes of each BA in PN samples 
compared to saline samples were plotted in Figure 4.6. For most BAs, levels of tauro-
conjugates were much higher than the unconjugated BAs, whereas levels of glycol-
conjugates were the lowest for most BAs (Figure 4.5). Total serum concentrations of 
the 20 BAs increased 5 fold in PN mice compared to saline controls (Table 4.4) (1601.2 
± 417.9 ng/mL (mean ± SEM) and 8112.4 ± 605 ng/mL (mean ± SEM), for saline control 
and PN mice, respectively, p-value < 0.05). Compared to saline controls, serum levels 
of TCDCA, β-MCA, T-β-MCA, T-α-MCA, ω-MCA, T-ω-MCA, TLCA, TUDCA increased 
significantly in PN mice (p-value < 0.05), whereas serum levels of GLCA in PN mice 
decreased dramatically below the detection limit (Figure 4.5). Among these, levels of 
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TCDCA, T-β-MCA, T-α-MCA, TLCA increased more than 10 fold in PN mice (Figure 
4.6). Levels of CDCA increased 3 fold in PN mice, though without significance (p-
value=0.09). Levels of TCA, GCA, α-MCA, and THDCA also increased dramatically in 
PN mice (Figure 4.5) and reaching significance (p-value < 0.07). The percentage of 
major BAs in the total serum BA pool was plotted in Figure 4.7. As shown, percentage 
of TCDCA, T-β-MCA, and T-α-MCA increased dramatically in PN mice. The total 
concentration and percentage of each BA species (unconjugated BA and its conjugates), 
total primary BAs and total secondary BAs, as well as the percentage of 12α-OH BAs 
(CA, DCA and their conjugates) and non-12α-OH BAs (CDCA, MCA, LCA, HDCA, 
UDCA and their conjugates) in the total BA pool were summarized in Table 4.4. As 
shown, the percentage of total primary and secondary BAs was similar in saline control 
mice (55.22% versus 44.78%), whereas in PN mice, the percentage of total primary 
BAs was 3.1 fold of that of the secondary BAs (75.75% versus 24.25%). In addition, the 
percentage of total 12α-OH BAs and non-12α-OH BAs was also similar in saline control 
mice (42.74% versus 57.26%), whereas the percentage of total non-12α-OH BAs was 
2.67 fold of that of total 12α-OH in PN mice (72.95% versus 27.05%). 
 
Liver Histology  
H&E staining showed that overall liver histology between PN and saline control 
mice was similar (Figure 4.8). This phenotype is consistent with the results obtained 
from liver functional tests, suggesting that 8 days PN infusion in mice still does not 





The PN regimen used in this study was modified based on a previous publication 
(El Kasmi et al. 2012), to maintain sufficient calorie intake for adult mice to prevent 
excessive body weight loss. From our unpublished data, when mice were infused with 
PN for 12 to 14 days, body weight loss was similar to that found in mice infused with PN 
for 8 days, average around 10%. So the daily calorie intake and infusion rate seem 
adequate to maintain steady energy requirement for the adult mice used in this study. 
One interesting change we observed in this model was that the liver weight decreased 
further in the PN mice. Future studies will be needed to uncover the underlying causes. 
Similar to the previous study (El Kasmi et al. 2012), ALT levels were not 
increased in the PN mice, whereas AST levels increased significantly in our model, but 
were still in the normal range. We also saw significantly increased TSBA levels in the 
PN mice, similar to the study previously reported (El Kasmi et al. 2012). Interestingly, 
ALP levels decreased significantly in the PN mice. The trend of decreased ALP levels in 
PN mice is on the contrary to what is commonly observed in the neonatal incentive care 
unit (NICU), that the neonatal patients with PNAC normally had elevated levels of ALP. 
This difference between the adult mice and neonates may be due to species differences 
between mice and humans. In humans, FGF19 has been found to be expressed in 
human hepatocytes (Holt et al. 2003) and gallbladder epithelial cells (Zweers et al. 
2012), whereas in adult WT mice, FGF15 is not expressed in the liver nor in the 
gallbladder (Inagaki et al. 2005). It has been shown that FGF15 is essential for 
gallbladder refill in mice (Inagaki et al. 2005). Therefore, the lack of enterohepatic 
circulation of BAs during PN infusion could lead to impaired FXR-FGF15 signaling, 
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causing diminished gallbladder refilling from the liver and subsequently less biliary 
exposure to BAs. In addition, recent studies also showed that elevated levels of ALP in 
patients with intestinal failure and PNALD could be caused by bone diseases, rather 
than liver diseases (Nandivada et al. 2014). From the KEGG pathway analysis, we did 
see that 10 out of 11 genes in the category of osteoclast differentiation were up-
regulated in the Microarray-PN/Saline. Other than liver diseases, it has been shown that 
PN could also lead to metabolic bone disorders (MBD), for which, the underlying 
mechanisms are still poorly studied (Nandivada et al. 2014). Our findings from the 
microarray analysis could potentially provide insights into the association of PN induced 
liver dysfunction to the development of MBD.  
The potential lack of enterohepatic FGF15 signaling could also be responsible for 
the up-regulation of Cyp7a1 gene expression seen in the PN mice. It has been shown 
that WT mice with bile duct ligation also had a 3 fold increase of Cyp7a1 expression, 
while expression of small heterodimer partner (Shp) was not changed (Inagaki et al. 
2005). The increased expression of Cyp7a1 might also lead to the accumulation of 
cholesterol metabolites in the liver, which could in term, activate LXRα and induce the 
expression of LXRα target genes, including Lpl, Srebp-1c, and Fas, as shown in Figure 
4.5 B. Long-term LXRα activation coupled with up-regulation of its target genes, could 
be responsible for PN induced liver steatosis, even though PN mice tend to lose body 
weight. 
Similar to previous findings from PN piglets (Vlaardingerbroek et al. 2014), we 
also detected decreased gene expression of Fxr, Bsep, and Mrp3 in the livers of PN 
mice. A previous report did show decreased expression of Fxr and Bsep in DSS 
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pretreated PN mice (PN/DSS), but the expression of these genes involved in BA 
homeostasis in PN-only mice were not reported (El Kasmi et al. 2012, El Kasmi et al. 
2013). Nevertheless, the similar trends of the decreased expression of these genes in 
the adult mice and preterm piglets suggest common underlying mechanisms in different 
species, which are most likely PN dependent. Future studies will be needed to dissect 
out the mechanisms underlined, especially for the down-regulation of Fxr gene 
expression and FXR signaling. The increase of Cyp7a1 and decrease of Fxr, Bsep and 
Mrp3 gene expression, together could lead to BA levels buildup in the hepatocytes, 
leading to subsequent elevation of TSBA in PN mice. And the BA accumulation in PN 
mice could lead to cholestasis after long-term PN especially with the presence of 
additional risk factors, such as catheter related infections and intestinal tract 
inflammation, which could push the liver stress further into drastic liver damages in 
relatively short time, as those detected in PN/DSS mice (El Kasmi et al. 2012).  
While expression of Cyp7a1 increased around 3 fold, relative mRNA levels of 
Cyp8b1 and Cyp7b1 decreased dramatically in PN mouse livers (Figure 4.3). It has 
been shown that both Cyp7b1 and Cyp8b1 are directly regulated by retinoic acid-related 
orphan receptor alpha (RORα) (Wada et al. 2008, Pathak, Li and Chiang 2013). From 
detailed comparison of our microarray data (Microarray-PN/Saline) to previously 
published microarray data obtained from RORα) and retinoic acid-related orphan 
receptor gamma (RORγ) double knockout (DKO) mice (Microarray-DKO/WT) (Kang et 
al. 2007), we found similar trends of alterations for a big number of genes in the two 
datasets, while a few genes with different trends were also identified (Table 4.2). RORα 
and RORγ have been shown to play critical roles in regulating the expression of many 
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genes involved in phase I and phase II metabolism (Kang et al. 2007). The expression 
patterns of many genes involved in cellular metabolism in the liver are also regulated by 
the fast-feed circadian rhythm (Zhang, Guo and Klaassen 2011, Xu et al. 2012). And it 
has been shown that the expression of RORα and RORγ exhibited an oscillatory pattern 
consistent with the liver circadian rhythm (Kang et al. 2007). Under continuous PN 
infusion, it is very likely that the normal fast-feed circadian rhythm, which is maintained 
in the saline control mice, is disrupted in the PN mice. It has also been shown that 
glucagon/protein kinase A (PKA) signaling could phosphorylate and stabilize RORα 
protein upon fasting, to induce CYP8B1 and diurnal rhythm (Pathak et al. 2013). The 
continuous supply of dextrose in the PN solution could potentially lead to down-
regulation of PKA signaling, and therefore suppressing RORα target genes, such as 
Cyp7b1 and Cyp8a1. Besides these direct targets of RORα and/or RORγ, many indirect 
target genes were also altered in the PN mice, possibly also due to the suppression of 
RORα and/or RORγ by the continuous PN infusion. It is also important to note that 
several genes listed in Table 4.2 showed opposite direction of gene expression 
alterations. These changes could be mediated by additional transcriptional factors 
caused by PN infusion. For example, the expression of cytochrome P450, family 2, 
subfamily b, polypeptide 10 (Cyp2b10) has been shown to be directly regulated by both 
CAR and PXR. In this case, the potential alterations of CAR and/or PXR signaling could 
explain the dramatic decrease of Cyp2b10 expression in PN mice. Future studies will be 
needed to validate the roles of RORα and/or RORγ, as well as other potential 
factors/mechanisms involved in the alteration of these genes in PN mice, and the 
potential contributions to the pathogenesis of PNALD. In the current clinical practice, 
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adult patients tend to receive cyclic PN, but still with continuous infusion. The 
continuous load of dextrose could still disrupt the normal fast-feed rhythm of many 
genes in these patients. Nevertheless, for preterm infants and neonates, continuous PN 
infusion is essential to promote their normal growth and development during the critical 
period. Therefore, it is critical to fully understand the underlying mechanism, in order to 
further optimize the PN strategy and prevent potential cause of liver damages.  
Finally, preliminary data obtained from serum BA profiling by UPLC-MS were 
consistent with the gene expression results. In detail, consistent with a 3 fold increase of 
Cyp7a1 gene expression, levels of the total 20 BAs increased dramatically in PN mice. 
CYP8B1 determines the ratio of 12α-OH BAs versus non-12α-OH BAs. As expected, 
the potential lack of intestinal FXR-FGF15 signaling and the decreased mRNA 
expression of Cyp8b1 in PN mice together could be the cause of the dramatic increase 
of both the levels and the percentages of TCDCA, T-β-MCA, and T-α-MCA in PN mice 
(Figure 4.6, 4.8). Serum levels of CA, TCA, DCA, and TDCA also increased in PN mice, 
while the percentage of these BA species all decreased. As a result of these changes, 
the percentage of total non-12α-OH BAs was much higher in PN mice (Table 4.3). The 
dramatic decrease of the percentage of total secondary BAs in PN mice could also be 
caused by the decreased bile flow from the liver into the intestinal tract, leading to the 
proportional decrease of secondary BA formation in the gut. While the levels of 
unconjugated secondary BAs in saline and PN mice were similar (Figure 4.5), the 
levels of conjugated secondary BAs were much higher in PN mice, except for GLCA 
(undetectable). The increased levels of conjugated secondary BAs in PN mice could be 
caused by the decreased fecal loss of BAs in the gut, since fecal excretion mainly 
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counts for the direct loss of secondary BAs. Previous studies in germ-free mice suggest 
that T-β-MCA and T-α-MCA are FXR antagonists (Sayin et al. 2013). Therefore, the 
dramatic increase of serum levels of T-β-MCA and T-α-MCA in the PN mice is 
potentially associated with the increase of these BAs in the livers of PN mice, which 
could eventually lead to the down-regulation of FXR signaling in the PN mice. 
In summary, we have established a valuable mouse PN model using C57BL/6J 
mice. Combining RNA microarray profiling and serum BA profiling, we characterized 
detailed the molecular and cellular alterations in the PN mice in great details. These 
findings will aid us in studying the underlying mechanisms of the pathogenesis of 
PNALD later on when PN infusion is combined with genetic, pharmacological, or 







Figure 4.1 Body Weight and Liver Weight for Saline and PN Mice 
 
(A) initial B.W. (body weight) of saline (n=6) and PN (n=9) mice upon infusion setup and 
final B.W. upon animal sacrifice; (B) the percentage of body weight change relative to 
the initial body weight upon infusion setup; (C) liver weight upon animal sacrifice; (D) 
the ratio of liver weight to the final body weight upon animal sacrifice. PN mice received 
PN infusion for 8 days. Data were expressed as mean ± SEM (standard error of the 





Figure 4.2 Serum Biochemical Analyses for Saline and PN Mice 
 
Serum levels of ALT (A), AST (B), ALP (C), and TSBA (D) in saline (n=6) and PN (n=9) 
mice. PN mice received PN infusion for 8 days. Compared with saline group, *p-value < 








Figure 4.3 Liver Gene Expression in Saline and PN mice 
 
RT-qPCR analysis of relative mRNA expression of genes involved in (A) BA 
homeostasis and (B) cholesterol and lipid metabolism, in the liver of saline (n=6) and 
PN (n=8) mice. Gene expression data were expressed as mean ± SEM. PN mice 
received PN infusion for 8 days. Relative mRNA levels were first normalized to β-actin, 
and then relative fold changes were normalized to saline control group. Compared with 





Figure 4.4 Validation of Microarray Analysis (Microarray-PN/Saline) 
 
RT-qPCR validation of selected genes retrieved from Microarray-PN/Saline (genes with 
full name were shown in Table 4.1, Nur77 is for Nr4a1). Gene expression data were 
expressed as mean ± SEM. PN mice (n=8) received PN infusion for 8 days. Relative 
mRNA levels were first normalized to β-actin, and then relative fold changes were 
normalized to saline control mice (n=6). Compared with saline control group, *p-value < 











Figure 4.5 Serum Levels of 20 BAs in Saline and PN Mice 
 
Quantified serum concentrations (ng/mL) of the 20 BAs in saline (n=4) and PN mice 
(n=5). Data were presented as mean ± SEM. Compared with saline control group, *p-
value < 0.05, student’s t-test.  
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Figure 4.6 Relative Levels of Serum BAs in Saline and PN Mice 
 
Relative levels of the 20 BAs in PN mice (n=5) was normalized to saline controls (n=4). 
For saline mice, the relative level of each BA was given arbitrarily as 1. Data were 








Figure 4.7 Compositions of Major BAs in Saline and PN Mice 
 





Figure 4.8 Liver Histology of Saline and PN Mice 
 












Direction Full Transcript Name 
Sult1e1 17.17 Up Sulfotransferase family 1E, member 1, mRNA 
Fmo3 7.68 Up Flavin containing monooxygenase 3 (Fmo3), mRNA 
Lepr 7.05 Up Leptin receptor (Lepr), transcript variant 2, mRNA 
Abcd2 5.97 Up 
ATP-binding cassette, sub-family D (ALD), member 2, 
mRNA 
Cyp17a1 5.28 Up 
Cytochrome P450, family 17, subfamily a, polypeptide 
1 (Cyp17a1), mRNA 
Nr4a1 5.16 Up 
Nuclear receptor subfamily 4, group A, member 1, 
mRNA 
Marco 5.15 Up 
Macrophage receptor with collagenous structure 
(Marco), mRNA 
Egr1 5.1 Up Early growth response 1 (Egr1), mRNA 
Ccrn4l 5.02 Up NOCTURNIN (Nocturnin) 
Btg2 4.64 Up 
B-cell translocation gene 2, anti-proliferative (Btg2), 
mRNA 
Cyp4a12a 9.17 Down 
Cytochrome P450, family 4, subfamily a, polypeptide 
12a, mRNA 
Ces2 8.37 Down Carboxylesterase 2 (Ces2), mRNA 
Cyp2b10 6.72 Down Cyp2b10-like pseudogene, mRNA sequence 
Orm3 6.61 Down Orosomucoid 3, mRNA 
Hist1h2bg 6.28 Down Histone cluster 1, H2bg, mRNA 
Clec2h 6.12 Down 
C-type lectin domain family 2, member h (Clec2h), 
mRNA 
Orm2 6.07 Down Orosomucoid 2 (Orm2), mRNA 
Cyp4a12b 4.87 Down highly similar to CYTOCHROME P450 4A8 
Cml5 4.85 Down Camello-like 5 (Cml5), mRNA 
Selenbp2 4.49 Down Selenium binding protein 2, mRNA 
Cyp2c55 4.28 Down 




Table 4.2 Comparison of Microarray Analysis 
 
Microarray-PN/Saline Microarray-DKO/WT 
Functional Category Gene Fold Change Direction Fold Change Direction 
Cytochrome P450 Cyp2b9 9.4 Up 8.9 Up 
 
Cyp8b1 3.56 Down 4.6 Down 
 
Cyp7b1 2.22 Down 7.4 Down 
 
Cyp2b10 6.72 Down 3.1 Up 
 
Cyp4a10 2.74 Down 2.5 Up 
Steroid Hmgcr 2.61 Up 2.5 Up 
 
Hsd17b7 1.68 Up 3 Up 
 
Hsd3b4 2.45 Down 5.4 Down 
 
Hsd3b5 2.39 Down 15.8 Down 
Lipid and fatty acid Scd2 2.11 Up 2.6 Up 
 
Elovl6 1.66 Up 3.9 Up 
 
Elovl3 3.01 Down 7.7 Down 
Cell signaling Igfbp1 2.88 Up 5.7 Up 
Transport Abcd2 5.97 Up 2.4 Up 
 
Apoa4 3.87 Up 2.1 Up 
Carbohydrate Ppp1r3c 3.55 Down 2.2 Down 
Circadian rhythm Rora 1.6 Down 3 Down 
 
Rorc 1.61 Down 2.3 Down 
 
Ccrn4l 5.02 Up 3.5 Up 
Miscellaneous Keg1 2.22 Down 2 Down 
 
Lpin2 2.57 Up 1.8 Up 
 
Selenbp2 4.49 Down 5.1 Down 
 
Ccnb1 2.22 Up 2.2 Down 
 
Selected genes with the corresponding fold changes and directions of change were 
retrieved from Microarray-PN/Saline and Microarray-DKO/WT. The functional categories 
of these genes were obtained from the previous microarray study (Kang et al. 2007). 
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The genes with different directions of changes in the two microarray datasets were 
highlighted in bold.   
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Table 4.3 KEGG Pathway Analysis for Microarray-PN/Saline 
KEGG Pathway List Up Down Gene Set 
Cytokine-cytokine receptor interaction 28 19 9 243 
Neuroactive ligand-receptor interaction 16 11 5 309 
Jak-STAT signaling pathway 15 12 3 146 
Natural killer cell mediated cytotoxicity 15 11 4 132 
Osteoclast differentiation 11 10 1 107 
Staphylococcus aureus infection 11 9 2 48 
Glycolysis / Gluconeogenesis 9 6 3 58 
p53 signaling pathway 9 7 2 65 
Inositol phosphate metabolism 7 7 0 55 
Fat digestion and absorption 6 6 0 41 
Biosynthesis of unsaturated fatty acids 5 4 1 24 
Steroid biosynthesis 4 4 0 18 
Drug metabolism - cytochrome P450 19 6 13 74 
Retinol metabolism 14 4 10 64 
Steroid hormone biosynthesis 13 5 8 46 
Arachidonic acid metabolism 12 4 8 82 
Complement and coagulation cascades 11 4 7 70 
Glutathione metabolism 8 0 8 53 
Pentose and glucuronate interconversions 7 1 6 22 
Fatty acid metabolism 6 0 6 45 
Circadian rhythm - mammal 4 1 3 21 
Bile secretion 16 9 7 65 
PPAR signaling pathway 15 8 7 74 
 
Total number of genes retrieved from Microarray-PN/Saline for each KEGG category 
was listed in the “List” column. Total number of genes for each category in DAVID was 




Table 4.4 Summary of Serum BAs in PN and Saline Mice 
 
Concentration (ng/mL) Percentage 
Total BAs Saline PN Fold* Saline PN 
Total CA 376.1 1938.3 5.2 28.6% 22.4% 
Total CDCA 21.0 507.8 24.2 1.5% 7.3% 
Total α/β-MCA 396.0 3863.2 9.8 25.2% 46.1% 
Total DCA 289.1 466.2 1.6 14.1% 4.7% 
Total LCA 6.5 1.9 0.3 0.5% 0.0% 
Total ω-MCA 415.6 1091.6 2.6 23.8% 16.3% 
Total HDCA 28.1 142.9 5.1 1.8% 2.0% 
Total UDCA 68.8 100.3 1.5 4.5% 1.3% 
Total primary BAs 793.1 6309.4 8.0 55.2% 75.8% 
Total secondary BAs 808.1 1803.0 2.2 44.8% 24.2% 
Total 12α-OH BA 665.1 2404.6 3.6 42.7% 27.1% 
Total non-12α-OH BA 936.0 5707.8 6.1 57.3% 72.9% 
Total BAs 1601.2 8112.4 5.1 
  
 
* “Fold” is calculated by dividing the corresponding serum BA concentration in PN mice 






Chapter 5: Summary and Future Directions 
For the first aim of this dissertation (Chapter 3), using genome-wide analysis 
tools, we obtained a global picture of FXR binding in HepG2 cells and PHHs, as well as 
the transcriptome profiles of PHHs upon GW4064 activation of FXR. Our comparison 
analysis showed overall similar profiles of FXR binding in cultured HepG2 cells and 
PHHs compared to that in mice in a genome-wide scale. These results will provide 
critical insights in future translational studies, especially when studies in mice need to 
be extrapolated into human conditions. In terms of species similarities, the pathway of 
complement and coagulation cascade is of particular interest. Both mouse and human 
FXR was found to bind to the promoter regions of many genes in this pathway (Table 
3.5), including the three genes encoding the three protein components of fibrinogen, 
fibrinogen alpha chain (FGA), fibrinogen beta chain (FGB), and fibrinogen gamma chain 
(FGG), and the gene encoding the important anti-coagulant protein antithrombin 
(SERPINC1) (Table 3.5). In addition, FXR has been shown to have physical interaction 
with HNF-4α and the two NRs co-regulate many genes in this pathway (Thomas et al. 
2013). Preliminary PN studies have also been performed in mice, but we encountered 
infusion problems for those mice. Preliminary dissections of mice died from the PN 
infusion suggest that these mice may have problems associated with their coagulation 
system. Nevertheless, biochemical analyses for serum samples obtained from non-
surgical FXR-hepKO mice didn’t show obvious alterations in these mice (data not 
shown). Therefore, we speculate that the FXR-hepKO mice are prone to have 
coagulation problems, likely stronger coagulation responses than control mice, and 
certain components in the PN solution pushed the coagulation system in these mice 
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further to pathological levels and caused the problems we have consistently seen in 
these mice. Future studies will be needed to dissect out the molecular mechanisms 
underlined, and the implications to the study of human FXR functions. In terms of 
species differences, the pathway of retinol metabolism may be worth future analysis. 
This pathway was enriched in the pathway analyses for both ChIP-seq and RNA-seq for 
the PHHs, but not enriched in the ChIP-seq analysis for the mouse livers (Table 3.4, 
3.5). 
For the second aim of this dissertation (Chapter 4), using microarray profiling and 
serum BA profiling, we identified novel molecular signatures of the PN mice, especially 
those involved in BAs synthesis and metabolism. The results obtained from this study 
will provide valuable insights in guiding future studies of PNALD in our laboratory. First 
of all, liver and intestinal BA profiles will be characterized, not only to uncover the 
comprehensive profiles of the enterohepatic circulation of BAs in the PN mice, but also 
to provide in-depth mechanistic insights about the potential roles of FXR and BA 
signaling and BA cytotoxicity in the pathogenesis of PNALD.  
As mentioned, we are also conducting PN studies in FXR-hepKO mice. 
Preliminary results obtained so far are still ambiguous, probably due to the coagulation 
problems mentioned previously. We are in the process of investigating and modifying 
different components in the PN solution, in order to avoid the potential coagulation 
problems and more importantly, to obtain valuable results from the FXR-hepKO-PN 
mice. These results will provide indispensable mechanistic insights associated with the 




We also plan to study the potential roles of FXR and BA signaling in PN/DSS 
mice once the PN/DSS mouse model is well established. In terms of new generations of 
lipid emulsions for PN study, we plan to start from FOLE. Eventually, different lipid 
emulsions, different pharmacological and/or toxicological treatment for mice, and mice 
with different genetic manipulations will be tested in various combinations to study the 
molecular and cellular mechanisms underlying the development, progression, and 
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